[go: up one dir, main page]

US20180200247A1 - Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators - Google Patents

Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators Download PDF

Info

Publication number
US20180200247A1
US20180200247A1 US15/574,243 US201615574243A US2018200247A1 US 20180200247 A1 US20180200247 A1 US 20180200247A1 US 201615574243 A US201615574243 A US 201615574243A US 2018200247 A1 US2018200247 A1 US 2018200247A1
Authority
US
United States
Prior art keywords
oxo
ethylsulfonyl
acetamide
phenyl
tetrahydroquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/574,243
Inventor
Ravi Kotrabasaiah UJJINAMATADA
Chetan Pandit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Publication of US20180200247A1 publication Critical patent/US20180200247A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to compounds useful for the treatment of diseases and/or disorder associated with Retinoic acid receptor-related orphan receptors (RORs), and more particularly compounds that modulate the function of ROR ⁇ .
  • RORs Retinoic acid receptor-related orphan receptors
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of diseases and/or disorder associated with ROR ⁇ .
  • Retinoid-related orphan receptors are transcription factors which belong to the steroid hormone nuclear receptor super family (Jetten & Joo, Adv. Dev. Biol. 16:313-355, 2006). Several nuclear receptors are still characterized as orphan receptors because the identification of ligands for these receptors is still elusive or controversial.
  • the ROR family consists of three members, ROR alpha (ROR ⁇ ), ROR beta (ROR ⁇ ) and ROR gamma (ROR ⁇ ), each encoded by a separate gene (RORA, RORB and RORC, respectively).
  • RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal A/B domain, a DNA-binding domain, a hinge domain, and a ligand binding domain. Each ROR gene generates several isoforms which differ only in their N-terminal A/B domain. Two isoforms of ROR ⁇ have been identified: ROR ⁇ 1 and ROR ⁇ t (also known as ROR ⁇ 2). ROR ⁇ is a term used to describe both ROR ⁇ 1 and/or ROR ⁇ t.
  • naive T helper cells Upon activation by antigen-presenting cells naive T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Th1 and Th2 subtypes.
  • cytokine secreting effector T cells such as Th1 and Th2 subtypes.
  • Th1 and Th2 subtypes A third and distinct effector subset has been identified, which plays a key role in providing immunity to bacteria and fungi at mucosal surfaces (Kastelein, et al., Ann. Rev. Immunol. 25: 221-242, 2007).
  • This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17A/F, IL-21 and IL-22, and is named Th17 (Miossec, et al., New Eng. J. Med. 361: 888-898, 2009).
  • ROR ⁇ 1 is expressed in a variety of tissues including thymus, muscle, kidney and liver, while ROR ⁇ t is exclusively expressed in the cells of the immune system. ROR ⁇ t is highly expressed in Th17 cells (He, et al., Immunity 9: 797-806, 1998). Studies have shown that Th17 cells are one of the important drivers of the inflammatory process in tissue-specific autoimmunity (Steinman, J. Exp. Med. 205:1517-1522, 2008; Leung, et al., Cell. Mol. Immunol. 7: 182-189, 2010).
  • Th17 cells are activated during the disease process and are responsible for recruiting other inflammatory cells types, especially neutrophils, to mediate pathology in the target tissues (Korn, et al., Ann. Rev. Immunol. 27:485-517, 2009).
  • Th17 cells or their products have been shown to be associated with the pathology of a variety of human inflammatory and autoimmune disorders including multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease and asthma (Jetten, Nucl. Recept. Signal. 7: e003, 2009; Manel, et al., Nat. Immunol. 9:641-649, 2008).
  • ROR ⁇ t was shown to play a crucial role in non-Th17 lymphoid cells.
  • ROR ⁇ t was critically important in innate lymphoid cells expressing Thyl, SCA-1 and IL-23R proteins. Genetic disruption of ROR ⁇ in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development (Buonocore, et al., Nature 464: 1371-1375, 2010).
  • ROR ⁇ t was shown to play a crucial role in other non-Th17 cells, such as mast cells (Hueber, et al., J Immunol. 184: 3336-3340, 2010).
  • ROR ⁇ t deficient mice show very little Th17 cells.
  • ROR ⁇ t deficiency resulted in amelioration of EAE.
  • Inhibition of ROR ⁇ t may also be beneficial in other diseases, which are characterized by increased levels of Th17 cells and/or elevated levels of Th17 hallmark cytokines such as IL-17, IL-22 and IL-23.
  • diseases are Kawasaki Disease (Jia, et al., Clin. Exp. Immunol. 162: 131-137, 2010) and Hashimoto's thyroiditis (Figueroa-Vega, et al., J Clin.Endocrinol.Metab. 95: 953-62, 2010).
  • ROR ⁇ inverse agonist SR2211 is a cell-permeable piperazine containing biphenyl compound that binds directly to retinoic acid receptor related orphan receptor ⁇ (ROR ⁇ ) and acts as a highly selective, inverse agonist. It is reported to block the transcriptional activity of ROR ⁇ and suppress the synthesis of IL-17 in EL-4 murine lymphoma cell line. SR2211 exhibits only a minimal effect on ROR alpha and LXR alpha activity, indicating that the functional effect is due to selective inhibition of ROR ⁇ alone.
  • Th17 cells The nature and relevance of Th17 cells in mouse models of cancer and human disease are known (Zou et al., Nature Reviews Immunology 10, 248-256 (April 2010)). Evidences suggest that the effector T cell subset is also involved in tumor immunology, thus giving a way to a new target for cancer therapy.
  • ROR ⁇ plays in the pathogenesis of diseases
  • ROR ⁇ plays in the pathogenesis of diseases
  • compounds that modulate ROR ⁇ activity which can be used in the treatment of diseases mediated by ROR ⁇ .
  • substituted tetrahydroquinolinone and related compounds that are useful as modulators of ROR-gamma activity.
  • substituted tetrahydroquinolinone and related compounds and pharmaceutical compositions thereof which are useful as ROR ⁇ modulators.
  • the present invention provides compounds of formula (I):
  • the present invention relates to pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof and processes for preparing such compositions.
  • the present invention relates to the preparation of the compounds of formula (I).
  • the present invention provides substituted tetrahydroquinolinone and related compounds which are useful for treatment of disease(s) or disorder(s) associated with Retinoic acid receptor-related orphan receptors (RORs), and more particularly compounds that modulate the function of ROR ⁇ .
  • RORs Retinoic acid receptor-related orphan receptors
  • the present invention relates to compounds of formula (I):
  • the present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein,
  • the present invention relates to compounds of formula (IA):
  • the present invention relates to compounds of formula (IB):
  • ring Het is monocyclic or bicyclic heterocyclic ring.
  • the ring Het is pyridyl, pyridazinyl, pyridazinone, pyrimidinyl, pyrazinyl, pyrazolyl, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl, imidazopyridazinyl or tetrahydroisoquinolinonyl.
  • the ring Het is pyrazinyl, pyridazinone, pyrazolyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl or tetrahydroisoquinolinonyl.
  • the ring Het is pyridyl
  • the ring Het is pyridazinyl.
  • the ring Het is pyrimidinyl.
  • the ring Het is imidazopyrazinyl.
  • the ring Het comprises its N-Oxides thereof.
  • 0-2 of Y 1 , Y 2 and Y 3 are N.
  • each Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are CH.
  • L is .—NHCOCH 2 — or .—CONHCH 2 — wherein the group marked with . is connected to the ring containing Y 1 , Y 2 and Y 3 .
  • R 1 and R 2 are independently hydrogen.
  • R 1 and R 2 are independently alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. methyl, ethyl or isopropyl).
  • R 1 is hydrogen and R 2 is alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. methyl).
  • R 3 is alkoxy, in another embodiment the alkoxy is methoxy or isopropyloxy.
  • R 3 is haloalkyl, in another embodiment the haloalkyl is —CF 3 .
  • R 3 is hydroxy.
  • R 3 is alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. methyl, ethyl or isopropyl).
  • R 3 is halo, in another embodiment the halo is —F or —Cl.
  • R 3 is haloalkyloxy, in another embodiment the haloalkyloxy is —OCF 3 .
  • R 3 is cycloalkyl, in another embodiment the cycloalkyl is cyclopropyl.
  • R 4 is alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. —CH 3 or —C 2 H 5 ).
  • R 4 is hydrogen
  • R 5 is alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. —CH 3 or —C 2 H 5 ).
  • R a is hydrogen
  • R a is alkyl, in another embodiment the alkyl is C 1 -C 6 alkyl (e.g. methyl or ethyl).
  • R a is halo, in another embodiment the halo is fluoro.
  • R 6 and R 7 are independently hydrogen.
  • m is 1 or 2.
  • the present invention provides a compound selected from the group consisting of:
  • the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
  • Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2 H (“D”), 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I and 125 I.
  • Isotopically labeled compounds of the present inventions can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • the present invention also provides a pharmaceutical composition that includes at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent).
  • the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein.
  • the compounds described in the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the compounds and pharmaceutical compositions of the present invention are useful for modulating the activity of ROR ⁇ , which is believed to be related to a variety of disease states.
  • the present invention further provides a method of modulating the function of ROR ⁇ in a subject in need thereof by administering to the subject one or more compounds described herein in the amount effective to cause inhibition of such receptor.
  • the compounds of the invention are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention.
  • the pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients.
  • the pharmaceutically acceptable excipients are approved by regulatory authorities or are generally regarded as safe for human or animal use.
  • the pharmaceutically acceptable excipients include, but are not limited to, carriers, diluents, glidants and lubricants, preservatives, buffering agents, chelating agents, polymers, gelling agents, viscosifying agents, solvents and the like.
  • suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.
  • the pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, suspending agents, preserving agents, buffers, sweetening agents, flavouring agents, colorants or any combination of the foregoing.
  • compositions may be in conventional forms, for example, tablets, capsules, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.
  • Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition can be carried out using any of the accepted routes of administration of pharmaceutical compositions.
  • the route of administration may be any route which effectively transports the active compound of the patent application to the appropriate or desired site of action.
  • Suitable routes of administration include, but are not limited to, oral, nasal, buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous, intravenous, intraurethral, intramuscular or topical.
  • Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges.
  • Liquid formulations include, but are not limited to, syrups, emulsions, and sterile injectable liquids, such as suspensions or solutions.
  • Topical dosage forms of the compounds include ointments, pastes, creams, lotions, powders, solutions, eye or ear drops, impregnated dressings, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration.
  • compositions of the present patent application may be prepared by conventional techniques known in literature.
  • Suitable doses of the compounds for use in treating the diseases or disorders described herein can be determined by those skilled in the relevant art.
  • Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms, and suitable pharmaceutical excipients can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present patent application.
  • Compounds of the present invention are particularly useful because they may modulate the activity of Retinoid-related orphan receptor gamma (ROR ⁇ ), i.e., they prevent, inhibit, or suppress the action of ROR ⁇ , and/or may elicit ROR ⁇ modulating effect.
  • ROR ⁇ Retinoid-related orphan receptor gamma
  • Compounds of the invention are thus useful in the treatment of those conditions in which inhibition of a ROR gamma activity is required.
  • the present invention provides a method of treating a ROR ⁇ mediated disorder or disease in a subject comprising administering to a subject in need thereof a compound of the present invention.
  • the present invention provides a method comprising conjointly administering to the subject a second therapeutic agent.
  • the present invention provides a method of reducing amount of IL-17 and other effector cytokines of Th17 cells in a subject, comprising administering to the subject a compound of the present invention.
  • one embodiment of the invention provides a method of treating a disorder or disease selected from the group consisting of immune or inflammatory disorder or disease.
  • the method comprises administering a therapeutically effective amount of a compound of the present invention, to a subject in need thereof to ameliorate a symptom of a ROR ⁇ mediated disorder or disease.
  • the disorder or disease is an immune disorder or disease.
  • the disorder or disease is an inflammatory disorder or disease.
  • the disorder or disease is an autoimmune disorder or disease.
  • the disorder or disease is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, asthma, epidermal hyperplasia, scleroderma or ulcerative colitis.
  • the disorder or disease is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, dermatom
  • the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis or erythrodermic psoriasis.
  • the disorder or disease is rheumatoid arthritis.
  • the subject is a mammal, e.g., a human.
  • the present invention provides compounds for use as a medicament.
  • the invention provides the use of the compounds of the present invention in the manufacture of a medicament.
  • the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of an immune disorder or an inflammatory disorder or disease.
  • the present invention provides compounds for use as a medicament.
  • the medicament is for treating a disease or disorder mediated by ROR ⁇ .
  • the present invention provides compounds for use as a medicament for the treatment of an immune or an inflammatory disorder or disease.
  • the compounds of the present invention can inhibit the activity of ROR ⁇ . Accordingly, another embodiment of the invention provides a method of inhibiting the activity of ROR ⁇ . The method comprises exposing a ROR ⁇ to an effective amount of a compound of the present invention to inhibit said ROR ⁇ .
  • the compounds of the present invention can reduce the amount of interleukin-17 (IL-17) and other effector cytokines of Th17 cells, in a subject.
  • IL-17 is a cytokine that affects numerous biological functions, including inducing and mediating pro-inflammatory responses.
  • another aspect of the invention provides a method of reducing the amount of IL-17 and other effector cytokines of Th17 cells, in a subject. The method comprises administering to a subject an effective amount of a compound of the present invention to reduce the amount of IL-17 and other effector cytokines of Th17 cells, in the subject.
  • administering the compound reduces the amount of IL-17 and other effector cytokines produced by Th17 cells, in the subject.
  • a change in the amount of IL-17 and other effector cytokines produced by, for example, Th17 cells can be measured using procedures described in the literature, such as an ELISA assay or intracellular staining assay.
  • compound of the present invention may inhibit the synthesis of IL-17 and other effector cytokines of Th17 cells, in a subject.
  • another aspect of the invention provides a method of inhibiting the synthesis of IL-17 and other effector cytokines of Th17 cells, in a subject.
  • the method comprises administering to a subject an effective amount of a compound of the present invention to inhibit the synthesis of IL-17 and other effector cytokines of Th17 cells, in the subject.
  • the subject is a human.
  • the method(s) of treatment of the present patent application comprise administering a safe and effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof to a patient (particularly a human) in need thereof.
  • the term ‘compound(s)’ comprises the compounds disclosed in the present invention.
  • the term ‘compound(s)’ comprises the compounds of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • the term “optionally substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamin
  • alkyl refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, and which is attached to the rest of the molecule by a single bond.
  • the alkane radical may be straight or branched.
  • C 1 -C 6 alkyl refers to a monovalent, straight, or branched aliphatic group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neo-pentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, and the like).
  • alkenyl refers to an aliphatic group containing at least one double bond and is intended to include both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the alkenyl group.
  • alkenyl groups are, but not limited to, ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl.
  • the substituents may occur on one or more carbons that are included or not included in one or more double bonds.
  • substituents include all those contemplated for alkyl groups, as discussed below, except where stability is prohibitive.
  • substitution of alkenyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups is contemplated.
  • alkynyl refers to an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the alkynyl group.
  • alkynyl groups are, but not limited to, ethynyl, propyn-1-yl or propyn-2-yl.
  • the substituents may occur on one or more carbons that are included or not included in one or more triple bonds.
  • substituents include all those contemplated for alkyl groups, as discussed above, except where stability is prohibitive.
  • substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups is contemplated.
  • alkoxy refers the radical —O-alkyl, wherein the alkyl is as defined above.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and heptyloxy.
  • the alkyl portion of the alkoxy may be optionally substituted.
  • alkoxyalkyl refers the radical -alkyl-O-alkyl, wherein the alkyl group is further substituted by alkoxy.
  • Representative examples of alkoxyalkyl include, but are not limited to, methoxymethyl, methoxyethyl, ethoxymethyl, isopropoxymethyl and ethoxy ethyl.
  • aryl alone or in combination with other term(s) means a carbocyclic aromatic system containing one or more rings wherein such rings may be fused.
  • fused means that the second ring is attached or formed by having two adjacent atoms in common with the first ring.
  • fused is equivalent to the term “condensed”.
  • an aryl group typically has from 6 to about 14 carbon atoms but the invention is not limited in that respect.
  • (C 6 -C 12 ) aryl refers to an aryl group having six to twelve carbon atoms. Examples of aryl groups include but are not limited to phenyl, naphthyl, indanyl, and the like. Unless otherwise specified, all aryl groups described herein may be optionally substituted.
  • cycloalkyl refers to C 3 -C 10 saturated cyclic hydrocarbon ring.
  • a cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • a cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls.
  • halo or halogen alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
  • haloalkyl means alkyl substituted with one or more halogen atoms, wherein the alkyl groups are as defined above.
  • halo is used herein interchangeably with the term “halogen” means F, Cl, Br or I.
  • haloalkyl include but are not limited to fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
  • haloalkoxy refers the radical —O-haloalkyl, wherein the haloalkyl is as defined above.
  • Representative examples of haloalkoxy include, but are not limited to, fluoromethoxy, trifluoromethoxy and 2-fluoroethoxy.
  • aminoalkyl refers to an alkyl group substituted with an amino group.
  • hydroxyalkyl refers to an alkyl as defined above, having one or more of the available hydrogen of the alkyl replaced by a hydroxyl group.
  • a hydroxyalkyl includes, but are not limited to, —CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH and —C(OH)(CH 3 )(CH 3 ).
  • heterocyclyl includes definitions of “heterocycloalkyl” and “heteroaryl”.
  • the heterocyclyl may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted.
  • heterocycloalkyl refers to a non-aromatic, saturated or partially saturated, monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or heterogroup selected from O, N, S, S(O), S(O) 2 , NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur.
  • Heterocycloalkyl include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, benzodioxolyl, tetrahydroisoquinolinonyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, dioxidothiomorpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl, 2-aza-bicyclo[2.2.2]
  • heteroaryl refers to an aromatic heterocyclic ring system containing 5 to 20 ring atoms, suitably 5 to 10 ring atoms, which may be a single ring (monocyclic) or multiple rings (bicyclic, tricyclic or polycyclic) fused together or linked covalently.
  • the rings may contain from 1 to 5 heteroatoms selected from N, O and S, wherein the N or S atom is optionally oxidized, or the N atom is optionally quarternized. Any suitable ring position of the heteroaryl moiety may be covalently linked to the defined chemical structure.
  • heteroaryl examples include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, oxadiazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridazinone, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, tetrahydroi soquinolinonyl, pyrazolyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazoliny
  • salts prepared from pharmaceutically acceptable bases or acids including inorganic or organic bases and inorganic or organic acids include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulf
  • the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions ⁇ e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives.
  • stabilizers and adjuvants known in literature.
  • stereoisomers refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of formula (I), wherever they are chiral or when they bear one or more double bond.
  • the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
  • SEA Syndrome refers to Seronegative Enthesopathy and Arthropathy Syndrome.
  • treating or “treatment” of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • subject includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • domestic animals e.g., household pets including cats and dogs
  • non-domestic animals such as wildlife.
  • the term “therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to effect such treatment.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • work-up includes distribution of the reaction mixture between the organic and aqueous phase indicated within parentheses, separation of layers and drying the organic layer over sodium sulphate, filtration and evaporation of the solvent.
  • Purification includes purification by silica gel chromatographic techniques, generally using ethyl acetate/hexane mixture of a suitable polarity as the mobile phase. Use of a different eluent system is indicated within parentheses.
  • Step-iii ethyl 2-(4-(ethylthio)phenyl)acetate
  • Step-ii Synthesis of 2,2,2-trichloro-1-(1-(2,2-diethoxyethyl)-1H-pyrrol-2-yl)ethan-1-one
  • Step-ii Synthesis of tert-butyl 2-cyano-2-(5-(ethylthio)pyridin-2-yl)acetate
  • Step-iii Synthesis of 2-(5-(ethylthio)pyridin-2-yl)acetonitrile
  • Step-ii Synthesis of 6-bromo-3-methoxy-4-methylpyridazine and 3-bromo-6-methoxy-4-methylpyridazine
  • Step i Synthesis of 1-((3-chloropyrazin-2-yl)amino)propan-2-ol
  • Step ii Synthesis of 1-((3-chloropyrazin-2-yl)amino)propan-2-one
  • Step-iii Synthesis of 8-chloro-3-(trifluoromethyl)imidazo[1,2-a]pyrazine
  • Step-ii Synthesis of Step-ii: Synthesis of 3-cyclopropylimidazo[1,2-a]pyrazin-8-ol
  • 3-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine (1.2 g, 6.0 mmol) was dissolved in 48% HBr in water (10 mL) and stirred at 60° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was azeotroped with toluene to get 3-cyclopropylimidazo[1,2-a]pyrazin-8-ol (1.0 g, 91%).
  • Step-iii Synthesis of 8-chloro-3-cyclopropylimidazo[1,2-a]pyrazine
  • Step-i Synthesis of methyl 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate
  • Step-ii Synthesis of 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid
  • Step-iii Synthesis of 7,8-dihydroquinoline-2,5(1H,6H)-dione 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid (8.5 g, 41 mmol) was taken in an RB fitted with a condenser was heated on a heating mantle till it melts. Then the molten reaction mixture was cooled to room temperature, dissolved in 10% methanol in DCM. This solution was filtered and the filtrate was concentrated to get the title compound (5 g, 74.7%). LC-MS: 164.0 [M+H] + .
  • Step-ii Synthesis of 3-hydroxy-8-oxo-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
  • This intermediate was prepared according to the protocol described in the synthesis of Intermediate-36 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Step-ii Synthesis of 2-chloro-6-(6-methoxypyridin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Step-ii 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-7,8-dihydroquinolin-5(6H)-one
  • Step-iii 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Step-i Synthesis of 2-chloro-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydro quinolin-5(6H)-one
  • Step-ii Synthesis of 2-chloro-4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-7,8-dihydroquinolin-5(6H)-one
  • the present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds according to the invention.
  • Step-i Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-((4-methoxybenzyl)oxy)pyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • Step-ii Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • Step-iii Synthesis of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-methoxy-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Step-v Synthesis of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydro quinolin-2-yl trifluoromethanesulfonate
  • Step-vi Synthesis of N-(6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methytl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl trifluoromethanesulfonate was coupled using the same protocol as explained in Example-1.
  • This compound was prepared by procedure similar to the one described in Example-3 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Step-i Synthesis of 2-amino-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Step-ii Synthesis of 2-amino-6-(6-chloropyridazin-3-yl)-4,6-dimethyl-7,8-dihydro quinolin-5(6H)-one
  • Step-iii Synthesis of 2-amino-6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Step-iv N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydro quinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • the reaction mixture was washed with water.
  • the organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product.
  • the crude product was purified by flash column chromatography (50-100% ethyl acetate in hexane) to get N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (0.04 g, 30%).
  • Step-ii 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxylic acid
  • Step-iii 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide
  • the organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product.
  • the crude product was purified by flash column chromatography (0-2% methanol in chloroform) to get 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide (0.11 g, 32%).
  • Step-ii Synthesis of 2-(2,6-dimethylpyrimidin-4-yl)-6-methoxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one
  • Step-iii Synthesis of 2-(2,6-dimethylpyrimidin-4-yl)-6-hydroxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one
  • Step-v Synthesis of N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • reaction mixture was purged with nitrogen for 15 min and then heated to 100° C. for 12 h.
  • the reaction was quenched with ice water, extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get the title compound (0.06 g, 12.6%).
  • Enantiomeric mixture of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide was separated by chiral preparative HPLC to obtain two separated enantiomers (Isomer-1, Compound-101 & Isomer-2, Compound-102).
  • Step-i Synthesis of methyl 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylate
  • Step-ii Synthesis of 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylic acid
  • Step-iii Synthesis of 7-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxamide
  • ROR gamma radioligand binding was performed using 3 H 25-Hydroxycholesterol in a competitive displacement assay using dextran charcoal method.
  • 5 nM 3 H 25-Hydroxycholesterol with 300 ng ROR ⁇ LBD (in house expressed in E.coli ) along with the compound were incubated in the binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.01% BSA and 5 mM MgCl 2 ) for 30 min at room temperature.
  • dextran-charcoal mixture (0.5% charcoal: 0.05% dextran
  • Dose response curves were generated for 10 compound concentrations using GraphPad Prism software Version 5 (San Diego, Calif., USA) using non-linear regression curve fit for sigmoidal dose response (variable slope).
  • the Ligand Binding Domain (LBD) of ROR gamma was cloned into pFN26A (BIND) hRluc-neo Flexi vector (Promega) which expresses a fusion protein comprised of a DNA binding domain of the yeast GAL4 gene, a linker segment and ROR gamma ligand binding domain.
  • BIND pFN26A
  • hRluc-neo Flexi vector Promega
  • the selected compounds were screened at 1 ⁇ M/10 ⁇ M concentration followed by IC 50 measurement and the results are summarized in the Table-1 below along with IC 50 (nM) details for selected compounds.
  • the IC 50 values of the selected compounds are set forth in below table wherein “A” refers to an IC 50 value of less than 150 nM, “B” refers to an IC 50 value in a range of 150-300 nM and C refers to an IC 50 value of greater than 300 nM.
  • ROR ⁇ ligand binding assay binding assay: ROR ⁇ ligand Compound % inhibition % inhibition @ binding assay: No. @1 ⁇ M 10 ⁇ M IC 50 (nM) 2 84 89 A 6 72 96 B 7 91 100 A 9 90 100 A 11 25 71 — 12 — — A 14 0 26 — 15 95 92 A 16 86 93 B 17 92 96 — 19 98 98 B 20 76 95 — 21 94 92 B 22 76 95 A 26 65 99 C 28 77 100 B 29 84 91 B 31 90 88 A 34 74 97 C 35 80 98 B 40 44 88 — 41 47 82 — 42 94 92 A 43 82 — A 45 66 73 — 46 56 92 C 47 82 98 A 49 93 82 B 50 91 90 A 56 96 94 A 61 90 74 A 62 96 91 A 84
  • IC 50 values of ROR ⁇ luciferase reporter assay for selected compounds are set forth in the Table-2 below wherein “A” refers to an IC 50 value of less than 100 nM, “B” refers to an IC 50 value in a range of 100-500 nM and C refers to an IC 50 value of greater than 500 nM.
  • ROR ⁇ luciferase Reporter assay IC 50 (nM) (in range) Compound No. A 15, 16, 17, 21, 29, 31, 45, 51, 52, 56, 64, 65, 66, 72, 74, 81, 105, 110, 113, 115, 118, 120, 125 and 129. B 2, 6, 7, 9, 12, 20, 22, 26, 28, 35, 49, 50, 58, 60, 68, 71, 75, 76, 77, 78, 83, 92, 96, 98, 104, 107, 112, 124 and 134.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Description

  • This application claims the benefit of Indian provisional application number 2448/CHE/2015, filed on May 15, 2015; the specifications of which are hereby incorporated by reference in their entirety.
    • FIELD OF THE INVENTION
  • This invention relates to compounds useful for the treatment of diseases and/or disorder associated with Retinoic acid receptor-related orphan receptors (RORs), and more particularly compounds that modulate the function of RORγ. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of diseases and/or disorder associated with RORγ.
    • BACKGROUND OF THE INVENTION
  • Retinoid-related orphan receptors (RORs) are transcription factors which belong to the steroid hormone nuclear receptor super family (Jetten & Joo, Adv. Dev. Biol. 16:313-355, 2006). Several nuclear receptors are still characterized as orphan receptors because the identification of ligands for these receptors is still elusive or controversial. The ROR family consists of three members, ROR alpha (RORα), ROR beta (RORβ) and ROR gamma (RORγ), each encoded by a separate gene (RORA, RORB and RORC, respectively). RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal A/B domain, a DNA-binding domain, a hinge domain, and a ligand binding domain. Each ROR gene generates several isoforms which differ only in their N-terminal A/B domain. Two isoforms of RORγ have been identified: RORγ1 and RORγt (also known as RORγ2). RORγ is a term used to describe both RORγ1 and/or RORγt.
  • Upon activation by antigen-presenting cells naive T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Th1 and Th2 subtypes. A third and distinct effector subset has been identified, which plays a key role in providing immunity to bacteria and fungi at mucosal surfaces (Kastelein, et al., Ann. Rev. Immunol. 25: 221-242, 2007). This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17A/F, IL-21 and IL-22, and is named Th17 (Miossec, et al., New Eng. J. Med. 361: 888-898, 2009).
  • RORγ1 is expressed in a variety of tissues including thymus, muscle, kidney and liver, while RORγt is exclusively expressed in the cells of the immune system. RORγt is highly expressed in Th17 cells (He, et al., Immunity 9: 797-806, 1998). Studies have shown that Th17 cells are one of the important drivers of the inflammatory process in tissue-specific autoimmunity (Steinman, J. Exp. Med. 205:1517-1522, 2008; Leung, et al., Cell. Mol. Immunol. 7: 182-189, 2010). There is evidence that Th17 cells are activated during the disease process and are responsible for recruiting other inflammatory cells types, especially neutrophils, to mediate pathology in the target tissues (Korn, et al., Ann. Rev. Immunol. 27:485-517, 2009). In addition, Th17 cells or their products have been shown to be associated with the pathology of a variety of human inflammatory and autoimmune disorders including multiple sclerosis, rheumatoid arthritis, psoriasis, Crohn's disease and asthma (Jetten, Nucl. Recept. Signal. 7: e003, 2009; Manel, et al., Nat. Immunol. 9:641-649, 2008).
  • RORγt was shown to play a crucial role in non-Th17 lymphoid cells. In these studies, RORγt was critically important in innate lymphoid cells expressing Thyl, SCA-1 and IL-23R proteins. Genetic disruption of RORγ in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development (Buonocore, et al., Nature 464: 1371-1375, 2010). In addition, RORγt was shown to play a crucial role in other non-Th17 cells, such as mast cells (Hueber, et al., J Immunol. 184: 3336-3340, 2010). Finally, RORγt expression and secretion of Th17-type of cytokines was reported for Lymphoid Tissue Inducer cells, NK T-cells, NK cells (Eberl, et al., Nat. Immunol. 5: 64-73, 2004) and gamma-delta T-cells (Sutton, et al., Nat. Immunol. 31: 331-341, 2009; Louten, et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009), suggesting an important function for RORγt in these subtypes of cells.
  • Based on the role of IL-17 producing cells (either Th17 or non-Th17 cells) RORγt has been identified as a key mediator in the pathogenesis of several diseases (Louten, et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009; Annunziato et al., Nat. Rev. Rheumatol. 5: 325-331, 2009). This was confirmed using several disease models representative of autoimmune diseases. Genetic ablation of the RORγ gene in mice prevented the development of experimental autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and colitis (Ivanov, et al., Cell 126: 1121-33, 2006; Buonocore, et al., Nature 464: 1371-1375, 2010).
  • Being a critical mediator in Th17-cells and other non-Th17 cells, inhibition of RORγt is expected to have a beneficial effect on autoimmune diseases, such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease and asthma (Annunziato, et al., Nat. Rev. Immunol. 5: 325-331, 2009; Louten, et al., J Allergy Clin. Immunol. 123: 1004-1011, 2009). RORγt deficient mice show very little Th17 cells. In addition, RORγt deficiency resulted in amelioration of EAE. Inhibition of RORγt may also be beneficial in other diseases, which are characterized by increased levels of Th17 cells and/or elevated levels of Th17 hallmark cytokines such as IL-17, IL-22 and IL-23. Examples of such diseases are Kawasaki Disease (Jia, et al., Clin. Exp. Immunol. 162: 131-137, 2010) and Hashimoto's thyroiditis (Figueroa-Vega, et al., J Clin.Endocrinol.Metab. 95: 953-62, 2010).
  • RORγ inverse agonist SR2211 is a cell-permeable piperazine containing biphenyl compound that binds directly to retinoic acid receptor related orphan receptor γ (RORγ) and acts as a highly selective, inverse agonist. It is reported to block the transcriptional activity of RORγ and suppress the synthesis of IL-17 in EL-4 murine lymphoma cell line. SR2211 exhibits only a minimal effect on ROR alpha and LXR alpha activity, indicating that the functional effect is due to selective inhibition of RORγ alone.
  • The nature and relevance of Th17 cells in mouse models of cancer and human disease are known (Zou et al., Nature Reviews Immunology 10, 248-256 (April 2010)). Evidences suggest that the effector T cell subset is also involved in tumor immunology, thus giving a way to a new target for cancer therapy.
  • Thus in view of the role RORγ plays in the pathogenesis of diseases, there is a need of compounds that modulate RORγ activity, which can be used in the treatment of diseases mediated by RORγ. Disclosed herein are substituted tetrahydroquinolinone and related compounds that are useful as modulators of ROR-gamma activity.
    • SUMMARY OF THE INVENTION
  • Provided herein are substituted tetrahydroquinolinone and related compounds and pharmaceutical compositions thereof, which are useful as RORγ modulators.
  • In one aspect, the present invention provides compounds of formula (I):
  • Figure US20180200247A1-20180719-C00001
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • ring Het is heterocyclyl;
      • each Y1, Y2 and Y3 are independently CRa or N, wherein 0-2 of Y1, Y2 and Y3 are N;
      • each Z1, Z2, Z3, Z4 and Z5 are independently CRa or N, wherein 0-3 of Z1, Z2, Z3, Z4 and Z5 are N;
      • L is .—NRb—C(O)—(CRbRc)n—, .—C(O)—NRb—(CRbRc)n—, .—NRb—S(O)2—(CRbRc)n— or *—S(O)2—NRb—(CRbRc)n—; wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3;
      • each R1, R2, R6 and R7 are independently hydrogen, halo, alkyl, hydroxy, hydroxyalkyl, cyano, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, —CORd or —COORd;
      • R3 at each occurrence is independently hydroxy, halo, alkyl, alkylamino, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; alternatively, two R3 on the same carbon together form an oxo (═O) group;
      • R4 is hydrogen, alkyl or alkoxy;
      • R5 is alkyl, —(CH2)nNRbRc, hydroxyalkyl, cycloalkyl, aryl or heterocyclyl;
      • Ra is hydrogen, alkyl, alkoxy, halo, cycloalkyl or aryl;
      • Rb and Rc are each independently hydrogen, alkyl or alkoxyalkyl;
      • alternatively, Rb and Rc on the same atom together form a ring;
      • Rd is hydrogen, alkyl, alkoxy or cycloalkyl;
      • m is 0 to 3; and
      • n is 0 to 3.
  • In a further aspect, the present invention relates to pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof and processes for preparing such compositions.
  • In yet another aspect, the present invention relates to the preparation of the compounds of formula (I).
  • In yet another aspect of the present invention, it provides substituted tetrahydroquinolinone and related compounds of formula (I), which are used for the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by steroid hormone nuclear receptors—particularly RORs, more particularly RORγ.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides substituted tetrahydroquinolinone and related compounds which are useful for treatment of disease(s) or disorder(s) associated with Retinoic acid receptor-related orphan receptors (RORs), and more particularly compounds that modulate the function of RORγ.
  • Each embodiment is provided by way of explanation of the invention, and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the compounds, compositions, and methods described herein without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be applied to another embodiment to yield a still further embodiment. Thus it is intended that the present invention include such modifications and variations and their equivalents. Other objects, features, and aspects of the present invention are disclosed in, or are obvious from, the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not to be construed as limiting the broader aspects of the present invention.
  • In certain embodiments, the present invention relates to compounds of formula (I):
  • Figure US20180200247A1-20180719-C00002
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • ring Het is heterocyclyl;
      • each Y1, Y2 and Y3 are independently CRa or N, wherein 0-2 of Y1, Y2 and Y3 are N;
      • each Z1, Z2, Z3, Z4 and Z5 are independently CRa or N, wherein 0-3 of Z1, Z2, Z3, Z4 and Z5 are N;
      • L is .—NRb—C(O)—(CRbRc)n—, .—C(O)—NRb—(CRbRc)n—, .—NRb—S(O)2—(CRbRc)n— or .—S(O)2—NRb—(CRbRc)n—; wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3;
      • each R1, R2, R6 and R7 are independently hydrogen, halo, alkyl, hydroxy, hydroxyalkyl, cyano, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, —CORd or —COORd;
      • R3 at each occurrence is independently hydroxy, halo, alkyl, alkylamino, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; alternatively, two R3 on the same carbon together form an oxo (═O) group;
      • R4 is hydrogen, alkyl or alkoxy;
      • R5 is alkyl, —(CH2)nNRbRc, hydroxyalkyl, cycloalkyl, aryl or heterocyclyl;
      • Ra is hydrogen, alkyl, alkoxy, halo, cycloalkyl or aryl;
      • Rb and Rc are each independently hydrogen, alkyl or alkoxyalkyl;
      • alternatively, Rb and Rc on the same atom together form a ring;
      • Rd is hydrogen, alkyl, alkoxy or cycloalkyl;
      • m is 0 to 3; and
      • n is 0 to 3.
  • In certain embodiments, the present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein,
      • ring Het is heterocyclyl;
      • Y1, Y2 and Y3 are each independently CRa or N, wherein 0-2 of Y1, Y2 and Y3 are N;
      • Z1, Z2, Z3, Z4 and Z5 are each independently CRa or N, wherein 0-3 of Z1, Z2, Z3, Z4 and Z5 are N;
      • L is .—NRb—C(O)—(CRbRc)n— or .—C(O)—NRb—(CRbRc)n—; wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3;
      • R1, R2, R6 and R7 are each independently hydrogen, halo or alkyl;
      • R3 at each occurrence is independently hydroxy, halo, alkyl, alkylamino, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; alternatively, two R3 on the same carbon together form an oxo (═O) group;
      • R4 is hydrogen, alkyl or alkoxy;
      • R5 is alkyl, —(CH2)nNRbRc or hydroxyalkyl;
      • Ra is hydrogen, alkyl, alkoxy, halo, cycloalkyl or aryl;
      • Rb and Rc are each independently hydrogen or alkyl;
      • alternatively, Rb and Rc on the same atom together form a ring;
      • m is 0 to 3; and
      • n is 0 to 3.
  • In certain embodiments, the present invention relates to compounds of formula (IA):
  • Figure US20180200247A1-20180719-C00003
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • ring Het, R1, R2, R3, R4, R5, R6, R7, Ra, L, Z1, Z2, Z3, Z4, Z5 and m are same as defined in formula (I).
  • In certain embodiments, the present invention relates to compounds of formula (IB):
  • Figure US20180200247A1-20180719-C00004
      • or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
      • ring Het, R1, R2, R3, R4, R5, Y1, Y2, Y3 and m are same as defined in formula (I).
        In certain embodiments, the present invention relates to compounds of formula (IC):
  • Figure US20180200247A1-20180719-C00005
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • ring Het, R1, R2, R3, R4, R5, Ra and m are same as defined in formula (I).
        In certain embodiments, the present invention relates to compounds of formula (ID):
  • Figure US20180200247A1-20180719-C00006
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • L, R1, R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5 and m are same as defined in formula (I).
        In certain embodiments, the present invention relates to compounds of formula (IE):
  • Figure US20180200247A1-20180719-C00007
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • L, R1 R2, R3, R4, R5, Z1, Z2, Z3, Z4, Z5 and m are same as defined in formula (I).
        In certain embodiments, the present invention relates to compounds of formula (IF):
  • Figure US20180200247A1-20180719-C00008
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • L, R1 R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5 and m are same as defined in formula (I).
        In certain embodiments, the present invention relates to compounds of formula (IG):
  • Figure US20180200247A1-20180719-C00009
      • or a pharmaceutically acceptable salt or a stereoisomer thereof;
        wherein,
      • L, R1 R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4 and Z5 are same as defined in formula (I).
  • In accordance with any of the foregoing embodiments, in certain embodiments, ring Het is monocyclic or bicyclic heterocyclic ring.
  • In yet further embodiments, the ring Het is pyridyl, pyridazinyl, pyridazinone, pyrimidinyl, pyrazinyl, pyrazolyl, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl, imidazopyridazinyl or tetrahydroisoquinolinonyl.
  • In yet further embodiments, the ring Het is pyrazinyl, pyridazinone, pyrazolyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl or tetrahydroisoquinolinonyl.
  • In yet further embodiments, the ring Het is pyridyl.
  • In yet further embodiments, the ring Het is pyridazinyl.
  • In yet further embodiments, the ring Het is pyrimidinyl.
  • In yet further embodiments, the ring Het is imidazopyrazinyl.
  • In yet further embodiments, the ring Het comprises its N-Oxides thereof.
  • In certain embodiments, 0-2 of Y1, Y2 and Y3 are N.
  • In yet further embodiments,
  • Figure US20180200247A1-20180719-C00010
  • In certain embodiments, each Z1, Z2, Z3, Z4 and Z5 are CH.
  • In yet further embodiments,
  • Figure US20180200247A1-20180719-C00011
  • In yet further embodiments, L is .—NHCOCH2— or .—CONHCH2— wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R1 and R2 are independently hydrogen.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R1 and R2 are independently alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. methyl, ethyl or isopropyl).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R1 is hydrogen and R2 is alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. methyl).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is alkoxy, in another embodiment the alkoxy is methoxy or isopropyloxy.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is haloalkyl, in another embodiment the haloalkyl is —CF3.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is hydroxy.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. methyl, ethyl or isopropyl).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is halo, in another embodiment the halo is —F or —Cl.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), two R3 on the same carbon together form an oxo (═O) group.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is haloalkyloxy, in another embodiment the haloalkyloxy is —OCF3.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R3 is cycloalkyl, in another embodiment the cycloalkyl is cyclopropyl.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R4 is alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. —CH3 or —C2H5).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R4 is hydrogen.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R5 is alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. —CH3 or —C2H5).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), Ra is hydrogen.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), Ra is alkyl, in another embodiment the alkyl is C1-C6 alkyl (e.g. methyl or ethyl).
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), Ra is halo, in another embodiment the halo is fluoro.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), R6 and R7 are independently hydrogen.
  • In certain embodiments of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), m is 1 or 2.
  • In certain embodiments, the present invention provides a compound selected from the group consisting of:
  • Compound
    No. IUPAC Name
    1 N-(4,6-dimethyl-5-oxo-6-(pyridin-2-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-
    (ethylsulfonyl)phenyl)acetamide;
    2 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-3-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    3 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(6-(trifluoromethyl)pyridin-3-
    yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    4 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridin-2-yl)-7,7-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    5 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridin-2-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    6 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    7 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    8 N-(6-methyl-5-oxo-6-(5-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    9 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    10 N-(6-(5-chloropyridin-2-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-
    (methylsulfonyl)phenyl)acetamide;
    11 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-3,6-dimethyl-5-
    oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    12 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    13 N-(6-(imidazo[1,2-a]pyridin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    14 N-(6-ethyl-6-(imidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-
    2-(4-(ethylsulfonyl)phenyl)acetamide;
    15 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(pyrrolo[1,2-a]pyrazin-1-yl)-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    16 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    17 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    18 N-(4,6-dimethyl-5-oxo-6-(pyridin-3-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-
    (ethylsulfonyl)phenyl)acetamide;
    19 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    20 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    21 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyrimidin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    22 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    23 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoropyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    24 N-(6-(5-chloro-3-methoxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    25 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidin-5-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    26 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-4,6-dimethyl-5-
    oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    27 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrazin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    28 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    29 N-(6-(4,6-dimethylpyrimidin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    30 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidin-4-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    31 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    32 N-(4,6-dimethyl-5-oxo-6-(5-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    33 N-(6-(imidazo[1,2-a]pyrazin-8-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    34 N-(4,6-dimethyl-6-(6-methylpyridazin-3-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    35 N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    36 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-hydroxypyrimidin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    37 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-4-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    38 N-(6-(5-chloro-3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    39 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    40 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridin-3-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)acetamide;
    41 N-(6-(6-ethylpyridazin-3-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-
    (4-(ethylsulfonyl)phenyl)acetamide;
    42 N-(6-(benzo[d][1,3]dioxol-5-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    43 N-(4,6-dimethyl-6-(1-methyl-1H-benzo[d]imidazol-5-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    44 N-(4,6-dimethyl-6-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    45 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(5-methylthiophen-2-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)acetamide;
    46 N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    47 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(1H-pyrazol-1-yl)-5,6,7,8-
    tetrahydroquinolin-2-yl)acetamide;
    48 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-6,8-dimethyl-5-
    oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    49 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    50 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-isopropylpyrimidin-4-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    51 N-(6-(2,6-dimethylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    52 N-(4,6-dimethyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    53 N-(4,6-dimethyl-5-oxo-6-(6-(trifluoromethyl)pyridazin-3-yl)-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    54 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-7-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    55 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(6-(trifluoromethyl)pyridazin-3-
    yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    56 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    57 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropoxypyridazin-3-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    58 2-(4-(ethylsulfonyl)-2-fluorophenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-
    a]pyrazin-8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    59 N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    60 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-isopropylpyrazin-2-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    61 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    62 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropylpyridazin-3-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    63 N-(6-(6-ethylpyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-
    2-(4-(ethylsulfonyl)phenyl)acetamide;
    64 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    65 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    66 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-
    6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    67 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methyl-6-(trifluoromethyl)-
    pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    68 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(5-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    69 N-(6-(2,6-dimethylpyrimidin-4-yl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    70 N-(4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    71 N-(6-(3-cyclopropylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    72 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(2-(trifluoromethyl)-
    imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    73 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    74 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3-(trifluoromethyl)-
    imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    75 N-(4,6-dimethyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    76 N-(6-(5-cyclopropyl-6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    77 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-b]pyridazin-6-yl)-4,6-dimethyl-5-
    oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    78 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methyl-2-(trifluoromethyl)-
    pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    79 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide;
    80 2-(5-(ethylsulfonyl)pyridin-2-yl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-
    oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    81 N-(6-(2,6-dimethylpyrimidin-4-yl)-6,7-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    82 N-(6-(2,6-dimethylpyrimidin-4-yl)-7-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    83 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinolin-
    3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    84 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    85 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    86 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxy-4-methylpyridin-3-yl)-4,6-dimethyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    87 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-7,7-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    88 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    89 N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(methylsulfonyl)phenyl)acetamide;
    90 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridin-2-yl)-7,7-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    91 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-7-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)acetamide;
    92 N-(6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    93 N-(6-(6-chloropyridazin-3-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-
    (4-(ethylsulfonyl)phenyl)acetamide;
    94 3-(2-(2-(4-(ethylsulfonyl)phenyl)acetamido)-4,6-dimethyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-6-yl)-6-methoxypyridazine 1-oxide;
    95 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-4-methylpyridazin-3-yl)-4,6-
    dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    96 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-5-methylpyridazin-3-yl)-4,6-
    dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    97 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    98 N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    99 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinoline-2-carboxamide;
    100 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    101 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-84);
    102 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-84);
    103 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-7);
    104 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-7);
    105 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-9);
    106 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-9);
    107 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-28);
    108 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-28);
    109 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-31);
    110 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-31);
    111 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-56);
    112 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-56);
    113 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-49);
    114 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-49);
    115 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-65);
    116 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-65);
    117 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-16);
    118 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin-8-yl)-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-16);
    119 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-64);
    120 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-64);
    121 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3-(trifluoromethyl)imidazo[1,2-
    a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of
    Compound-74);
    122 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3-(trifluoromethyl)imidazo[1,2-
    a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of
    Compound-74);
    123 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide; (Isomer-1 of Compound-79);
    124 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-
    yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide; (Isomer-2 of Compound-79);
    125 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinoline-2-carboxamide; (Isomer-1 of Compound-99);
    126 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-
    5,6,7,8-tetrahydroquinoline-2-carboxamide; (Isomer-2 of Compound-99);
    127 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinolin-
    3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-83);
    128 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinolin-
    3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-83);
    129 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-
    6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    130 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-
    6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    131 N-(6-(6-ethyl-2-methylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    132 N-(6-(2-ethyl-6-methylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-
    tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    133 N-(6-(2,6-diethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-
    2-(4-(ethylsulfonyl)phenyl)acetamide;
    134 7-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-methyl-8-oxo-
    5,6,7,8-tetrahydroisoquinoline-3-carboxamide;
    135 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-4,6-
    dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    136 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroquinolin-3-
    yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    137 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinazolin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    138 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoxalin-
    2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide;
    139 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methyl-6-(trifluoromethoxy)-
    pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide;
    140 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-isopropyl-5-oxo-
    5,6,7,8-tetrahydroquinoline-2-carboxamide;
    141 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-8-isopropyl-5-oxo-
    5,6,7,8-tetrahydroquinoline-2-carboxamide; and
    142 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-isopropyl-6-methyl-
    5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide;
  • or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • In certain embodiments, the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses. Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2H (“D”), 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36Cl, 123I and 125I. Isotopically labeled compounds of the present inventions can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • The present invention also provides a pharmaceutical composition that includes at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. The compounds described in the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • The compounds and pharmaceutical compositions of the present invention are useful for modulating the activity of RORγ, which is believed to be related to a variety of disease states.
  • The present invention further provides a method of modulating the function of RORγ in a subject in need thereof by administering to the subject one or more compounds described herein in the amount effective to cause inhibition of such receptor.
  • The compounds of the invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention. The pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients. Typically, the pharmaceutically acceptable excipients are approved by regulatory authorities or are generally regarded as safe for human or animal use. The pharmaceutically acceptable excipients include, but are not limited to, carriers, diluents, glidants and lubricants, preservatives, buffering agents, chelating agents, polymers, gelling agents, viscosifying agents, solvents and the like.
  • Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.
  • The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, suspending agents, preserving agents, buffers, sweetening agents, flavouring agents, colorants or any combination of the foregoing.
  • The pharmaceutical compositions may be in conventional forms, for example, tablets, capsules, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.
  • Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted routes of administration of pharmaceutical compositions. The route of administration may be any route which effectively transports the active compound of the patent application to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous, intravenous, intraurethral, intramuscular or topical.
  • Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges.
  • Liquid formulations include, but are not limited to, syrups, emulsions, and sterile injectable liquids, such as suspensions or solutions.
  • Topical dosage forms of the compounds include ointments, pastes, creams, lotions, powders, solutions, eye or ear drops, impregnated dressings, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration.
  • The pharmaceutical compositions of the present patent application may be prepared by conventional techniques known in literature.
  • Suitable doses of the compounds for use in treating the diseases or disorders described herein can be determined by those skilled in the relevant art. Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms, and suitable pharmaceutical excipients can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present patent application.
  • Compounds of the present invention are particularly useful because they may modulate the activity of Retinoid-related orphan receptor gamma (RORγ), i.e., they prevent, inhibit, or suppress the action of RORγ, and/or may elicit RORγ modulating effect. Compounds of the invention are thus useful in the treatment of those conditions in which inhibition of a ROR gamma activity is required.
  • In certain embodiments, the present invention provides a method of treating a RORγ mediated disorder or disease in a subject comprising administering to a subject in need thereof a compound of the present invention.
  • In certain embodiments, the present invention provides a method comprising conjointly administering to the subject a second therapeutic agent.
  • In certain embodiments, the present invention provides a method of reducing amount of IL-17 and other effector cytokines of Th17 cells in a subject, comprising administering to the subject a compound of the present invention.
  • It is contemplated that compounds disclosed in the present invention, provide therapeutic benefits to subjects suffering from immune or inflammatory disorder or disease. Accordingly, one embodiment of the invention provides a method of treating a disorder or disease selected from the group consisting of immune or inflammatory disorder or disease. The method comprises administering a therapeutically effective amount of a compound of the present invention, to a subject in need thereof to ameliorate a symptom of a RORγ mediated disorder or disease.
  • In certain embodiments, the disorder or disease is an immune disorder or disease.
  • In certain embodiments, the disorder or disease is an inflammatory disorder or disease.
  • In certain embodiments, the disorder or disease is an autoimmune disorder or disease.
  • In certain embodiments, the disorder or disease is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, asthma, epidermal hyperplasia, scleroderma or ulcerative colitis.
  • In certain embodiments, the disorder or disease is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, or an immune disorder or disease associated with or arising from activity of pathogenic lymphocytes.
  • In certain embodiments, the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis or erythrodermic psoriasis.
  • In certain embodiments, the disorder or disease is rheumatoid arthritis.
  • In certain embodiments, the subject is a mammal, e.g., a human.
  • In certain embodiments, the present invention provides compounds for use as a medicament.
  • In certain embodiments, the invention provides the use of the compounds of the present invention in the manufacture of a medicament.
  • In certain embodiments, the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of an immune disorder or an inflammatory disorder or disease.
  • In certain embodiments, the present invention provides compounds for use as a medicament.
  • In certain embodiments, the medicament is for treating a disease or disorder mediated by RORγ.
  • In certain embodiments, the present invention provides compounds for use as a medicament for the treatment of an immune or an inflammatory disorder or disease.
  • Further, it is contemplated that the compounds of the present invention can inhibit the activity of RORγ. Accordingly, another embodiment of the invention provides a method of inhibiting the activity of RORγ. The method comprises exposing a RORγ to an effective amount of a compound of the present invention to inhibit said RORγ.
  • Also, it is contemplated that the compounds of the present invention can reduce the amount of interleukin-17 (IL-17) and other effector cytokines of Th17 cells, in a subject. IL-17 is a cytokine that affects numerous biological functions, including inducing and mediating pro-inflammatory responses. Accordingly, another aspect of the invention provides a method of reducing the amount of IL-17 and other effector cytokines of Th17 cells, in a subject. The method comprises administering to a subject an effective amount of a compound of the present invention to reduce the amount of IL-17 and other effector cytokines of Th17 cells, in the subject.
  • In certain embodiments, administering the compound reduces the amount of IL-17 and other effector cytokines produced by Th17 cells, in the subject. A change in the amount of IL-17 and other effector cytokines produced by, for example, Th17 cells can be measured using procedures described in the literature, such as an ELISA assay or intracellular staining assay.
  • Further, it is contemplated that compound of the present invention may inhibit the synthesis of IL-17 and other effector cytokines of Th17 cells, in a subject.
  • Accordingly, another aspect of the invention provides a method of inhibiting the synthesis of IL-17 and other effector cytokines of Th17 cells, in a subject. The method comprises administering to a subject an effective amount of a compound of the present invention to inhibit the synthesis of IL-17 and other effector cytokines of Th17 cells, in the subject.
  • In certain embodiments, the subject is a human.
  • The method(s) of treatment of the present patent application comprise administering a safe and effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof to a patient (particularly a human) in need thereof.
  • Compounds of the invention are indicated both in the therapeutic and/or prophylactic treatment of the above-mentioned conditions. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder or disease indicated.
    • Definitions and Abbreviations:
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning and the meaning of such terms is independent at each occurrence thereof and is as commonly understood by one of skill in art to which the subject matter herein belongs. That notwithstanding and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “hydroxyalkyl,” “haloalkyl,” “—O-alkyl,” etc.
  • As used herein, the term ‘compound(s)’ comprises the compounds disclosed in the present invention. Preferably, the term ‘compound(s)’ comprises the compounds of formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof.
  • As used herein, the term “optionally substituted” refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic and aliphatic. It is understood that the substituent may be further substituted.
  • As used herein, the term “alkyl” refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, and which is attached to the rest of the molecule by a single bond. The alkane radical may be straight or branched. For example, the term “C1-C6 alkyl” refers to a monovalent, straight, or branched aliphatic group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neo-pentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, and the like).
  • As used herein, the term “alkenyl”, as used herein, refers to an aliphatic group containing at least one double bond and is intended to include both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the alkenyl group. Examples of alkenyl groups are, but not limited to, ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl. The substituents may occur on one or more carbons that are included or not included in one or more double bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed below, except where stability is prohibitive. For example, substitution of alkenyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups is contemplated.
  • As used herein, the term “alkynyl”, as used herein, refers to an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the alkynyl group. Examples of alkynyl groups are, but not limited to, ethynyl, propyn-1-yl or propyn-2-yl. The substituents may occur on one or more carbons that are included or not included in one or more triple bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed above, except where stability is prohibitive. For example, substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups is contemplated.
  • As used herein, the term “alkoxy” refers the radical —O-alkyl, wherein the alkyl is as defined above. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and heptyloxy. The alkyl portion of the alkoxy may be optionally substituted.
  • As used herein, the term “alkoxyalkyl” refers the radical -alkyl-O-alkyl, wherein the alkyl group is further substituted by alkoxy. Representative examples of alkoxyalkyl include, but are not limited to, methoxymethyl, methoxyethyl, ethoxymethyl, isopropoxymethyl and ethoxy ethyl.
  • As used herein, the term “aryl” alone or in combination with other term(s) means a carbocyclic aromatic system containing one or more rings wherein such rings may be fused. The term “fused” means that the second ring is attached or formed by having two adjacent atoms in common with the first ring. The term “fused” is equivalent to the term “condensed”. Unless otherwise specified, an aryl group typically has from 6 to about 14 carbon atoms but the invention is not limited in that respect. The term (C6-C12) aryl refers to an aryl group having six to twelve carbon atoms. Examples of aryl groups include but are not limited to phenyl, naphthyl, indanyl, and the like. Unless otherwise specified, all aryl groups described herein may be optionally substituted.
  • As used herein, the term “cycloalkyl” refers to C3-C10 saturated cyclic hydrocarbon ring. A cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls.
  • As used herein, the term “halo” or “halogen” alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
  • As used herein, the term “haloalkyl” means alkyl substituted with one or more halogen atoms, wherein the alkyl groups are as defined above. The term “halo” is used herein interchangeably with the term “halogen” means F, Cl, Br or I. Examples of “haloalkyl” include but are not limited to fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
  • As used herein, the term “haloalkoxy” refers the radical —O-haloalkyl, wherein the haloalkyl is as defined above. Representative examples of haloalkoxy include, but are not limited to, fluoromethoxy, trifluoromethoxy and 2-fluoroethoxy.
  • As used herein, the term “aminoalkyl” refers to an alkyl group substituted with an amino group.
  • “Hydroxy” or “hydroxyl” refers to —OH group.
  • As used herein, the term “hydroxyalkyl” refers to an alkyl as defined above, having one or more of the available hydrogen of the alkyl replaced by a hydroxyl group. For example, a hydroxyalkyl includes, but are not limited to, —CH2CH2OH, —CH2CH2CH2OH and —C(OH)(CH3)(CH3).
  • As used herein, the term “heterocyclyl” includes definitions of “heterocycloalkyl” and “heteroaryl”. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted.
  • The term “heterocycloalkyl” refers to a non-aromatic, saturated or partially saturated, monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or heterogroup selected from O, N, S, S(O), S(O)2, NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur. Examples of “Heterocycloalkyl” include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, benzodioxolyl, tetrahydroisoquinolinonyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, dioxidothiomorpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl, 2-aza-bicyclo[2.2.2]octanyl, azocinyl, chromanyl, xanthenyl and N-oxides thereof. A heterocycloalkyl group can be optionally substituted with one or more suitable groups by one or more aforesaid groups.
  • The term “heteroaryl” refers to an aromatic heterocyclic ring system containing 5 to 20 ring atoms, suitably 5 to 10 ring atoms, which may be a single ring (monocyclic) or multiple rings (bicyclic, tricyclic or polycyclic) fused together or linked covalently. The rings may contain from 1 to 5 heteroatoms selected from N, O and S, wherein the N or S atom is optionally oxidized, or the N atom is optionally quarternized. Any suitable ring position of the heteroaryl moiety may be covalently linked to the defined chemical structure. Examples of heteroaryl include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, oxadiazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridazinone, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, tetrahydroi soquinolinonyl, pyrazolyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolyl, isoquinolyl, thiadiazolyl, indolizinyl, acridinyl, phenazinyl and phthalazinyl. Unless set forth or recited to the contrary, all heteroaryl groups described or claimed herein may be substituted or unsubstituted.
  • The term “pharmaceutically acceptable salt” includes salts prepared from pharmaceutically acceptable bases or acids including inorganic or organic bases and inorganic or organic acids. Examples of such salts include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate, diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Examples of salts derived from inorganic bases include, but are not limited to, aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, potassium, sodium, and zinc.
  • As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions {e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants known in literature.
  • The term “stereoisomers” refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of formula (I), wherever they are chiral or when they bear one or more double bond. When the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
  • The term “SEA Syndrome” refers to Seronegative Enthesopathy and Arthropathy Syndrome.
  • The term “treating” or “treatment” of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • The term “subject” includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • As used herein, the term “therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to effect such treatment. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.
  • As used herein, the term “comprise” or “comprising” is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
  • As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • As used herein, the term “including” as well as other forms, such as “include”, “includes” and “included” is not limiting.
  • The abbreviations used in the entire specification may be summarized herein below with their particular meaning.
    • Xantphos—4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene; K2CO3—potassium carbonate; HATU—1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3 -oxid hexafluorophosphate; DIPEA—N,N-Diisopropylethylamine; ° C.—Degree Celsius; M+—Molecular ion; m—Multiplet; mL—Milliliter; h—Hour(s); δ—Delta; Pd/C—Palladium on activated Carbon; MS—Mass Spectroscopy; DMF—N,N-dimethyl formamide; RM—Reaction mixture; RT—Room temperature; RB/RBF—Round Bottom Flask THF—Tetrahydrofuran; Conc—Concentrated; LC-MS—Liquid Chromatography-Mass Spectroscopy; 1H or H—proton; NMR—Nuclear Magnetic Resonance; MHz—Megahertz (frequency); CDCl3—Deuterated Chloroform; CD3OD—Deuterated Methanol; Hz—Hertz; s—Singlet; br s—Broad singlet; d—Doublet; dd—doublet of doublets; td—triplet of doublets; ddd—doublet of doublet of doublets; dt—doublet of triplets; q—Quartet; t—Triplet; J—Coupling constant; DMSO-d6—Deuterated Dimethylsulfoxide; %—Percentage; H2—Hydrogen; M—Molarity; N—Normality; g—Gram; min—Minutes; mol—Moles; wt—Weight.
  • Methods for preparing compounds described herein are illustrated in the following examples. The schemes are given for the purpose of illustrating the invention, and are not intended to limit the scope or spirit of the invention. Starting materials shown in the schemes can be obtained from commercial sources or prepared based on procedures described in the literature. Furthermore, where specific acids, bases, reagents, coupling agents, solvents, etc. are mentioned, it is understood that other suitable acids, bases, reagents, coupling agents etc. may be used and are included within the scope of the present invention. Modifications to reaction conditions, for example, temperature, duration of the reaction or combinations thereof, are envisioned as part of the present invention. All possible stereoisomers are envisioned within the scope of this invention.
  • The intermediates required for the synthesis are commercially available or alternatively, these intermediates can be prepared using known literature methods. The invention is described in greater detail by way of specific examples.
  • Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phase indicated within parentheses, separation of layers and drying the organic layer over sodium sulphate, filtration and evaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographic techniques, generally using ethyl acetate/hexane mixture of a suitable polarity as the mobile phase. Use of a different eluent system is indicated within parentheses.
  • It is contemplated that some of the intermediates disclosed in the present invention are used for the next step without any characterization data.
  • The MS data provided in the examples described below were obtained as follows:
  • Mass spectrum: Shimadzu LCMS 2020; Agilent 1100; LCMSD VL and Agilent 1100; API 2000
  • The NMR data provided in the examples described below were obtained as follows:
  • 1H NMR: Varian 300 and 400 MHz.
    • Intermediates: Intermediate-1: Synthesis of 2-(4-(ethylsulfonyl)phenyl)acetamide
  • Figure US20180200247A1-20180719-C00012
    • Step-i: 2-(4-((ethoxycarbonothioyl)thio)phenyl)acetic acid
  • To a 250 mL round bottom flask, was added 4-aminophenylacetic acid (8.5 g, 52.0 mmol), water (28 mL) and conc. hydrochloric acid (11.5 mL) and then cooled to 0° C. To the same flask, aqueous sodium nitrite (3.9 g, 56.2 mmol in 28 mL of water) was added drop wise and reaction mass was stirred at 0° C. for 45 minutes. The resulting cold diazonium salt solution was added drop wise to a mixture of potassium ethylxanthate (10.4 g, 648 mmol), water (16.8 mL) and 2 M sodium carbonate (42 mL). The reaction mixture was maintained at 45° C. for 2 h. The reaction mixture was cooled to 0° C., acidified to pH 1.0 with conc. hydrochloric acid and extracted with diethyl ether. The combined organic layer was washed with water followed by brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to get crude titled compound (19 g). The crude product was used for the next step immediately without any further purification.
    • Step-ii: 2-(4-mercaptophenyl)acetic acid
  • To a 250 mL round bottom flask, was added 2-(4-((ethoxycarbonothioyl)thio)phenyl)acetic acid (19 g, 74.1 mmol) and ethanol (72 mL). To the same flask, was added a solution of potassium hydroxide (15 g, 267.0 mmol) in water (72 mL) and then refluxed for 20 h. The major portion of ethanol was evaporated under reduced pressure to get a residue. The residue was acidified to pH 2.0 with conc. hydrochloric acid at 0° C. The aqueous layer was extracted with diethyl ether. The organic layer was washed with water followed brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to get crude product (7 g). The crude product was used for next step without any further purification. LC-MS: 166.9 [M−H]+.
    • Step-iii: ethyl 2-(4-(ethylthio)phenyl)acetate
  • To a 100 mL round bottom flask, was added 2-(4-mercaptophenyl)acetic acid (7 g, 41.6 mmol), potassium carbonate (23 g, 166.4 mmol) and N,N-dimethylformamide (50 mL). To the same flask, was added ethyl bromide (13.6 g, 124.8 mmol) and stirred at room temperature for 2.5 h. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was separated and washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to obtain crude product. The crude product was purified by column chromatography using 10% ethyl acetate in hexane as eluent to get titled compound (6 g, 65%). 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J=8.0 Hz, 2H), 7.22 (d, J=8.0 Hz, 2H), 4.18 (q, J′=7.2 Hz, J″=14.4 Hz, 2H), 3.57 (s, 2H), 2.96 (q, J′=7.6 Hz, J″=14.8 Hz, 2H), 1.33 (t, J=7.6 Hz, 3H), 1.25 (t, J=7.6 Hz, 3H).
    • Step-iv: ethyl 2-(4-(ethylsulfonyl)phenyl) acetate
  • To a 250 mL round bottom flask, was added ethyl 2-(4-(ethylthio)phenyl)acetate (5.5 g, 24.5 mmol) and dichloromethane (82.5 mL). The reaction mixture was cooled to 0° C. To the same flask, was added m-chloroperbenzoic acid (12.6 g, 73.0 mmol) at 0° C. The reaction mixture was stirred at room temperature for 12 h. The resulting suspension was filtered through a pad of celite. The filtrate was washed with water followed by saturated sodium bicarbonate solution and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to get crude product. The crude product was purified by column chromatography using 60-120 mesh silica gel and 50% ethyl acetate in hexane as eluents to get titled compound (5.1 g, 82%). 1H NMR (400 MHz, DMSO-d6): δ 7.84 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.8 Hz, 2H), 4.10 (q, J′=7.2 Hz, J″=14.4 Hz, 2H), 3.83 (s, 2H), 3.31 (q, J′=7.2 Hz, J″=14.8 Hz, 2H), 1.07-1.21 (m, 6H); LC-MS: 257.2 [M+H]+.
    • Step-v: 2-(4-(ethylsulfonyl)phenyl)acetic acid
  • To a 50 mL round bottom flask, was added ethyl 2-(4-(ethylsulfonyl)phenyl)acetate (2.5 g, 9.8 mmol) and ethanol (18 mL). To the same flask, was added a solution of sodium hydroxide in water (1.42 g, 35.5 mmol in 18 mL of water) and then stirred at room temperature for 12 h. The volatiles were evaporated under reduced pressure to obtain the residue. The residue was acidified to pH 5.0 with 1.0 N hydrochloric acid and was extracted with ethyl acetate. The organic layer was separated and washed with brine, dried over sodium sulfate and evaporated under reduced pressure to get titled compound (2.4 g, 91%). 1H NMR (400 MHz, DMSO-d6): δ 12.5 (brs, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 3.74 (s, 2H), 3.13 (q, J′=7.2 Hz, J″=14.8 Hz, 2H), 1.20 (t, J=7.6 Hz, 3H).
    • Step-vi: 2-(4-(ethylsulfonyl)phenyl)acetamide
  • To a 50 mL round bottom flask, was added 2-(4-(ethylsulfonyl)phenyl)acetic acid (0.5 g, 2.3 mmol) and thionyl chloride (5 mL). The reaction mixture was stirred at room temperature for 6 h. The volatiles were evaporated under reduced pressure to get the solid. The solid was dissolved in dichloromethane (10 mL) and treated with aqueous ammonia (5 mL) at room temperature for 12 h. The volatiles were evaporated to get the crude residue. The crude residue was extracted with 10% methanol in chloroform. The combined organic phase was washed with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the titled compound (0.36 g, 72%). 1H NMR (300 MHz, DMSO-d6): δ 7.80-7.83 (m, 2H), 7.58 (br s, 1H), 7.54-7.51 (m, 2H), 7.00 (br s, 1H), 3.52 (s, 2H), 3.33 (q, J′=9.6 Hz, J″=16.8 Hz, 2H), 1.21 (t, J=7.5 Hz, 3H). LC-MS: 228.1 [M+H]+.
  • The below intermediates were prepared according to the protocol described in the synthesis of Intermediate-1 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Intermediate Characterization
    No. Structure Data
    2
    Figure US20180200247A1-20180719-C00013
         		LC-MS: 214.2 [M + H]+.
    3
    Figure US20180200247A1-20180719-C00014
         		LC-MS: 245.9 [M + H]+.
    • Intermediate-4: Synthesis of 2-iodo-3-((4-methoxybenzyl)oxy)pyridine
  • Figure US20180200247A1-20180719-C00015
  • To a mixture of 2-iodopyridin-3-ol (1.5 g, 6.7 mmol) and 1-(chloromethyl)-4-methoxybenzene (1.27 g, 8.1 mmol) in DMF (10 mL) was added potassium carbonate (1.87 g, 13.5 mmol) and heated to 80° C. for 2 h. Reaction mixture was cooled to RT, diluted with water, extracted into ethyl acetate, organic portion washed with water, brine solution, dried over sodium sulphate and concentrated to get the titled compound (2.2 g, 95%). 1H NMR (300 MHz, DMSO-d6): δ 7.98-7.99 (m, 1H), 7.36-7.40 (m, 2H), 7.12-7.16 (m, 2H), 6.89-7.03 (m, 3H), 5.1 (s, 2H), 3.81-3.80 (s, 3H). LC-MS: 342.2 [M+H]+.
  • The below intermediates were prepared according to the protocol described in the synthesis of Intermediate-4 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Intermediate
    No. Structure Characterization Data
    5
    Figure US20180200247A1-20180719-C00016
         		1H NMR (300 MHz, DMSO-d6): δ 8.07 (d, J = 2.1 Hz, 1H), 7.83 (d, J = 2.1 Hz, 1H), 7.39-7.42 (m, 2H), 6.96-6.99 (m, 2H), 5.2 (s, 2H), 3.81- 3.76 (s, 3H).
    6
    Figure US20180200247A1-20180719-C00017
         		LC-MS: 264.4 [M + H]+
    • Intermediate-7: Synthesis of 3-iodo-2-((4-methoxybenzyl)oxy)pyridine
  • Figure US20180200247A1-20180719-C00018
  • To a mixture of 2-chloro-3-iodopyridine (1 g, 4.1 mmol) and (4-methoxyphenyl)methanol (0.57 g, 4.1 mmol) in THF (10 mL), was added potassium tert-butoxide (0.7 g, 6.2 mmol) and then heated to 100° C. in a sealed tube for 2 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed with water. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to get titled compound (1.75 g). This was used as such in the next step without further purification. LC-MS: 342.1 [M+H]+.
    • Intermediate-8: Synthesis of 3-bromo-2-((4-methoxybenzyl)oxy)-6-methylpyridine
  • Figure US20180200247A1-20180719-C00019
  • This intermediate was prepared using the similar protocol described in the synthesis of Intermediate-7.
    • Intermediate-9: Synthesis of 8-chloroimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00020
  • 2-bromo-1,1-dimethoxyethane (3.7 g, 19.3 mmol) was added to a mixture of 48% hydrobromic acid and water (0.5 mL+5 mL) and refluxed for an hour. The reaction mixture was cooled to room temperature and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulphate, filtered and concentrated to get residue. This residue was dissolved in 1,2-dimethoxyethane, and added into a mixture of 3-chloropyrazin-2-amine (1 g, 7.7 mmol) and 48% Aq. HBr (0.15 mL) and refluxed for 3 h. The reaction mixture was cooled and the dark solid formed was filtered, washed with water and dried to get the titled compound. LC-MS: 154.2 [M+H]+.
    • Intermediate-10: Synthesis of 8-chloro-2-methylimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00021
  • A mixture of 3-chloropyrazin-2-amine (2 g, 15.4 mmol) and 1-chloropropan-2-one (4 mL) was heated to 90° C. for 16 h in a sealed tube. The reaction mixture was then cooled to room temperature and the solid formed was filtered, washed with ether and dried to get the titled compound (1.4 g, 53%). LC-MS: 168.3 [M+H]+.
    • Intermediate-11: Synthesis of 8-bromo-6-methylimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00022
  • A mixture of 3-bromo-5-methylpyrazin-2-amine (1 g, 5.3 mmol) in chloroacetaldehyde (5 mL) was heated to 100° C. for 1 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulphate, filtered and concentrated to get residue. The residue was purified by flash chromatography using 20% ethyl acetate in hexanes to get pure titled compound (0.6 g, 53%). 1H NMR (300 MHz, DMSO-d6): δ 8.40 (d, J=0.9 Hz, 1H), 8.02 (d, J=0.6 Hz, 1H), 7.79 (d, J=0.9 Hz, 1H), 2.37 (s, 3H).
    • Intermediate-12: Synthesis of 8-bromoimidazo[1,2-a]pyridine
  • Figure US20180200247A1-20180719-C00023
  • 8-bromoimidazo[1,2-a]pyridine was prepared by procedure similar to the one described in the synthesis of Intermediate-10 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions. LC-MS: 197.2 [M]+.
    • Intermediate-13: Synthesis of 1-bromopyrrolo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00024
    • Step-i: Synthesis of 1-(2,2-diethoxyethyl)-1H-pyrrole
  • To a solution of 1H-pyrrole (20 g, 298 mmol) in DMF (200 mL) was added 60% sodium hydride (10.7 g, 447 mmol) at 0° C. then warmed to room temperature and stirred for 10-15 minutes at the same temperature and then cooled back to 0° C. To this mixture, 2-bromo-1,1-diethoxyethane (58.5 g, 298 mmol) was added dropwise. The reaction mixture was warmed gradually to room temperature and then heated to 70° C. for 6 h. The reaction was quenched with ice-water, extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get residue which on purification by column chromatography using 10% ethyl acetate in hexane as eluent yielded the titled compound (25 g, 45.8%). LC-MS: 184.0 [M+H]+.
    • Step-ii: Synthesis of 2,2,2-trichloro-1-(1-(2,2-diethoxyethyl)-1H-pyrrol-2-yl)ethan-1-one
  • To a stirred mixture of 1-(2,2-diethoxyethyl)-1H-pyrrole (25 g, 136.6 mmol) and 2,6-lutidine (16 g, 150 mmol) in chloroform (250 mL) was added trichloroacetyl chloride (27 g, 150 mmol) over a duration of 6 h. The reaction mixture was then stirred at room temperature for 12 h. The volatiles were evaporated under reduced pressure to get crude compound which on purification by column chromatography using 10% ethyl acetate in hexane as eluent yielded the titled compound (25 g, 56%). 1H NMR (300 MHz, CDCl3): δ 7.54-7.56 (m, 1H), 7.09-7.10 (m, 1H), 6.22-6.25 (m, 1H), 4.63-4.66 (m, 3H), 4.39-4.40 (m, 2H), 3.60-3.70 (m, 2H), 3.41-3.49 (m, 2H), 1.12-1.16 (t, J=6.9 Hz, 6H).
    • Step-iii: Synthesis of 1-(2,2-diethoxyethyl)-1H-pyrrole-2-carboxamide
  • 2,2,2-trichloro-1-(1-(2,2-diethoxyethyl)-1H-pyrrol-2-yl)ethan-1-one (25 g, 76 mmol) was slowly added to a mixture of ammonium hydroxide (125 mL) and ethyl acetate (270 mL) at 0° C. The reaction mixture was then stirred at room temperature for 16 h. The reaction mixture was extracted into ethyl acetate. The organic layer was dried over sodium sulphate, filtered and concentrated to get residue which on purification by column chromatography using 30% ethyl acetate in hexane yielded the titled compound (8 g, 46.2%). 1H NMR (300 MHz, DMSO-d6): δ 7.47 (br s, 1H), 6.84-6.86 (m, 1H), 6.78-6.80 (m, 1H), 5.96-5.98 (m, 1H), 4.59-4.63 (m, 3H), 4.30-4.32 (m, 2H), 3.52-3.60 (m, 2H), 3.29-3.21-3.29 (m, 2H), 0.9-1.02 (m, 6H).
    • Step-iv: Synthesis of pyrrolo[1,2-a]pyrazin-1(2H)-one
  • A mixture of 1-(2,2-diethoxyethyl)-1H-pyrrole-2-carboxamide (3 g, 13.2 mmol) in acetic acid (30 mL) was heated to reflux for 6 h. The reaction mixture was cooled to room temperature and the volatiles were evaporated to get residue. Diethyl ether was added to this to get solid. The solid was filtered and washed with ether to get pure titled compound (1.7 g, 96.5%). LC-MS: 135.4 [M+H]+.
    • Step-v: Synthesis of 1-bromopyrrolo[1,2-a]pyrazine
  • To a mixture of pyrrolo[1,2-a]pyrazin-1(2H)-one (2.5 g, 18.6 mmol) in acetonitrile (25 mL) was added POBr3 (10.5 g, 37 mmol) and heated to 80° C. for 3 h. The reaction mixture was slowly poured onto ice cold water, neutralized with aqueous ammonium hydroxide and extracted into ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get residue, which on purification by column chromatography using 30% ethyl acetate in hexane as eluent yielded the titled compound (1.8 g, 50%). LC-MS: 198.9 [M+2H]+.
    • Intermediate-14: Synthesis of 3-chloro-6-vinylpyridazine
  • Figure US20180200247A1-20180719-C00025
  • A stirred mixture of 3,6-dichloropyridazine (5 g, 33.5 mmol), vinyl boronic acid pinacol ester (5.1 g, 40.3 mmol,) and potassium carbonate (13.8 g, 100.5 mmol) in a mixture of 1,4-dioxane (50 mL) and water (20 mL) was degassed with nitrogen gas for 15 min. Pd(dppf)Cl2 (245.1 mg, 0.4 mmol) was then added and the mixture heated to 80° C. for 3 h. The reaction mixture was cooled to room temperature and separated aqueous layer. The organic portion was dried over Na2SO4, filtered and concentrated to get residue. The residue was purified by flash chromatography (SiO2) using 40% ethyl acetate in hexanes to yield the titled compound. LC-MS: 140.9 [M+H]+.
    • Intermediate-15: Synthesis of 2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide
  • Figure US20180200247A1-20180719-C00026
    • Step-i: Synthesis of 2-bromo-5-(ethylthio)pyridine
  • To a solution of 3-Amino-6-bromopyridine (5.5 g, 31.8 mmol) and diethyl disulfide (5.83 g, 47.7 mmol) in EDC (50 mL) at 60° C. was dropwise added 90% tert-butyl nitrite (5.5 g, 47.7 mmol) and the stirring was continued at 60° C. for 1 h. The reaction mixture was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel and 0-12% EtOAc in hexane) to obtain 2-bromo-5-(ethylthio)pyridine (3.5 g, 51%). 1H NMR (300 MHz, CDCl3): δ 8.30 (d, J=2.7 Hz, 1H), 7.47-7.51 (m, 1H), 7.38-7.41 (m, 1H), 2.91-2.98 (m, 2H), 1.34 (t, J=7.2 Hz, 3H); LC-MS: 220.0 [M+2H]+.
    • Step-ii: Synthesis of tert-butyl 2-cyano-2-(5-(ethylthio)pyridin-2-yl)acetate
  • To the degassed mixture of 2-bromo-5-(ethylthio)pyridine (7.0 g, 25.1 mmol), tert-butyl 2-cyanoacetate (6.49 g, 50.2 mmol) and cesium carbonate (24.53 g, 75.3 mmol) in dioxane (100 mL) in a sealed tube, was added copper iodide (0.96 g, 5.02 mmol) and pyridine-2-carboxylic acid (1.24 g, 10.04 mmol). The sealed tube was screw capped. The contents of the sealed tube were stirred at 110° C. for 6 h. The reaction mixture was cooled to room temperature and filtered through a pad of celite. The filtrate was evaporated to dryness under reduced pressure and subjected to column chromatography (60-120 mesh silica gel, 10-30% ethyl acetate) in hexane to obtain tert-butyl 2-cyano-2-(5-(ethylthio)pyridin-2-yl)acetate (5 g, 71%). 1H NMR (300 MHz, CDCl3): δ 14.02 (br s, 1H), 7.60-7.63 (m,1H), 7.53-7.57 (m, 1H), 7.23-7.24 (m, 1H), 2.76-2.83 (m, 2H), 1.53 (s, 9H), 1.28 (t, J=7.2 Hz, 3H); LC-MS: 222.9 [M−56+H]+.
    • Step-iii: Synthesis of 2-(5-(ethylthio)pyridin-2-yl)acetonitrile
  • To a solution of tert-butyl 2-cyano-2-(5-(ethylthio)pyridin-2-yl)acetate (5 g, 17.9 mmol) in DCM (25 mL) was added trifluoroacetic acid (25 mL). The reaction mixture was stirred at room temperature for 6 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was partitioned between water and DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel and 20-50% EtOAc in hexane) to obtain 2-(5-(ethylthio)pyridin-2-yl)acetonitrile (1.4 g, 44%). 1H NMR (300 MHz, CDCl3): δ 8.51 (d, J=2.4 Hz, 1H), 7.65-7.68 (m, 1H), 7.36 (d, J=7.8 Hz, 1H), 3.91 (s, 2H), 2.93-3.00 (m, 2H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: 178.8 [M+H]+.
    • Step-iv: Synthesis of 2-(5-(ethylsulfonyl)pyridin-2-yl)acetonitrile
  • To a solution of 2-(5-(ethylthio)pyridin-2-yl)acetonitrile (1.3 g, 7.3 mmol) in DCM (50 mL) at 0° C., was slowly added m-chloroperbenzoic acid (˜77%, 3.6 g, 16.1 mmol). The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of celite. The filtrate was washed with water, saturated aqueous sodium bicarbonate and brine. Then, the organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel and 10-30% EtOAc in hexane) to obtain 2-(5-(ethylsulfonyl)pyridin-2-yl)acetonitrile (1.14 g, 75%). 1H NMR (300 MHz, CDCl3): δ 9.08 (d, J=2.4 Hz, 1H), 8.4-8.27 (m, 1H), 7.70 (d, J=8.1 Hz, 1H), 4.08 (s, 2H), 3.15-3.26 (m, 2H), 1.36 (t, J=7.2 Hz, 3H); LC-MS: 211.0 [M+H]+.
    • Step-v: Synthesis of 2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide
  • A mixture of 2-(5-(ethylsulfonyl)pyridin-2-yl)acetonitrile (1.05 g, 5.0 mmol) and 90% aqueous sulfuric acid (5.0 mL) was stirred at 70° C. for 1.5 h. The reaction mixture was cooled to room temperature, neutralized with saturated aqueous sodium bicarbonate and extracted with 10% methanol in chloroform. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide (0.7 g, 61%). 1H NMR (400 MHz, DMSO-d6): δ 8.92 (d, J=2.4 Hz, 1H), 8.20-8.24 (m, 1H), 7.61-7.64 (m, 2H), 7.10 (br s, 1H), 3.74 (s, 2H), 3.35-3.42 (m, 2H), 1.55 (t, J=7.2 Hz, 3H); LC-MS: 229.0 [M+H]+.
    • Intermediate-16 (Mixture): Synthesis of 6-bromo-3-methoxy-4-methylpyridazine and 3-bromo-6-methoxy-4-methylpyridazine
  • Figure US20180200247A1-20180719-C00027
    • Step-i: Synthesis of 3,6-dibromo-4-methylpyridazine
  • A suspension of 3,6-dichloro-4-methylpyridazine (10 g, 61.3 mmol) in 30-33% HBr in acetic acid (200 mL) was stirred at room temperature for 24 h. The precipitate was collected by filtration. The precipitate was suspended in DCM and neutralized with saturated aqueous sodium bicarbonate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 3,6-dibromo-4-methylpyridazine (6.8 g, 44%). 1H NMR (300 MHz, CDCl3): δ 7.50 (d, J=1.2 Hz, 1H), 2.41 (d, J=0.6 Hz, 3H); LC-MS: 253.1 [M+3H]+.
    • Step-ii: Synthesis of 6-bromo-3-methoxy-4-methylpyridazine and 3-bromo-6-methoxy-4-methylpyridazine
  • To 3,6-dibromo-4-methylpyridazine (4.7 g, 18.7 mmol) in THF (25 mL) and methanol (25 mL) was added sodium methoxide (2.35 g, 37.4 mmol) and stirred at 25° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the mixture of 6-bromo-3-methoxy-4-methylpyridazine and 3-bromo-6-methoxy-4-methylpyridazine (3.5 g, 89%). 1H NMR (300 MHz, CDCl3): δ 7.31 (d, J=0.9 Hz, 1H), 6.80 (d, J=0.6 Hz, 1H), 4.10 (s, 3H), 4.07 (s, 3H), 2.34 (d, J=1.2 Hz, 3H), 2.20 (d, J=0.9 Hz, 1H); LC-MS: 205.1 [M+3H]+.
    • Intermediate-17: Synthesis of 4-bromo-2-isopropylpyrimidine
  • Figure US20180200247A1-20180719-C00028
    • Step-i: Synthesis of 2-isopropylpyrimidin-4(3H)-one
  • The mixture of methyl 3-methoxyacrylate (4.0 g, 34.4 mmol), isobutyrimidamide hydrochloride (12.64 g, 103.2 mmol) and potassium carbonate (15.2 g, 110.1 mmol) in ethanol (50 mL) was stirred at 85° C. for 10 h. The reaction mixture was filtered through a pad of celite. The filtrate was evaporated under reduced pressure to get 2-isopropylpyrimidin-4(3H)-one (4.0 g, 84%). 1H NMR (400 MHz, DMSO-d6): δ 12.37 (br s, 1H), 7.84 (d, J=6.6 Hz, 1H), 6.14 (d, J=6.6 Hz, 1H), 2.71-2.83 (m, 1H), 0.97 (d, J=6.9 Hz, 6H)); LC-MS: 138.9 [M+H]+.
    • Step-ii: Synthesis of 4-bromo-2-isopropylpyrimidine
  • To the suspension of 2-isopropylpyrimidin-4(3H)-one (2.0 g, 14.5 mmol) in acetonitrile (30 mL) was added phosphorus oxybromide (6.24 g, 21.75 mmol). The reaction mixture was stirred at 90° C. for 1 h. The obtained clear solution was evaporated under reduced pressure to get the residue. The residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel, 10-30% EtOAc in hexane) to obtain 4-bromo-2-isopropylpyrimidine (1.85 g, 59%). 1H NMR (300 MHz, CDCl3): δ 8.34 (d, J=5.4 Hz, 1H), 7.34 (d, J=5.1 Hz, 1H), 3.15-3.24 (m, 1H), 1.35 (d, J=6.6 Hz, 6H); LC-MS: 203.2 [M+2H]+.
    • Intermediate-18: Synthesis of 8-chloro-3-fluoro-2-methylimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00029
  • To a solution of 8-chloro-2-methylimidazo[1,2-a]pyrazine (2.5 g, 14.9 mmol) in acetonitrile (25 mL) at 0° C., was added a solution of Selectfluor (5.3 g, 14.9 mmol) in THF:Water (1:1, 25 mL) for 20 min. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 72 h. The reaction mixture was concentrated under reduced pressure to get the residue. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel and 0-30% ethyl acetate in hexane) to get 8-chloro-3-fluoro-2-methylimidazo[1,2-a]pyrazine (0.8 g, 27%). 1H NMR (300 MHz, CDCl3): δ 7.82 (d, J=4.5 Hz, 1H), 7.70 (d, J=4.5 Hz, 1H), 2.51 (s, 3H); LC-MS: 186.2[M+H]+.
    • Intermediate-19: Synthesis of 8-chloro-3-methylimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00030
    • Step i: Synthesis of 1-((3-chloropyrazin-2-yl)amino)propan-2-ol
  • A mixture of 2,3-dichloropyrazine (29 g, 194 mmol) and 2-hydroxy-1-propanamine (29 g, 400 mmol) in dioxane (100 mL) was refluxed for 7 h under nitrogen atmosphere and the solvent was evaporated under vacuum. The residue was partitioned between chloroform and water, then the chloroform layer was washed with water, dried over sodium sulphate, filtered and concentrated under vacuum to afford 1-((3-chloropyrazin-2-yl)amino)propan-2-ol as an oil and subjected to column chromatography (230-400 mesh silica gel, 10-30% hexane in ethyl acetate to obtain 1-((3-chloropyrazin-2-yl)amino)propan-2-ol (29 g, 80.5%). LC-MS: 188.3 [M+H]+.
    • Step ii: Synthesis of 1-((3-chloropyrazin-2-yl)amino)propan-2-one
  • A solution of oxalyl chloride (23.3 g, 140 mmol) in DCM (100 ml) was cooled to −78° C. under nitrogen atmosphere. To the reaction mixture, was added DMSO (28.5 g, 366 mmol) at −78° C. and stirred for 10 min. A solution of 1-((3-chloropyrazin-2-yl)amino)propan-2-ol (26.4 g, 140 mmol) in DCM (150 ml) was added to the reaction mixture at −78° C., stirred for 45 min, added TEA (71.0 g, 700 mmol) and then stirred at room temperature for 3 h. The mixture was treated with 300 g ice and extracted with DCM. The DCM extract was washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure to give 1-((3-chloropyrazin-2-yl)amino)propan-2-one (22 g, 84%). 1HNMR (300 MHz, CDCl3): δ 7.93 (d, J=2.7 Hz, 1H), 7.64(d, J=3.0 Hz ,1H), 6.00 (bars, 1H), 4.34 (t, J=4.8 Hz, 2H) 2.29 (s, 3H), LC-MS: 186.2 [M+H]+.
    • Step iii: Synthesis of 8-chloro-3-methylimidazo[1,2-a]pyrazine
  • A mixture of 1-((3-chloropyrazin-2-yl)amino)propan-2-one (11 g, 59 mmol), TFA (22.5 ml) and triflic anhydride (35 ml) was stirred at rt for 2 h. The volatiles were evaporated under reduced pressure to obtain a residue. The residue was extracted with DCM and the DCM extract was washed with water, dried over sodium sulfate, filtered and concentrated under vacuum to obtain 8-chloro-3-methylimidazo[1,2-a]pyrazine (7.9 g, 80%). 1HNMR (400 MHz, DMSO-d6): δ 8.46 (d, J=4.8 Hz, 1H), 7.76 (d, J=4.4 Hz, 1H), 7.68 (s, 1H), 2.23 (s, 3H), LC-MS: 168.2 [M+H]+.
    • Intermediate-20: Synthesis of 8-chloro-3-(trifluoromethyl)imidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00031
    • Step-i: Synthesis of 8-methoxy-3-(trifluoromethyl)imidazo[1,2-a]pyrazine
  • To a well stirred solution of silver(I)fluoride (3.4 g, 26.5 mmol) in DMF (20 ml), was added trifluoromethyltrimethylsilane and stirred at room temperature for 0.5 h. To the reaction mixture, was added copper (2.4 g, 39.0 mmol) and stirred at room temperature for 4 h. Then added 3-bromo-8-methoxyimidazo[1,2-a]pyrazine (5.5 g, 24.1 mmol) and stirred at 90° C. for 5 h. The reaction mixture was cooled and partitioned between ethyl acetate and water. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel and 10-20% EtOAc in hexane) to obtain 8-methoxy-3-(trifluoromethyl)imidazo[1,2-a]pyrazine (1.5 g, 29%). LC-MS: 218.3 [M+H]+.
    • Step-ii: Synthesis of 3-(trifluoromethyl)imidazo[1,2-a]pyrazin-8-ol
  • 8-methoxy-3-(trifluoromethyl)imidazo[1,2-a]pyrazine (1.5 g, 7.0 mmol) was dissolved in 48% HBr in water (10 mL) and stirred at 60° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get 3-(trifluoromethyl)imidazo[1,2-a]pyrazin-8-ol (0.85 g, 57%). LC-MS: 204.2 [M+H]+.
    • Step-iii: Synthesis of 8-chloro-3-(trifluoromethyl)imidazo[1,2-a]pyrazine
  • The mixture of 3-(trifluoromethyl)imidazo[1,2-a]pyrazin-8-ol (0.8 g, 3.9 mmol) and phosphorous oxychloride (10 mL) and N,N-dimethylaniline (0.1 mL) was stirred at 130° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 8-chloro-3-(trifluoromethyl)imidazo[1,2-a]pyrazine (0.54 g, 63%). 1H NMR (300 MHz,DMSO-d6): δ 8.70 (d, J=4.5 Hz, 1H), 8.47 (s, 1H), 7.98 (d, J=4.8 Hz, 1H); LC-MS: 222.2 [M+2H]+.
    • Intermediate-21: Synthesis of 4-bromo-6-methyl-2-(trifluoromethyl)pyrimidine
  • Figure US20180200247A1-20180719-C00032
  • A suspension of 6-methyl-2-(trifluoromethyl)pyrimidin-4-ol (0.4 g, 2.3 mmol) and phosphorous oxybromide (3.9 g, 0.013.8 mmol) in acetonitrile (20 mL) was stirred at 90° C. for 2 h. The volatiles were concentrated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 4-bromo-6-methyl-2-(trifluoromethyl)pyrimidine (0.38 g, 70%). 1H NMR (300 MHz,CDCl3): δ 7.59 (s,1H), 2.62 (s, 3H).
    • Intermediate-22: Synthesis of 3-bromo-6-ethylpyridazine
  • Figure US20180200247A1-20180719-C00033
  • A suspension of 6-ethylpyridazin-3-ol (6.0 g, 48.3 mmol) and phosphorous oxybromide (28 g, 9.7 mmol) in acetonitrile (60 mL) was stirred at 90° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography (230-400 mesh silica gel and 0-15% EtOAc in hexane) to obtain 3-bromo-6-ethylpyridazine (3.8 g, 42%). LC-MS: 186.8 [M+H]+.
    • Intermediate-23: Synthesis of 8-chloro-3-cyclopropylimidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00034
    • Step-i: Synthesis of 3-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine
  • To a degassed mixture of 3-bromo-8-methoxyimidazo[1,2a]pyrazine (1.4 g, 6.2 mmol), cyclopropylboronic acid (0.8 g, 9.3 mmol) potassium phosphate (4.6 g, 21.5 mmol) in water (5 ml) and toluene (30 ml), was added Palladium(ii)acetate and tricyclohexyl phosphine. The resulting reaction mixture was stirred at 90° C. for 12 h. The reaction mixture was cooled and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography (230-400 mesh silica gel and 10-30% EtOAc in hexane) to obtain 3-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine (1.0 g, 91%). 1H NMR (300 MHz,CDCl3): δ 7.79 (d, J=4.8 Hz, 1H), 7.41 (d, J=4.8 Hz, 1H), 7.33 (s, 1H),4.13 (s, 3H), 1.84-1.83 (m, 1H), 1.07-1.02(m, 2H) 0.77-0.73(m,2H); LC-MS: 190.3 [M+H]+.
    • Step-ii: Synthesis of Step-ii: Synthesis of 3-cyclopropylimidazo[1,2-a]pyrazin-8-ol
  • 3-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine (1.2 g, 6.0 mmol) was dissolved in 48% HBr in water (10 mL) and stirred at 60° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was azeotroped with toluene to get 3-cyclopropylimidazo[1,2-a]pyrazin-8-ol (1.0 g, 91%). 1H NMR (300 MHz, DMSO-d6): δ 12.25(br s, 1H), 7.85 (s, 1H), 7.76 (d, J=4.2 Hz, 1H), 7.36 (t, J=5.7 Hz, 1H), 2.10-2.05 (m, 1H), 1.08-1.02 (m, 2H) 0.82-0.77(m, 2H); LC-MS: 176.3 [M+H]+.
    • Step-iii: Synthesis of 8-chloro-3-cyclopropylimidazo[1,2-a]pyrazine
  • The mixture of 3-cyclopropylimidazo[1,2-a]pyrazin-8-ol (1.0 g, 5.7 mmol) and phosphorous oxychloride (15 mL) and N,N-dimethylaniline (0.1 mL) was stirred at 130° C. for 2 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 8-chloro-3-cyclopropylimidazo[1,2-a]pyrazine (0.42 g, 38%). LC-MS: 194.3 [M+H]+.
    • Intermediate-24: Synthesis of 4-bromo-2-methyl-6-(trifluoromethyl)pyrimidine
  • Figure US20180200247A1-20180719-C00035
  • A suspension of 6-methyl-2-(trifluoromethyl)pyrimidin-4-ol (3.0 g, 16.8 mmol) and phosphorous oxybromide (19.3 g, 67.3 mmol) in acetonitrile (30 mL) was stirred at 80° C. for 6 h. The volatiles were concentrated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted ethyl acetate. Then the organic portion was washed with water, brine and dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 4-bromo-2-methyl-6-(trifluoromethyl)pyrimidine (2.5 g, 62.5%). LC-MS: 243.2 [M+H]+.
    • Intermediate-25: Synthesis of 8-bromo-2-(trifluoromethyl)imidazo[1,2-a]pyrazine
  • Figure US20180200247A1-20180719-C00036
  • A suspension of 2-amino-3-bromopyrazine (2.5 g, 19.3 mmol) in DME (20 mL) was added 3-bromo-1,1,1-trifluoroacetone (13.7 g, 72.0 mmol) and 4 Å molecular sieves (1.0 g). The reaction mixture was then stirred at 90° C. for 4 h and quenched by the addition of water (25 mL). This mixture was extracted with ethyl acetate. The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to give 8-chloro-2-trifluoromethyl-imidazo [1,2-a] pyrazine (0.8 g, 25%). 1H NMR (400 MHz, CDCl3): δ 8.13-8.10 (m, 2H), 7.84-7.82 (m, 1H); LC-MS: 268.3.0 [M+2H]+.
    • Intermediate-26: Synthesis of 2-bromo-5-isopropylpyrazine
  • Figure US20180200247A1-20180719-C00037
    • Step-i: Synthesis of 5-isopropylpyrazin-2-ol
  • A solution of 2-amino-3-methylbutanamide hydrochloride (14.5 g, 95.3 mmol) in 140 mL of methanol and 140 mL of water at −40° C. was added 15 mL of aqueous glyoxal (40% by wt) dropwise. The mixture was stirred at −40° C. for 5 min, and then 14.5 mL of 50% aqueous sodium hydroxide was added. The resultant mixture was allowed to stir at room temperature for 18 h. The solution was cooled to 0° C. and 17.5 mL of concentrated hydrochloric acid was added, followed by 21.8 g of sodium bicarbonate. The mixture was stirred at room temperature for 5 min, and then an additional 21.8 g of sodium bicarbonate was added. After stirring for 20 min, the mixture was filtered. The filtrate was extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 5-isopropylpyrazin-2-ol (4.5 g, 34%) LC-MS: 139.0 [M+H]+.
    • Step-ii: Synthesis of 2-bromo-5-isopropylpyrazine
  • A suspension of 5-isopropylpyrazin-2-ol (4.5 g, 32.0 mmol) and phosphorous oxybromide (27 g, 94.0 mmol) in acetonitrile (45 mL) was stirred at 90° C. for 3 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 2-bromo-5-isopropylpyrazine (4.2 g, 64%). LC-MS: 200.9 [M+H]+.
    • Intermediate-27: Synthesis of 3-bromo-6-isopropylpyridazine
  • Figure US20180200247A1-20180719-C00038
    • Step-i: Synthesis of 6-isopropylpyridazin-3-ol
  • A mixture of glyoxalic acid monohydrate(15.0 g, 163.0 mmol), and methyl isopropyl ketone (52 ml), was heated to120° C. for 2 h. The reaction mixture was cooled to 40° C. and 60 ml of water and 100 ml of aqueous ammonia were added. The mixture was extracted with DCM. The aqueous phase was added with hydrazine hydrate (8.2 g, 0.163.0 mmol), refluxed for18 h and then cooled to room temperature. The reaction mass was extracted into DCM, the organic layer was washed with brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get the crude product (6.5 g, 30%). LC-MS: 139.2 [M+H]+.
    • Step-ii: Synthesis of 3-bromo-6-isopropylpyridazine
  • A suspension of 6-isopropylpyridazin-3-ol (6.5 g, 47.0 mmol) and phosphorous oxybromide (25 g, 87.0 mmol) in acetonitrile (15 mL) was stirred at 130° C. for 2 h. Poured into ice cold water and extracted ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to get 3-bromo-6-isopropylpyridazine (2.5 g, 26.5%), LC-MS: 203.1 [M+2H]+.
    • Intermediate-28: Synthesis of 4,6-dimethylcyclohexane-1,3-dione
  • Figure US20180200247A1-20180719-C00039
  • A solution of potassium tert-butoxide (15.45 g, 13.8 mmol) in dry THF (500 mL) was cooled to 0° C. and was added butan-2-one (10.0 g, 13.8 mmol), methyl methacrylate (11.6 g, 13.8 mmol) in dry THF over a period of 30 min. Then the reaction mixture was gradually warmed to RT and stirred for 2 h. The reaction was quenched with ice water and adjusted the pH- to 4 using 2N HCl. This mixture was extracted with ethyl acetate and the combined organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get the compound (8 g). LC-MS: 141.1 [M]+
    • Intermediate-29: Synthesis of 2-chloro-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00040
    • Step-i: Synthesis of methyl 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate
  • A solution of cyclohexane-1,3-dione (200 g, 1785 mmol), DMF-DMA (201.8 g, 1785 mmol) in DCM (2 L) was stirred at room temperature for an hour. The reaction mixture was cooled to room temperature and the volatiles were evaporated under reduced pressure to get yellow solid. This was dissolved in methanol, added methyl 2-cyanoacetate (130 g, 1149 mmol) and refluxed for 12 h. The reaction mixture was cooled to room temperature and the solid formed was filtered and washed with cold methanol to get the title compound (160 g, 54%). LC-MS: 222.0 [M+H]+.
    • Step-ii: Synthesis of 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid
  • To a mixture of methyl 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (10 g, 45.2 mmol) in 200 ml of MeOH/THF (1:1) was added a solution of lithium hydroxide (9.4 g, 226 mmol) in water (100 mL). The reaction mixture was then heated to 80° C. for 2 h to get clear solution. The reaction mixture was cooled to room temperature and solvents were evaporated under reduced pressure. The aqueous portion was acidified with dil. HCl to pH 4. The solid formed was filtered, washed with water and dried to get the title compound (8.5 g, 91.3%). LC-MS: 208.2 [M+H]+.
    • Step-iii: Synthesis of 7,8-dihydroquinoline-2,5(1H,6H)-dione 2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid (8.5 g, 41 mmol) was taken in an RB fitted with a condenser was heated on a heating mantle till it melts. Then the molten reaction mixture was cooled to room temperature, dissolved in 10% methanol in DCM. This solution was filtered and the filtrate was concentrated to get the title compound (5 g, 74.7%). LC-MS: 164.0 [M+H]+. Step-iv: Synthesis of 2-chloro-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 7,8-dihydroquinoline-2,5(1H,6H)-dione (5 g, 27.6 mmol) in acetonitrile (50 mL) was added POCl3 (12.6 g, 82.5 mmol) dropwise at 0° C. The cooling bath was removed and the reaction mixture was refluxed for 2 h. The reaction mixture was cooled to room temperature and the volatiles were evaporated under reduced pressure to get the residue, which was neutralized with ammonium hydroxide and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated to get the title compound (5 g, 90.9%). LC-MS: 181.9 [M+H]+.
  • The below Intermediates were prepared according to the protocol described in the synthesis of Intermediate-29 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Intermediate
    No. Structure Characterization data
    30
    Figure US20180200247A1-20180719-C00041
         		LC-MS: 210.2 [M + H]+.
    31
    Figure US20180200247A1-20180719-C00042
         		LC-MS: 196.1 [M + H]+.
    32
    Figure US20180200247A1-20180719-C00043
         		—
    33
    Figure US20180200247A1-20180719-C00044
         		LC-MS: 210.0 [M]+
    • Intermediate-34: Synthesis of 3-chloro-6,7-dihydroisoquinolin-8(5H)-one
  • Figure US20180200247A1-20180719-C00045
    • Step-i: Synthesis of 3-hydroxy-8-oxo-5,6,7,8-tetrahydroisoquinoline-4-carboxamide
  • A solution of cyclohexane-1,3-dione (3 g, 26 mmol), DMF-DMA(3.35 g, 28.1 mmol) in DCM (30 mL) was stirred at room temperature for an hour. The reaction mixture was cooled to room temperature and the volatiles were evaporated to get yellow solid. This solid was dissolved in ethanol (78 mL), then added 2-cyanoacetamide (2.18 g, 84.08 mmol), piperidine (1.3 mL), DMF (26 mL) and refluxed for 16 h. The reaction mixture was cooled to room temperature and the solid formed was filtered and washed with cold ethanol to get the title compound (2.06 g, 37.3%). LC-MS: 207.1 [M+H]+.
    • Step-ii: Synthesis of 3-hydroxy-8-oxo-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
  • A mixture of methyl 3-hydroxy-8-oxo-5,6,7,8-tetrahydroisoquinoline-4-carboxamide (2.06 g, 1.0 mmol) in Conc.HCl (10 mL) was heated to 100° C. for 6 h to get a clear solution. The reaction mixture was cooled to room temperature and the solid formed was filtered, washed with water, ethanol and dried to get the title compound (1.2 g, 58%). LC-MS: 207.8 [M+H]+.
    • Step-iii: Synthesis of 3-hydroxy-6,7-dihydroisoquinolin-8(5H)-one
  • 3-hydroxy-8-oxo-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid (8.5 g, 41 mmol) was taken in an RB fitted with a condenser was heated on a heating mantle till it melts. Then the molten reaction mixture was cooled to room temperature, and powdered to get the title compound (0.7 g, quantitative). LC-MS: 164.3 [M+H]+.
    • Step-iv: Synthesis of 3-chloro-6,7-dihydroisoquinolin-8(5H)-one
  • A solution of 3-hydroxy-6,7-dihydroisoquinolin-8(5H)-one (1 g, 5.5 mmol) in acetonitrile (15 mL) was added POCl3 (2 mL) at RT. The reaction mixture was refluxed for 2 h. The reaction mixture was cooled to room temperature and the volatiles were evaporated under reduced pressure to get residue, which was neutralized with ammonium hydroxide and diluted with ethyl acetate. The organic portion was then dried over sodium sulfate, filtered and concentrated to get the titled compound (0.7 g, 64%). LC-MS: 182.2 [M+H]+.
    • Intermediate-35: Synthesis of 2-methoxy-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00046
  • To a solution of 2-chloro-6-methyl-7,8-dihydroquinolin-5(6H)-one (1.5 g, 7.7 mmol) in methanol (25 mL) was added sodium methoxide (8.4 mmol) and stirred at room temperature for 12 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was dissolved in ethyl acetate and washed with water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get 2-methoxy-6-methyl-7,8-dihydroquinolin-5(6H)-one (1.2 g, 86%). 1H NMR (400 MHz, CDCl3): δ 8.17 (d, J=8.4 Hz, 1H), 6.65 (d, J=8.8 Hz, 1H), 3.98 (s, 3H), 3.03-3.06 (m, 2H), 2.53-2.59 (m, 1H), 2.19-2.24(m, 1H), 1.88-1.91 (m, 1H), 2.27 (d, J=6.8 Hz, 3H); LC-MS: 192.0 [M+H]+.
    • Intermediate-36: Synthesis of 2-chloro-6-(4-methoxyphenyl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00047
    • Step-i: Synthesis of 4-methyl-7,8-dihydro-2H-chromene-2,5(6H)-dione
  • A mixture of cyclohexane-1,3-dione (5 g, 44 mmol), ethylaceto acetate (6.9 g, 53 mmol), DMAP (1.09 g, 89 mmol) was heated to 120° C. for 10 h. The reaction mixture was cooled to room temperature and the volatiles evaporated under reduced pressure to get a residue. The residue was dissolved in ethyl acetate, washed with water followed by brine. The separated organic layer was dried over sodium sulphate, filtered and concentrated to get residue which was purified by silica gel column (230-400 mesh) using 5-10% ethyl acetate in hexanes as eluent to afford the title compound (3.2 g, 40.2%). LC-MS: 179.2 [M+H]+.
    • Step-ii: Synthesis of 4-methyl-7,8-dihydroquinoline-2,5(1H,6H)-dione
  • A mixture of 4-methyl-7,8-dihydro-2H-chromene-2,5(6H)-dione (3.1 g, 17.4 mmol) and methanolic ammonia (50 mL) was taken in a steel bomb and heated to 180° C. for 12 h. The reaction mixture was cooled and the volatiles were evaporated under reduced pressure to get the product (3 g, 97%). LC-MS: 178.3 [M+H]+.
    • Step-iii: Synthesis of 2-chloro-4-methyl-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 4-methyl-7,8-dihydroquinoline-2,5(1H,6H)-dione (3 g, 0.0169 mmol) in acetonitrile (30 mL) was added phosphorous oxychloride(12.9 g, 84 mmol) and heated to 75° C. for 2 h. The reaction mixture was cooled to room temperature and the volatiles were evaporated under reduced pressure to get residue which was purified on 100-200 mesh silica gel column using 5% ethyl acetate in hexanes to obtain the title compound (4.8 g, 66.6%). 1H NMR (300 MHz, CDCl3): δ 7.11 (s, 1H), 3.11-3.13 (m, 2H), 2.64-2.68 (m, 4H), 2.08-2.16 (m, 2H). LC-MS: 196.2 [M+H]+.
    • Intermediate 37: Synthesis of 2-chloro-3-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00048
  • This intermediate was prepared according to the protocol described in the synthesis of Intermediate-36 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
    • Intermediate-38: 2-chloro-6-(6-methoxypyridin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00049
    • Step-i: Synthesis of 2-chloro-6-(6-methoxypyridin-3-yl)-7,8-dihydroquinolin-5(6H)-one
  • A mixture of 2-chloro-7,8-dihydroquinolin-5(6H)-one (0.4 g, 2.2 mmol), 5-bromo-2-methoxypyridine (0.45 g, 2.4 mmol) and sodium tert-butoxide (0.42 g, 4.4 mmol) in toluene (20 mL) was taken in a sealed tube, was degassed with nitrogen gas and added Pd(amphos)Cl2 (0.0155 g, 0.02 mmol) at room temperature. Later, the reaction mixture was heated to 70° C. for 2 h, cooled it to room temperature, quenched with water and extracted with ethyl acetate. The organic portion was washed with water followed by brine. The separated organic layer was dried over sodium sulphate, filtered and concentrated to get residue which was purified by column chromatography (Silica: 230-400 mesh) using 10% ethyl acetate in hexanes as eluent to afford the title compound (0.2 g, 33%).
    • Step-ii: Synthesis of 2-chloro-6-(6-methoxypyridin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 2-chloro-6-(6-methoxypyridin-3-yl)-7,8-dihydroquinolin-5(6H)-one (0.2 g, 0.69 mmol) in DMF (10 mL) was added sodium hydride (0.17 g, 0.76 mmol) at 0° C., stirred for 10 min. Methyl iodide (0.12 g, 0.83 mmol) was then added and stirred for 30 min. The reaction mixture was quenched with ice-water, extracted into ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate, filtered and concentrated to get residue which on purification by column chromatography (Silica: 230-400 mesh) using 5% ethyl acetate in hexanes as eluents yielded the title compound (0.165 g, 79%). 1H NMR (300 MHz, CDCl3): δ 8.30-8.33 (m, 1H), 7.9 (m, 1H), 7.47-7.43-7.47 (m, 1H), 7.31 (m, 1H), 6.69-6.72 (m, 1H), 3.87 (s, 3H), 2.97-3.11 (m, 3H), 2.62-2.67 (m, 2H), 2.32 (m, 1H), 1.51 (s, 3H). LC-MS: 303.0 [M+H]+.
  • The below intermediates were prepared according to the protocol described in the synthesis of intermediate-38 or 38a with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Intermediate
    No. Structure Characterization Data
     39
    Figure US20180200247A1-20180719-C00050
         		LC-MS: 341.3 [M + H]+.
     40
    Figure US20180200247A1-20180719-C00051
         		LC-MS: 317.1 [M + H]+.
     41
    Figure US20180200247A1-20180719-C00052
         		LC-MS: 303.3 [M + H]+.
     42
    Figure US20180200247A1-20180719-C00053
         		LC-MS: 313.2 [M + H]+.
     43
    Figure US20180200247A1-20180719-C00054
         		LC-MS: 301.9 [M + H]+.
     44
    Figure US20180200247A1-20180719-C00055
         		LC-MS: 341.0 [M + H]+.
     45
    Figure US20180200247A1-20180719-C00056
         		LC-MS: 326.9 [M + H]+.
     46
    Figure US20180200247A1-20180719-C00057
         		LC-MS: 307.0 [M + H]+.
     47
    Figure US20180200247A1-20180719-C00058
         		LC-MS: 327.0 [M + H]+.
     48
    Figure US20180200247A1-20180719-C00059
         		LC-MS: 303.9 [M + H]+.
     49
    Figure US20180200247A1-20180719-C00060
         		LC-MS: 312.2 [M + H]+.
     50
    Figure US20180200247A1-20180719-C00061
         		LC-MS: 326.9 [M + H]+.
     51
    Figure US20180200247A1-20180719-C00062
         		LC-MS: 312.2 [M + H]+.
     52
    Figure US20180200247A1-20180719-C00063
         		LC-MS: 327.4 [M + H]+.
     53
    Figure US20180200247A1-20180719-C00064
         		LC-MS: 317.3 [M + H]+.
     54
    Figure US20180200247A1-20180719-C00065
         		LC-MS: 287.1 [M + H]+.
     55
    Figure US20180200247A1-20180719-C00066
         		LC-MS: 317.1 [M + H]+.
     56
    Figure US20180200247A1-20180719-C00067
         		LC-MS: 316.9 [M + H]+.
     57
    Figure US20180200247A1-20180719-C00068
         		LC-MS: 318.1 [M + H]+.
     58
    Figure US20180200247A1-20180719-C00069
         		LC-MS: 317.3 [M + H]+.
     59
    Figure US20180200247A1-20180719-C00070
         		LC-MS: 305.1 [M + H]+.
     60
    Figure US20180200247A1-20180719-C00071
         		No ionization
     61
    Figure US20180200247A1-20180719-C00072
         		LC-MS: 318.2 [M + H]+.
     62
    Figure US20180200247A1-20180719-C00073
         		LC-MS: 327.3 [M + H]+.
     63
    Figure US20180200247A1-20180719-C00074
         		—
     64
    Figure US20180200247A1-20180719-C00075
         		LC-MS: 286.8 [M + H]+.
     65
    Figure US20180200247A1-20180719-C00076
         		LC-MS: 316.3 [M + H]+.
     66
    Figure US20180200247A1-20180719-C00077
         		LC-MS: 316.3 [M + H]+.
     67
    Figure US20180200247A1-20180719-C00078
         		LC-MS: 317.9 [M + H]+.
     68
    Figure US20180200247A1-20180719-C00079
         		LC-MS: 318.3 [M + H]+.
     69
    Figure US20180200247A1-20180719-C00080
         		LC-MS: 355.1 [M + H]+.
     70
    Figure US20180200247A1-20180719-C00081
         		LC-MS: 302.0 [M + H]+.
     71
    Figure US20180200247A1-20180719-C00082
         		LC-MS: 423.3 [M + H]+.
     72
    Figure US20180200247A1-20180719-C00083
         		LC-MS: 423.3 [M + H]+.
     73
    Figure US20180200247A1-20180719-C00084
         		LC-MS: 437.3 [M + H]+.
     74
    Figure US20180200247A1-20180719-C00085
         		LC-MS: 393.3 [M + H]+.
     75
    Figure US20180200247A1-20180719-C00086
         		LC-MS: 456.9 [M + H]+.
     76
    Figure US20180200247A1-20180719-C00087
         		LC-MS: 393.2 [M + H]+.
     77
    Figure US20180200247A1-20180719-C00088
         		LC-MS: 409.3 [M + H]+.
     78
    Figure US20180200247A1-20180719-C00089
         		LC-MS: 423.3 [M + H]+.
     79
    Figure US20180200247A1-20180719-C00090
         		LC-MS: 340.3 [M + H]+.
     80
    Figure US20180200247A1-20180719-C00091
         		LC-MS: 329.8 [M + H]+.
     81
    Figure US20180200247A1-20180719-C00092
         		LC-MS: 369.0 [M + H]+.
     82
    Figure US20180200247A1-20180719-C00093
         		LC-MS: 316.3 [M + H]+.
     83
    Figure US20180200247A1-20180719-C00094
         		LC-MS: 327.2 [M + H]+.
     84
    Figure US20180200247A1-20180719-C00095
         		LC-MS: 315.7 [M + H]+.
     85
    Figure US20180200247A1-20180719-C00096
         		LC-MS: 340.9 [M + H]+.
     86
    Figure US20180200247A1-20180719-C00097
         		LCMS: 341.0 [M + H]+.
     87
    Figure US20180200247A1-20180719-C00098
         		LCMS: 356.0 [M + H]+.
     88
    Figure US20180200247A1-20180719-C00099
         		—
     89
    Figure US20180200247A1-20180719-C00100
         		LCMS: 342.3 [M + H]+
     90
    Figure US20180200247A1-20180719-C00101
         		LC-MS: 303.6 [M + H]+.
     91
    Figure US20180200247A1-20180719-C00102
         		LC-MS: 332.0 [M + H]+.
     92
    Figure US20180200247A1-20180719-C00103
         		LC-MS: 317.0 [M + 2H]+.
     93
    Figure US20180200247A1-20180719-C00104
         		LC-MS: 318.0 [M + H]+.
     94
    Figure US20180200247A1-20180719-C00105
         		LC-MS: 316.2 [M + H]+.
     95
    Figure US20180200247A1-20180719-C00106
         		LC-MS: 316.3 [M + H]+.
     96
    Figure US20180200247A1-20180719-C00107
         		LC-MS: 317.9 [M + H]+
     97
    Figure US20180200247A1-20180719-C00108
         		LC-MS: 318.2 [M + H]+.
     98
    Figure US20180200247A1-20180719-C00109
         		LC-MS: 345.2 [M + H]+.
     99
    Figure US20180200247A1-20180719-C00110
         		LC-MS: 356.2 [M + H]+.
    100
    Figure US20180200247A1-20180719-C00111
         		LC-MS: 327.0 [M + H]+.
    101
    Figure US20180200247A1-20180719-C00112
         		LC-MS: 316.4 [M + H]+.
    102
    Figure US20180200247A1-20180719-C00113
         		LC-MS: 353.2 [M + H]+.
    103
    Figure US20180200247A1-20180719-C00114
         		LC-MS: 381.3 [M + H]+.
    104
    Figure US20180200247A1-20180719-C00115
         		LC-MS: 318.2 [M + H]+.
    105
    Figure US20180200247A1-20180719-C00116
         		LC-MS: 381.3 [M + H]+.
    106
    Figure US20180200247A1-20180719-C00117
         		LC-MS: 341.3 [M + H]+.
    107
    Figure US20180200247A1-20180719-C00118
         		LC-MS: 358.4 [M + H]+.
    108
    Figure US20180200247A1-20180719-C00119
         		LC-MS: 327.1 [M + H]−
    109
    Figure US20180200247A1-20180719-C00120
         		LC-MS: 356.3 [M + H]−.
    110
    Figure US20180200247A1-20180719-C00121
         		LC-MS: 316.3 [M + H]+
    111
    Figure US20180200247A1-20180719-C00122
         		LC-MS: 302.2 [M + H]−
    112
    Figure US20180200247A1-20180719-C00123
         		LC-MS: 302.3 [M + H]+
    • Intermediate-113: Synthesis of 2-chloro-6-methyl-6-(5-methylthiophen-2-yl)-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00124
  • Intermediate 2-chloro-4,6-dimethyl-6-(5-methylthiophen-2-yl)-7,8-dihydroquinolin-5(6H)-one (Intermediate-113) was synthesized using the same procedure as described in Step-i to Step-iv of Intermediate-29. LC-MS: 292.3 [M+H]+.
    • Intermediate-114: Synthesis of 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00125
    • Step-i: 6-bromo-2-chloro-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 2-chloro-7,8-dihydroquinolin-5(6H)-one (2 g, 11.2 mmol) in HBr (20 mL) was added Br2 (1.79 g, 11.2 mmol) in DCM (20 mL) at RT and stirred for 2 h at the same temperature. The reaction was quenched with ice-water, extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get the title compound (1.8 g, 64%). LC-MS: 260.1 [M]+, 262.1 [M+2H]+.
    • Step-ii: 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 6-bromo-2-chloro-7,8-dihydroquinolin-5(6H)-one (0.6 g, 2.32 mmol) in DMF (15 mL) was added 3,5-dimethyl-1H-pyrazole (1.13 g, 11.6 mmol) at RT and the reaction mixture was heated to 60° C. for 6 h. The reaction was quenched with ice-water, extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get residue, which on purification by column chromatography using 30% ethyl acetate in hexane as eluent yielded the titled compound (0.24 g, 37.1%). LC-MS: 276.2 [M+H]+.
    • Step-iii: 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Alkylation of 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-7,8-dihydroquinolin-5(6H)-one by using the similar protocol as described in the step-ii of Intermediate-38, this yielded the title compound (0.16 g, 60%). LC-MS: 290.1 [M+H]+.
    • Intermediate-115: Synthesis of 2-chloro-4,6-dimethyl-6-(1H-pyrazol-1-yl)-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00126
  • This intermediate was prepared using the same protocol as described in the synthesis of Intermediate-114 (0.13 g, 49.4%). LC-MS: 276.3 [M+H]+.
    • Intermediate-116: Synthesis of 2-chloro-6-(2-hydroxypyridin-4-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00127
  • A mixture of 2-chloro-6-(2-methoxypyridin-4-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (Intermediate-82, 0.2 g, 0.63 mmol) and 48% aqueous HBr (1 mL) in acetic acid (2 mL) was heated to 90° C. for 12 h. The reaction mixture was cooled to room temperature, neutralized with ammonium hydroxide, and extracted with ethyl acetate. The organic portion was dried over sodium sulphate, filtered and concentrated to get the title compound (0.11 g, 57.9%). LC-MS: 303.2 [M+H]+.
    • Intermediate-117: Synthesis of 2-chloro-6-(6-hydroxypyridin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00128
  • 2-chloro-6-(6-hydroxypyridin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one was prepared using the protocol as described in the synthesis of Intermediate-116 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions. LC-MS: 303.2 [M+H]+.
    • Intermediate-118: Synthesis of 2-chloro-6-(4-hydroxypyrimidin-2-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00129
  • A mixture of 2-chloro-6-(4-methoxypyrimidin-2-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (Intermediate-57, 0.45 g, 1.46 mmol), sodium iodide (0.32 g, 2.12 mmol) and trimethylsilyl chloride (0.23 g, 2.12 mmol) in acetonitrile (10 mL) was heated to 70° C. for 12 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was acidified with citric acid and extracted with ethyl acetate. Then the organic phase was washed with water followed by brine. The separated organic layer was dried over sodium sulfate, filtered and concentrated to get the title compound (0.15 g, 35%). LC-MS: 304.3 [M+H]+.
    • Intermediate-119: Synthesis of 2-chloro-6-(6-hydroxypyridin-2-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00130
  • 2-chloro-6-(6-hydroxypyridin-2-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one was prepared using the protocol as described in the synthesis of Intermediate-118 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions. LC-MS: 303.2 [M+H]+.
    • Intermediate-120: Synthesis of 2-chloro-6-(5-chloro-3-hydroxypyridin-2-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00131
  • A mixture of 2-chloro-6-(5 -chloro-3 -((4-methoxybenzyl)oxy)pyridin-2-yl)-4, 6-dimethyl-7,8-dihydroquinolin-5(6H)-one(0.35 g, 0.76 mmol) in TFA was heated to 100° C. for 30 min. The reaction mixture was concentrated to dryness and the crude was purified by flash chromatography using 20% ethyl acetate in hexanes to afford the titled compound (0.3 g, 85.6%). LC-MS: 337.2 [M+H]+.
    • Intermediate-121: Synthesis of 2-chloro-6-(6-ethylpyridazin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00132
  • 2-chloro-6-methyl-7,8-dihydroquinolin-5(6H)-one (0.2 g, 1.1 mmol) was coupled with 3-chloro-6-vinylpyridazine(0.185 g, 1.32 mmol) using the same procedure as described in the step-i of Intermediate-38. The residue after coupling was dissolved in methanol, added 10% Pd—C carefully under nitrogen atmosphere and stirred under the positive pressure of hydrogen using a bladder for 30 min. The reaction mixture was filtered through celite and filtrate was concentrated to get the titled compound as crude (0.4 g). LC-MS: 302.0.1 [M+H]+.
    • Intermediate-122: Synthesis of 2-chloro-6-(6-hydroxypyridin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00133
  • 2-chloro-6-(6-hydroxypyridin-3-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one was prepared using the protocol as described in the synthesis of Intermediate-116 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
    • Intermediate-123 (mixture): Synthesis of 2-chloro-6-(6-methoxy-4-methylpyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one and 2-chloro-6-(6-methoxy-5-methylpyridazin-3 -yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00134
  • Intermediate 2-chloro-6-(6-methoxy-4-methylpyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one and 2-chloro-6-(6-methoxy-5-methylpyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (mixture) was prepared using the same protocol explained in the synthesis of Intermediate-38 and isolated as a mixture of positional isomers. LC-MS: 332.2 [M+H]+.
    • Intermediate-124: Synthesis of N-(4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • Figure US20180200247A1-20180719-C00135
    • Step-i: Synthesis of 2-chloro-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydro quinolin-5(6H)-one
  • A mixture of 2-chloro-6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.4 g, 1.2 mmol) and 48 wt. % hydrobromic acid in water (4 mL) was stirred at 50° C. for 3 h. The reaction mixture was neutralized with 10% aqueous sodium bicarbonate solution, extracted with ethyl acetate. The organic layer was separated, washed with, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to get 2-chloro-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.3 g, 79%). LC-MS: 304.3 [M+H]+.
    • Step-ii: Synthesis of 2-chloro-4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-7,8-dihydroquinolin-5(6H)-one
  • To a solution of 2-chloro-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.3 g, 0.9 mmol) in DMF (5 mL), was added 60% sodium hydride in mineral oil (0.045 g, 0.18 mmol) and then the reaction mixture was heated to 60° C. At this moment, was added methyl iodide (0.7 g, 4.5 mmol) and the reaction mixture was stirred at 60° C. for 1 h. The reaction mass was quenched with ice cold water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate and concentrated to get 2-chloro-4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydro pyridazin-3-yl)-7,8-dihydroquinolin-5(6H)-one (0.26 g, 83%). LC-MS: 317.9 [M+H]+.
    • Intermediate-125: Synthesis of 2-chloro-6-(imidazo[1,2-a]pyrazin-8-yl)-6,8-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00136
  • 2-chloro-6-methyl-7,8-dihydroquinolin-5(6H)-one, (0.2 g, 1.1 mmol) was coupled with 3-chloro-6-vinylpyridazine (0.185 g, 1.32 mmol) using the same procedure as described in the step-i of Intermediate-38. LC-MS: 327.0 [M+H]+.
    • Intermediate-126: Synthesis of 2-chloro-6-(6-ethyl-2-methylpyrimidin-4-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00137
    • Step-i: Synthesis of 6-ethyl-2-methylpyrimidin-4-ol
  • A 250 mL round bottom flask was added dry methanol (100 mL) followed by careful addition of sodium metal (1.77 g, 76.84 mmol) and stirred at room temperature until all metal had dissolved. To the generated sodium methoxide in methanol, was added acetamidine hydrochloride (10.0 g, 76.84 mmol) and methyl 3-oxo-pentanoate (7.27 g, 76.84 mmol). The resulting reaction mixture was stirred at room temperature for 12 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was extracted with hot chloroform. The organic layer was evaporated under reduced pressure to obtain 6-ethyl-2-methylpyrimidin-4-ol (7.0 g, 66%). 1H NMR (300 MHz, CDCl3): δ 8.93 (br s, 1H), 6.16 (s, 1H), 2.51-2.59 (m, 2H), 2.45 (s, 3H), 1.24 (t, J=7.5 Hz, 3H); LC-MS: 139.3 [M+H]+.
    • Step-ii: Synthesis of 4-chloro-6-ethyl-2-methylpyrimidine
  • A suspension of 6-ethyl-2-methylpyrimidin-4-ol (7.0 g, 50.7 mmol) in acetonitrile (14 mL) in a 50 mL round bottomed flask was added phosphorous oxychloride (14 mL) and stirred at 80° C. for 3 h. The reaction mixture was cooled to room temperature, added slowly into ice-cold water and basified to pH 7-8 with aqueous ammonia, keeping the temperature below 0° C. The aqueous layer was extracted with diethyl ether. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 4-chloro-6-ethyl-2-methylpyrimidine (6.1 g, 77%). 1H NMR (300 MHz, CDCl3): δ 7.03 (s, 1H), 2.70-2.78 (m, 2H), 2.68 (s, 3H), 1.24 (t, J=7.5 Hz, 3H); LC-MS: 157.0 [M+H]+.
    • Step-iii: Synthesis of 4-ethyl-2-methyl-6-(phenylthio)pyrimidine
  • A 250 mL round bottom flask, was added ethanol (50 mL), then carefully added sodium metal (0.97 g, 42.1 mmol) and stirred at room temperature until all metal had dissolved. To the generated sodium ethoxide in ethanol, was added thiophenol (4.64 g, 42.1 mmol) and refluxed for 30 min. To the reaction mixture, was added 4-chloro-6-ethyl-2-methylpyrimidine (6.6 g, 42.1 mmol) and refluxed for 2 h. To the reaction mixture, was added water (2 mL) and the volatiles were evaporated under reduced pressure to get the residue. The residue was dissolved in aqueous 20% HCl and washed with diethyl ether. The aqueous layer was basified to pH 7-8 with solid potassium carbonate and extracted with chloroform. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum to get 4-ethyl-2-methyl-6-(phenylthio)pyrimidine (6.1 g, 63%). LC-MS: 231.0 [M+H]+.
    • Step-iv: Synthesis of 4-ethyl-2-methyl-6-(phenylsulfonyl)pyrimidine
  • To a 100 mL round bottom flask, was added 4-ethyl-2-methyl-6-(phenylsulfonyl)pyrimidine (6.0 g, 26.1 mmol) and dichloromethane (100 mL). The reaction mixture was cooled to 0-5° C., and portion wise added 77% mCPBA (11.7 g, 52.2 mmol) and stirred at room temperature for 12 h. The reaction mixture was cooled to 0-5° C., and portion wise added 77% mCPBA (2.33 g, 10.4 mmol) and stirred at room temperature for 2 h. The reaction mixture was filtered through a pad of celite. The pad was washed with DCM. The combined filtrate was washed with 30% aqueous potassium carbonate solution. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulfate and evaporated under vacuum to get the crude product. The crude product was purified by column chromatography (60-120 mesh silica gel, 5-15% EtOAc in hexane) to get 4-ethyl-2-methyl-6-(phenylsulfonyl)pyrimidine (4.1 g, 60%). LC-MS: 263.0 [M+H]+.
    • Step-v: Synthesis of 2-chloro-6-(6-ethyl-2-methylpyrimidin-4-yl)-7,8-dihydroquinolin-5(6H)-one
  • To a 50 mL round bottom flask, was added tetrahydrofuran (15 ml). To the same flask, was added 60% sodium hydride in mineral oil (0.88 g, 22.0 mmol), 2-chloro-7,8-dihydroquinolin-5(6H)-one (1.0 g, 5.5 mmol) and 4-ethyl-2-methyl-6-(phenylsulfonyl)pyrimidine (2.89 g, 11.0 mmol) under nitrogen atmosphere. The reaction mixture was refluxed for 30 min. The reaction mixture was quenched with ice cold water and extracted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 2-chloro-6-(6-ethyl-2-methylpyrimidin-4-yl)-7,8-dihydroquinolin-5(6H)-one (1.65 g, crude product). The obtained crude product was used in the next step without further purification. LC-MS: 302.2 [M+H]+.
    • Step-vi: Synthesis of 2-chloro-6-(6-ethyl-2-methylpyrimidin-4-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • This step was done using the same protocol explained in step-ii of Intermediate-38. LC-MS: 316.3 [M+H]+.
  • The below intermediates (127-128) were prepared by a procedure similar to the one described in Intermediate-126 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Intermediate
    No Structure Characterization data
    127
    Figure US20180200247A1-20180719-C00138
         		LC-MS: 316.3 [M + H]+.
    128
    Figure US20180200247A1-20180719-C00139
         		LC-MS: 330.3 [M + H]+.
    • Intermediate-129: Synthesis of 2-chloro-6-(2-methoxy-6-methylpyrimidin-4-yl)-4-methyl-7,8-dihydroquinolin-5(6H)-one
  • Figure US20180200247A1-20180719-C00140
  • This intermediate was prepared using the same protocol explained in the synthesis of intermediate-38. LC-MS: 318.2 [M+H]+.
    • EXAMPLES
  • The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds according to the invention.
    • Example-1 Synthesis of N-(4,6-dimethyl-5-oxo-6-(pyridin-2-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (Compound-1)
  • Figure US20180200247A1-20180719-C00141
  • A stirred mixture of 2-chloro-4,6-dimethyl-6-(pyridin-2-yl)-7,8-dihydroquinolin-5(6H)-one (0.25 g, 0.83 mmol) and 2-(4-(ethylsulfonyl)phenyl)acetamide (0.245 g, 1.07 mmol) in 1,4-dioxane (20 mL) and K2CO3 (0.344 g, 2.49 mmol) taken in a screw cap sealed tube was degassed using argon. To this mixture was added palladium(II)acetate (0.093 g, 0.041 mmol), xantphos (0.048 g, 0.08 mmol) and heated to 110° C. for 12 h. The RM was cooled to RT, diluted with ethyl acetate, washed with water, brine solutions, dried over sodium sulfate and concentrated to get residue. The residue was purified by preparative TLC using 50% ethyl acetate in hexanes to get the title compound (0.127 g, 32.22%). 1H NMR (300 MHz, CDCl3) δ 8.48 (d, J=3.63 Hz, 1H), 7.84-7.96 (m, 4H), 7.48-7.60 (m, 3H), 7.06-7.14 (m, 2H), 3.79 (s, 2H), 3.11 (q, J=7.58 Hz, 2H), 2.81-2.95 (m, 3H), 2.71 (s, 3H), 2.08-2.28 (m, 1H), 1.51 (s, 3H), 1.28 (t, J=7.42 Hz, 3H). LC-MS: 478.3 [M+H]+.
  • The below compounds (2-83) were prepared by a procedure similar to the one described in Example-1 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Com-
    pound
    No. Structure Characterization Data
    2
    Figure US20180200247A1-20180719-C00142
         		1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 8.9 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.88- 8.00 (m, 4H), 7.53 (d, J = 8.1 Hz, 2H), 7.45 (dd, J = 8.7, 2.6 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 2H), 3.07-3.17 (m, 2H), 2.77-2.93 (m, 2H), 2.54-2.66 (m, 1H), 2.18-2.32 (m, 1H), 1.49-1.53 (m, 3H), 1.26-1.32 (m, 3H); LC-MS: 494.3 [M + H]+.
    3
    Figure US20180200247A1-20180719-C00143
         		1H NMR (400 MHz, CDCl3): δ 8.64 (br s, 1H), 8.41 (d, J = 8.6 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.88-7.99 (m, 3H), 7.69 (br s, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.54 (d, J = 7.8 Hz, 2H), 3.85 (s, 2H), 3.12 (q, J = 7.3 Hz, 2H), 2.95 (br s, 1H), 2.75-2.87 (m, 1H), 2.69 (d, J = 14.2 Hz, 1H), 2.34 (d, J = 10.2 Hz, 1H), 1.57 (br s, 3H), 1.26-1.32 (m, 3H); LC-MS: 532.3 [M + H]+.
    4
    Figure US20180200247A1-20180719-C00144
         		1H NMR (300 MHz, CDCl3): δ 8.32 (d, J = 8.6 Hz, 1H), 8.04-8.22 (m, 3H), 7.93 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.06-7.19 (m, 2H), 3.86 (s, 2H), 3.81 (s, 3H), 3.68 (s, 1H), 3.28 (d, J = 17.1 Hz, 1H), 3.13 (q, J = 7.3 Hz, 2H), 2.75 (d, J = 17.1 Hz, 1H), 1.30 (s, 3H), 1.08 (s, 3H), 0.95 (s, 3H); LC-MS: 508.3 [M + H]+.
    5
    Figure US20180200247A1-20180719-C00145
         		1H NMR (400 MHz, CDCl3): δ 8.40 (d, J = 8.6 Hz, 1H), 8.33 (d, J = 6.2 Hz, 1H), 8.12 (d, J = 8.9 Hz, 1H), 7.92-7.90 (m, 3H), 7.53 (d, J = 8.1 Hz, 2H), 6.61-6.68 (m, 2H), 3.82 (s, 2H), 3.77 (s, 3H), 3.12 (q, J = 7.5 Hz, 2H), 2.74-3.01 (m, 3H), 2.10-2.28 (m, 1H), 1.55 (s, 3H), 1.29 (s, 3H); LC- MS: 494.3 [M + H]+.
    6
    Figure US20180200247A1-20180719-C00146
         		1H NMR (300 MHz, CDCl3): δ 8.46 (d, J = 8.6 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 8.05 (s, 1H), 7.95-7.99 (m, 1H), 7.90-7.94 (m, 2H), 7.68-7.72 (m, 2H), 7.63 (s, 1H), 7.55 (d, J = 8.2 Hz, 2H), 3.84 (s, 2H), 3.59- 3.71 (m, 1H), 3.12 (d, J = 7.5 Hz, 2H), 2.96-3.07 (m, 1H), 2.69-2.81 (m, 1H), 2.12-2.21 (m, 1H), 1.30 (t, J = 7.4 Hz, 3H); LC-MS: 504.3 [M + H]+.
    7
    Figure US20180200247A1-20180719-C00147
         		1H NMR (300 MHz, CDCl3): δ 8.38 (d, J = 8.78 Hz, 1H), 8.14 (d, J = 8.78 Hz, 1H), 7.89-7.98 (m, 3H), 7.53 (d, J = 8.23 Hz, 2H), 6.77 (s, 1H), 3.83 (s, 2H), 3.12 (q, J = 7.32 Hz, 2H), 2.96 (d, J = 4.39 Hz, 1H), 2.85-2.93 (m, 2H), 2.61 (s, 3H), 2.39 (s, 3H), 2.08-2.19 (m, 1H), 1.52 (s, 3H), 1.29 (s, 3H); LC-MS: 492.9 [M + H]+.
    8
    Figure US20180200247A1-20180719-C00148
         		1H NMR (400 MHz, CDCl3): δ 8.75 (s, 1H), 8.38 (d, J = 8.77 Hz, 1H), 8.12 (d, J = 8.77 Hz, 1H), 7.94 (d, J = 8.33 Hz, 3H), 7.77-7.84 (m, 1H), 7.52 (d, J = 8.33 Hz, 2H), 7.31 (d, J = 8.33 Hz, 1H), 3.81 (s, 2H), 3.46 (d, J = 7.02 Hz, 1H), 3.04 (s, 3H), 2.78-2.96 (m, 3H), 2.15-2.27 (m, 1H), 1.15-1.35 (m, 2H); LC-MS: 518 [M + H]+.
    9
    Figure US20180200247A1-20180719-C00149
         		1H NMR (400 MHz, DMSO-d6): δ 11.23 (s, 1H), 8.42 (d, J = 4.57 Hz, 1H), 8.26 (d, J = 8.60 Hz, 1H), 8.08 (d, J = 8.60 Hz, 1H), 7.84 (d, J = 3.76 Hz, 3H), 7.58-7.64 (m, 3H), 3.90 (s, 2H), 3.49-3.61 (m, 1H), 3.37 (br s, 1H), 3.27 (d, J = 7.52 Hz, 2H), 2.96- 3.06 (m, 1H), 2.59 (m, 1H), 2.36 (s, 3H), 2.06-2.14 (m, 1H), 1.71 (s, 3H), 1.09 (t, J = 7.25 Hz, 3H); LC-MS: 517.8 [M + H]+.
    10
    Figure US20180200247A1-20180719-C00150
         		1H NMR (400 MHz, CDCl3): δ 8.45 (d, J = 2.45 Hz, 1H), 8.13 (d, J = 8.80 Hz, 1H), 7.96 (d, J = 8.07 Hz, 3H), 7.51-7.58 (m, 3H), 7.14 (d, J = 8.56 Hz, 1H), 3.83 (s, 2H), 3.48 (q, J = 7.09 Hz, 2H), 3.06 (s, 3H), 2.84-2.88 (m, 2H), 1.55 (s, 3H); LC- MS: 484.1 [M + H]+.
    11
    Figure US20180200247A1-20180719-C00151
         		1H NMR (300 MHz, CDCl3): δ 8.24 (s, 1H), 7.98 (d, J = 4.57 Hz, 1H), 7.78-7.88 (m, 3H), 7.67-7.73 (m, 2H), 7.63 (s, 1H), 7.52 (d, J = 8.05 Hz, 2H), 4.16 (br s, 2H), 3.56-3.69 (m, 1H), 2.99-3.16 (m, 3H), 2.81 (d, J = 5.12 Hz, 1H), 2.25 (s, 3H), 2.15 (dd, J = 4.76, 8.14, 13.45 Hz, 1H), 1.83 (s, 3H), 1.27 (s, 3H); LC-MS: 518.2 [M + H]+.
    12
    Figure US20180200247A1-20180719-C00152
         		1H NMR (300 MHz, CDCl3): δ 8.37 (d, J = 8.60 Hz, 1H), 8.01-8.18 (m, 2H), 7.91 (d, J = 8.23 Hz, 2H), 7.54 (d, J = 8.23 Hz, 2H), 7.36 (d, J = 9.15 Hz, 1H), 6.92 (d, J = 9.33 Hz, 1H), 4.08 (s, 3H), 3.83 (s, 2H), 2.81- 3.22 (m, 5H), 2.20-2.38 (m, 1H), 1.57 (s, 3H), 1.29 (t, J = 7.41 Hz, 3H); LC-MS: 494.9 [M + H]+.
    13
    Figure US20180200247A1-20180719-C00153
         		1H NMR (300 MHz, CDCl3): δ 8.44 (d, J = 8.60 Hz, 1H), 8.11-8.22 (m, 2H), 8.05 (d, J = 6.77 Hz, 1H), 7.96 (d, J = 8.23 Hz, 2H), 7.55 (d, J = 7.14 Hz, 4H), 6.87 (d, J = 6.95 Hz, 1H), 6.63-6.72 (m, 1H), 3.83 (s, 2H), 3.79 (s, 1H), 3.06 (s, 3H), 2.95-3.04 (m, 1H), 2.69-2.86 (m, 1H), 1.90-2.08 (m, 1H), 1.76 (s, 3H); LC-MS: 488.7 [M + H]+.
    14
    Figure US20180200247A1-20180719-C00154
         		1H NMR (300 MHz, DMSO-d6): δ 10.98 (s, 1H), 8.53 (d, J = 4.39 Hz, 1H), 8.13 (s, 1H), 7.97 (d, J = 8.42 Hz, 1H), 7.81-7.90 (m, 3H), 7.69-7.75 (m, 2H), 7.62 (d, J = 8.23 Hz, 2H), 3.87 (s, 2H), 3.70 (q, J = 6.95 Hz, 2H), 3.21-3.28 (m, 2H), 2.82- 3.01 (m, 4H), 1.08 (t, J = 7.32 Hz, 3H), 0.98 (t, J = 6.95 Hz, 3H); LC-MS: 518 [M + H]+.
    15
    Figure US20180200247A1-20180719-C00155
         		1H NMR (400 MHz, CDCl3): δ 8.37 (d, J = 8.60 Hz, 1H), 8.11 (d, J = 8.60 Hz, 1H), 8.00 (s, 1H), 7.90 (d, J = 8.06 Hz, 2H), 7.67 (d, J = 4.57 Hz, 1H), 7.52 (d, J = 8.33 Hz, 2H), 7.31-7.37 (m, 2H), 6.72-6.81 (m, 2H), 3.81 (s, 2H), 3.11 (q, J = 7.43 Hz, 3H), 2.96-3.06 (m, 1H), 2.90 (s, 1H), 2.12- 2.26 (m, 1H), 1.28 (s, 3H); LC-MS: 503.1 [M + H]+.
    16
    Figure US20180200247A1-20180719-C00156
         		1H NMR (400 MHz, CDCl3): δ 8.43 (d, J = 8.60 Hz, 1H), 8.15 (d, J = 8.60 Hz, 1H), 8.04 (s, 1H), 7.92 (d, J = 8.06 Hz, 2H), 7.77 (s, 1H), 7.64 (s, 1H), 7.48-7.57 (m, 3H), 3.83 (s, 2H), 3.56-3.67 (m, 1H), 3.12 (q, J = 7.52 Hz, 2H), 2.96-3.05 (m, 1H), 2.72-2.82 (m, 1H), 2.34 (s, 3H), 2.13 (dd, J = 5.10, 8.06, 13.43 Hz, 1H), 1.82 (s, 3H), 1.29 (s, 3H); LC-MS: 518 [M + H]+.
    17
    Figure US20180200247A1-20180719-C00157
         		1H NMR (400 MHz, CDCl3): δ 7.99 (s, 1H), 7.85-7.93 (m, 3H), 7.53 (d, J = 8.06 Hz, 2H), 7.43 (dd, J = 2.55, 8.73 Hz, 1H), 6.70 (d, J = 8.87 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 2H), 3.07-3.15 (m, 2H), 2.78- 2.98 (m, 2H), 2.72 (s, 3H), 2.52-2.62 (m, 1H), 2.18 (s, 1H), 1.46 (s, 3H), 1.29 (t, J = 7.52 Hz, 3H); LC-MS: 508.3 [M + H]+.
    18
    Figure US20180200247A1-20180719-C00158
         		1H NMR (400 MHz, CDCl3): δ 8.41-8.50 (m, 2H), 7.87-7.99 (m, 3H), 7.45-7.56 (m, 3H), 7.22 (dd, J = 4.84, 7.52 Hz, 1H), 3.81 (s, 2H), 3.12 (q, J = 7.25 Hz, 2H), 2.90 (br s, 1H), 2.79 (br s, 1H), 2.72 (s, 3H), 2.64 (d, J = 14.24 Hz, 1H), 2.22-2.32 (m, 1H), 1.51 (s, 3H), 1.28 (s, 3H); LC-MS: 477.9 [M + H]+.
    19
    Figure US20180200247A1-20180719-C00159
         		1H NMR (400 MHz, CDCl3): δ 7.82-7.96 (m, 4H), 7.52 (d, J = 8.06 Hz, 2H), 7.45 (t, J = 7.79 Hz, 1H), 6.69 (d, J = 7.52 Hz, 1H), 6.53 (d, J = 8.06 Hz, 1H), 3.80 (s, 2H), 3.72 (s, 3H), 3.11 (d, J = 7.25 Hz, 2H), 2.86 (d, J = 5.37 Hz, 2H), 2.74-2.81 (m, 1H), 2.71 (s, 3H), 2.11-2.22 (m, 1H), 1.29 (t, J = 7.52 Hz, 3H). LC-MS: 508.4 [M + H]+.
    20
    Figure US20180200247A1-20180719-C00160
         		1H NMR (400 MHz, CDCl3): δ 8.17 (br s,, 1H), 7.83-7.96 (m, 4H), 7.51 (d, J = 6.72 Hz, 2H), 6.94-7.16 (m, 2H), 3.79 (br s, 6H), 3.11 (d, J = 6.72 Hz, 2H), 2.78-2.95 (m, 3H), 2.70 (br s, 3H), 2.15 (br s, 1H), 1.48 (s, 3H), 1.26-1.30 (m, 3H); LC-MS: 508.3 [M + H]+.
    21
    Figure US20180200247A1-20180719-C00161
         		1H NMR (400 MHz, CDCl3): δ 8.31 (d, J = 5.64 Hz, 1H), 7.85-7.97 (m, 4H), 7.53 (d, J = 8.06 Hz, 2H), 6.50 (d, J = 5.37 Hz, 1H), 3.80 (s, 2H), 3.77 (s, 3H), 3.12 (q, J = 7.43 Hz, 2H), 2.86 (br s, 3H), 2.70 (s, 3H), 2.08- 2.22 (m, 1H), 1.56 (s, 3H), 1.27-1.31 (m, 3H); LC-MS: 509.3 [M + H]+.
    22
    Figure US20180200247A1-20180719-C00162
         		1H NMR (400 MHz, CDCl3): δ 8.32 (d, J = 5.64 Hz, 1H), 7.91 (d, J = 8.33 Hz, 4H), 7.53 (d, J = 8.33 Hz, 2H), 6.58-6.66 (m, 2H), 3.81 (s, 2H), 3.77 (s, 3H), 3.12 (q, J = 7.34 Hz, 2H), 2.81-2.99 (m, 3H), 2.72 (s, 3H), 2.11-2.22 (m, 1H), 1.51 (s, 3H), 1.29 (t, J = 7.52 Hz, 3H); LC-MS: 509.4 [M + H]+.
    23
    Figure US20180200247A1-20180719-C00163
         		1H NMR (400 MHz, CDCl3): δ 8.30 (d, J = 4.57 Hz, 1H), 7.88-7.98 (m, 3H), 7.54 (d, J = 8.06 Hz, 2H), 7.28-7.35 (m, 1H), 7.17 (td, J = 4.26, 8.40 Hz, 1H), 3.81 (s, 2H), 3.12 (q, J = 7.52 Hz, 2H), 2.83-3.02 (m, 3H), 2.68 (s, 3H), 2.03-2.21 (m, 1H), 1.59 (s, 3H), 1.29 (t, J = 7.39 Hz, 3H); LC-MS: 496.3 [M + H]+.
    24
    Figure US20180200247A1-20180719-C00164
         		1H NMR (400 MHz, CDCl3): δ 8.07-8.14 (m, 1H), 8.04 (d, J = 1.88 Hz, 1H), 7.89 (d, J = 8.06 Hz, 2H), 7.55 (d, J = 8.33 Hz, 2H), 7.08 (d, J = 1.88 Hz, 1H), 3.85 (s, 2H), 3.71 (s, 3H), 2.90-3.15 (m, 5H), 2.68 (s, 3H), 1.51 (s, 3H), 1.26-1.30 (m, 4H); LC- MS: 542.3 [M + H]+.
    25
    Figure US20180200247A1-20180719-C00165
         		1H NMR (400 MHz, CDCl3): δ 8.35 (s, 2H), 7.98 (s, 1H), 7.92 (d, J = 8.06 Hz, 2H), 7.88 (s, 1H), 7.53 (d, J = 8.06 Hz, 2H), 3.97 (s, 3H), 3.83 (s, 2H), 3.12 (q, J = 7.34 Hz, 2H), 2.94-3.04 (m, 1H), 2.78- 2.89 (m, 1H), 2.70 (s, 3H), 2.58 (td, J = 4.84, 14.24 Hz, 1H), 2.18-2.31 (m, 1H), 1.53 (s, 3H), 1.29 (t, J = 7.39 Hz, 3H); LC- MS: 509.3 [M + H]+.
    26
    Figure US20180200247A1-20180719-C00166
         		1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 8.06 Hz, 4H), 7.84 (br s, 1H), 7.67-7.72 (m, 2H), 7.59 (s, 1H), 7.52 (d, J = 8.06 Hz, 2H), 3.79 (s, 2H), 3.44-3.55 (m, 1H), 3.11 (d, J = 7.52 Hz, 2H), 2.85-3.03 (m, 2H), 2.72 (s, 3H), 2.15 (dd, J = 5.64, 8.87, 13.97 Hz, 1H), 1.75 (s, 3H), 1.28 (t, J = 7.52 Hz, 3H); LC-MS: 518.1 [M + H]+.
    27
    Figure US20180200247A1-20180719-C00167
         		1H NMR (400 MHz, CDCl3): δ 8.13 (d, J = 1.07 Hz, 1H), 7.83-7.97 (m, 5H), 7.53 (d, J = 8.06 Hz, 2H), 3.90 (s, 3H), 3.81 (s, 2H), 3.12 (q, J = 7.52 Hz, 2H), 2.78-2.95 (m, 3H), 2.70 (s, 3H), 2.10-2.23 (m, 1H), 1.52 (s, 3H), 1.29 (t, J = 7.52 Hz, 3H); LC- MS: 509.3 [M + H]+.
    28
    Figure US20180200247A1-20180719-C00168
         		1H NMR (400 MHz, DMSO-d6): δ 11.05 (s, 1H), 7.77-7.88 (m, 3H), 7.58 (d, J = 8.06 Hz, 2H), 7.17 (s, 1H), 3.86 (s, 2H), 3.18-3.30 (m, 3H), 2.94 (d, J = 18.27 Hz, 1H), 2.74 (dd, J = 4.70, 14.10 Hz, 2H), 2.57 (s, 3H), 2.39 (d, J = 18.00 Hz, 6H), 2.09-2.19 (m, 1H), 1.38 (s, 3H), 1.08 (t, J = 7.25 Hz, 3H); LC-MS: 506.8 [M + H]+.
    29
    Figure US20180200247A1-20180719-C00169
         		1H NMR (400 MHz, CDCl3): δ 7.89 (d, J = 8.23 Hz, 3H), 7.82 (s, 1H), 7.52 (d, J = 8.23 Hz, 2H), 6.76 (s, 1H), 3.78 (s, 2H), 3.40-3.54 (m, 1H), 3.11 (q, J = 7.38 Hz, 2H), 2.78-2.98 (m, 3H), 2.69 (s, 3H), 2.31 (s, 6H), 2.03-2.19 (m, 1H), 1.51 (s, 3H), 1.28 (t, J = 7.41 Hz, 3H); LC-MS: 507.3 [M + H]+.
    30
    Figure US20180200247A1-20180719-C00170
         		1H NMR (300 MHz, CDCl3): δ 8.39 (d, J = 5.12 Hz, 1H), 7.86-8.00 (m, 4H), 7.53 (d, J = 8.23 Hz, 2H), 6.75 (d, J = 5.12 Hz, 1H), 3.89 (s, 3H), 3.82 (s, 2H), 3.12 (q, J = 7.50 Hz, 2H), 2.79-2.96 (m, 3H), 2.69 (s, 3H), 2.04-2.23 (m, 1H), 1.52 (s, 3H), 1.29 (t, J = 7.41 Hz, 3H); LC-MS: 509.3 [M + H]+.
    31
    Figure US20180200247A1-20180719-C00171
         		1H NMR (300 MHz, CDCl3): δ 7.83-8.03 (m, 4H), 7.52 (d, J = 8.05 Hz, 2H), 7.28- 7.32 (m, 1H), 6.91 (d, J = 9.15 Hz, 1H), 4.07 (s, 3H), 3.81 (s, 2H), 3.11 (q, J = 7.44 Hz, 3H), 2.84-3.01 (m, 2H), 2.68 (s, 3H), 2.13-2.31 (m, 1H), 1.55 (s, 3H), 1.28 (s, 3H); LC-MS: 509.3 [M + H]+.
    32 Error! Objects cannot be created 1H NMR (400 MHz, CDCl3): δ 8.73 (s,
    from editing field codes. 1H), 7.93 (d, J = 8.33 Hz, 3H), 7.74-7.84
    (m, 2H), 7.50 (d, J = 7.89 Hz, 2H), 7.27 (s,
    1H), 3.79 (s, 2H), 3.03 (s, 3H), 2.83-2.92
    (m, 3H), 2.69 (s, 3H), 2.11-2.26 (m, 1H),
    1.53 (s, 3H); LC-MS: 531.9 [M + H]+.
    33
    Figure US20180200247A1-20180719-C00172
         		1H NMR (300 MHz, CDCl3): δ 7.97-8.06 (m, 1H), 7.90-7.95 (m, 4H), 7.66-7.72 (m, 2H), 7.59 (s, 1H), 7.51 (d, J = 8.05 Hz, 2H), 3.79 (s, 2H), 3.44-3.53 (m, 2H), 3.05 (s, 3H), 2.89-2.98 (m, 2H), 2.71 (s, 3H), 2.15 (dd, J = 5.85, 8.69, 14.00 Hz, 1H), 1.75 (s, 3H); LC-MS: 504.7 [M + H]+.
    34
    Figure US20180200247A1-20180719-C00173
         		1H NMR (300 MHz, DMSO-d6): δ 11.03 (s, 1H), 7.78-7.84 (m, 3H), 7.69 (d, J = 8.78 Hz, 1H), 7.53-7.58 (m, 3H), 3.84 (s, 2H), 3.13-3.29 (m, 3H), 2.71 (br s, 1H), 2.55 (s, 5H), 2.25 (s, 1H), 1.42 (s, 3H), 1.22 (br s, 1H), 1.06 (t, J = 7.41 Hz, 4H); LC-MS: 493.19 [M + H]+.
    35
    Figure US20180200247A1-20180719-C00174
         		1H NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.33 Hz, 4H), 7.55 (d, J = 8.06 Hz, 2H), 7.32 (d, J = 9.13 Hz, 1H), 6.93 (d, J = 9.13 Hz, 1H), 4.10 (s, 3H), 3.83 (s, 2H), 3.51 (s, 1H), 3.07 (s, 4H), 2.89-3.00 (m, 2H), 2.70 (s, 3H), 1.58 (s, 3H); LC-MS: 494.9 [M + H]+.
    36
    Figure US20180200247A1-20180719-C00175
         		1H NMR (400 MHz, DMSO-d6): δ 11.11 (s, 1H), 7.80-7.93 (m, 3H), 7.60 (d, J = 8.33 Hz, 2H), 3.89 (s, 2H), 3.28 (q, J = 7.34 Hz, 3H), 3.00 (d, J = 18.00 Hz, 1H), 2.69-2.85 (m, 2H), 2.56 (s, 3H), 2.01- 2.16 (m, 1H), 1.48 (s, 3H), 1.09 (t, J = 7.39 Hz, 3H); LC-MS: 495.1 [M + H]+.
    37
    Figure US20180200247A1-20180719-C00176
         		1H NMR (400 MHz, CDCl3): δ 8.79 (s, 1H), 7.98 (s, 1H), 7.88 (d, J = 8.06 Hz, 2H), 7.53 (d, J = 8.33 Hz, 2H), 7.21 (d, J = 6.72 Hz, 1H), 6.29 (s, 1H), 6.10 (d, J = 6.98 Hz, 1H), 4.13 (d, J = 6.99 Hz, 1H), 3.85 (d, J = 2.69 Hz, 1H), 3.13 (q, J = 7.34 Hz, 2H), 2.89-2.93 (m, 2H), 2.68 (s, 3H), 2.45-2.55 (m, 1H), 2.18 (s, 1H), 2.05 (s, 1H), 1.46 (s, 3H), 1.27 (d, J = 7.52 Hz,
    4H); LC-MS: 494.3 [M + H]+.
    38
    Figure US20180200247A1-20180719-C00177
         		1H NMR (400 MHz, CDCl3): δ 8.35 (s, 1H), 7.97 (d, J = 1.88 Hz, 1H), 7.86 (d, J = 8.33 Hz, 2H), 7.59 (d, J = 8.06 Hz, 2H), 7.11 (d, J = 1.61 Hz, 1H), 3.95 (s, 2H), 3.05-3.31 (m, 6H), 2.77 (s, 3H), 1.96- 2.22 (m, 1H), 1.24-1.30 (m, 5H); LC-MS: 528.3 [M + H]+.
    39
    Figure US20180200247A1-20180719-C00178
         		1H NMR (400 MHz, DMSO-d6): δ 11.1 (br s, 1H), 7.88-7.82 (m, 3H), 7.56-7.58 (m, 2H), 7.20 (br s, 1H), 5.55-5.7 (m, 1H), 3.88 (s, 2H), 3.24-3.26 (m, 3H), 2.96- 3.08 (m, 2H), 2.70-2.80 (m, 2H) 2.67 (s, 3H), 1.99-2.08 (m, 2H), 1.06-1.10 (m, 3H); LC-MS: 494.3 [M + H]+.
    40
    Figure US20180200247A1-20180719-C00179
         		1H NMR (400 MHz, CDCl3): δ 9.24 (br s, 1H), 8.35 (d, J = 8.87 Hz, 1H), 8.19 (d, J = 8.60 Hz, 1H), 7.86 (d, J = 8.33 Hz, 2H), 7.55 (d, J = 8.06 Hz, 2H), 7.46 (dd, J = 2.42, 9.67 Hz, 1H), 7.07 (s, 1H), 6.59 (d, J = 9.40 Hz, 1H), 3.89 (s, 2H), 3.48 (q, J = 6.98 Hz, 1H), 3.12 (q, J = 7.43 Hz, 2H), 2.80-3.03 (m, 2H), 2.51 (d, J = 14.51 Hz, 1H), 2.19-2.33 (m, 1H), 1.48 (s, 3H), 1.27- 1.30 (m, 3H); LC-MS: 480.3 [M + H]+.
    41
    Figure US20180200247A1-20180719-C00180
         		1H NMR (400 MHz, CD3OD): δ 9.02 (br s, 1H), 8.13 (d, J = 8.60 Hz, 1H), 7.98 (d, J = 8.87 Hz, 1H), 7.72-7.83 (m, 4H), 7.54 (d, J = 8.06 Hz, 2H), 3.82 (s, 2H), 3.11 (q, J = 7.25 Hz, 1H), 2.99-3.05 (m, 2H), 2.94 (t, J = 8.33 Hz, 2H), 1.87-2.24 (m, 4H), 1.19 (s, 3H), 1.12 (s, 3H); LC-MS: 493.3 [M + H]+.
    42
    Figure US20180200247A1-20180719-C00181
         		1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 8.06 Hz, 3H), 7.52 (d, J = 8.33 Hz, 2H), 6.63-6.70 (m, 2H), 6.53 (dd, J = 1.48, 8.19 Hz, 1H), 5.90 (d, J = 2.96 Hz, 2H), 3.80 (s, 2H), 3.11 (q, J = 7.34 Hz, 2H), 2.79-2.97 (m, 2H), 2.71 (s, 3H), 2.50- 2.58 (m, 1H), 2.14-2.26 (m, 1H), 1.43 (s, 3H), 1.28 (t, J = 7.52 Hz, 3H); LC-MS: 521.3 [M + H]+.
    43
    Figure US20180200247A1-20180719-C00182
         		1H NMR (400 MHz, CDCl3): δ 7.97 (s, 1H), 7.91 (s, 1H), 7.88 (d, J = 8.06 Hz, 2H), 7.83 (s, 1H), 7.60 (s, 1H), 7.49 (d, J = 8.33 Hz, 2H), 7.30 (d, J = 8.33 Hz, 1H), 7.10 (dd, J = 1.48, 8.46 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 2H), 3.10 (q, J = 7.43 Hz, 2H), 2.80-2.99 (m, 2H), 2.74 (s, 3H), 2.70 (d, J = 2.69 Hz, 1H), 2.28 (dd, J = 5.64, 11.82, 14.24 Hz, 1H), 1.51 (s, 3H), 1.27 (t, J = 7.39 Hz, 3H) LC-MS: 531.4 [M + H]+.
    44
    Figure US20180200247A1-20180719-C00183
         		1H NMR (400 MHz, CDCl3): δ 8.00 (d, J = 5.10 Hz, 2H), 7.87-7.94 (m, 3H), 7.52 (d, J = 8.06 Hz, 2H), 7.01-7.10 (m, 2H), 3.80 (s, 2H), 3.52 (t, J = 6.72 Hz, 2H), 3.14 (s, 2H), 3.11 (d, J = 7.52 Hz, 2H), 2.93 (dt, J = 2.82, 6.51 Hz, 2H), 2.83 (dd, J = 4.03, 8.33 Hz, 2H), 2.72 (s, 3H), 2.68 (br s, 1H), 2.16- 2.26 (m, 1H), 1.46 (s, 3H), 1.28 (t, J = 7.39 Hz, 3H) LC-MS: 560.3 [M + H]+.
    45
    Figure US20180200247A1-20180719-C00184
         		1H NMR (400 MHz, DMSO-d6): δ 8.40 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.00 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 6.48 (s, 1H), 6.42 (d, J = 3.6 Hz, 1H), 3.14-3.06 (m, 3H), 2.89- 2.80 (m, 1H), 2.51-2.05 (m, 4H), 1.30-1.25 (m, 4H). LC-MS: 483.1 [M + H]+.
    46
    Figure US20180200247A1-20180719-C00185
         		1H NMR (400 MHz, CD3OD): δ 8.00 (d, J = 8.33 Hz, 1H), 7.91 (d, J = 8.06 Hz, 2H), 7.82 (d, J = 8.33 Hz, 1H), 7.67 (d, J = 8.33 Hz, 2H), 6.01 (s, 1H), 3.92 (s, 2H), 3.37 (s, 3H), 3.23 (q, J = 7.25 Hz, 2H), 3.11 (t, J = 8.19 Hz, 2H), 2.73-2.81 (m, 2H), 2.24 (d, J = 12.09 Hz, 6H), 1.24 (t, J = 7.39 Hz, 3H); LC-MS: 481.2 [M + H]+.
    47
    Figure US20180200247A1-20180719-C00186
         		1H NMR (400 MHz, DMSO-d6): δ 7.80- 7.90 (m, 4H), 7.59 (d, J = 8.33 Hz, 2H), 7.40 (d, J = 13.4 Hz, 1H), 6.29 (s, 1H), 3.88 (s, 2H), 3.62 (br s, 3H), 3.18-3.43 (m, 2H), 2.80-3.10 (m, 3H), 2.27-2.37 (m, 1H), 1.64 (s, 3H), 1.08 (t, J = 7.25 Hz, 3H); LC-MS: 467.3 [M + H]+.
    48
    Figure US20180200247A1-20180719-C00187
         		1H NMR (400 MHz, CDCl3): δ 8.46 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 8.8 Hz, 1H), 8.01 (s, 1H), 7.92-7.90 (m, 3H), 7.79 (s, 1H), 7.60 (s, 1H), 7.56-7.54 (m, 3H), 3.84 (s, 2H), 3.78-3.74 (m, 1H), 3.15-3.09 (m, 2H), 2.54-2.53 (m, 1H), 2.02-1.99 (m, 1H), 1.87 (s, 3H), 1.31-1.27 (m, 6H). LC-MS: 518.0 [M + H]+.
    49
    Figure US20180200247A1-20180719-C00188
         		1H NMR (400 MHz, CDCl3): δ 8.45 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.01 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.72 (s, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.49 (s, 1H), 3.83 (s, 1H), 3.69-3.62 (m, 1H), 3.15-3.09 (m, 2H), 3.19-2.96 (m, 1H), 2.77-2.70 (m, 1H), 2.47 (s, 3H), 2.19- 2.12 (m, 1H), 1.84 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); LC-MS: 518.1 [M + H]+.
    50
    Figure US20180200247A1-20180719-C00189
         		1H NMR (300 MHz, CDCl3): δ 8.53 (d, J = 5.1 Hz, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.04- 8.15 (m, 2H), 7.92 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.1 Hz, 2H), 6.98 (d, J = 5.4 Hz, 1H), 3.83 (s, 2H), 3.07-3.16 (m, 3H), 2.87- 2.93 (m, 3H), 2.15-2.21 (m, 1H), 1.55 (s, 3H), 1.21-1.31 (m, 9H); LC-MS: 507.3 [M + H]+.
    51
    Figure US20180200247A1-20180719-C00190
         		1H NMR (400 MHz, CDCl3): δ 8.44 (d, J = 8.8 Hz, 1H), 8.17-8.13 (m, 2H), 7.93 (d, J = 8.4 Hz, 2H), 7.67 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 3.83 (s, 2H), 3.70-3.64 (m, 1H), 3.16-3.10 (m, 2H), 2.99-2.94 (m, 1H), 2.73-2.65 (m, 1H), 2.42 (s, 3H), 2.27 (s, 3H), 2.21-2.10 (m, 1H), 1.83 (s, 3H), 1.32- 1.27 (m, 3H). LC-MS: 532.0 [M + H]+.
    52
    Figure US20180200247A1-20180719-C00191
         		1H NMR (400 MHz, DMSO-d6): δ 11.0 (br s, 1H), 8.39 (d, J = 4.4 Hz, 1H), 7.83-7.80 (m, 4H), 7.68 (d, J = 4.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 2H), 3.84 (s, 2H), 3.34-3.23 (m, 3H), 3.00-2.96 (m, 2H), 2.75-2.68 (m, 1H), 2.67 (s, 3H), 2.38 (s, 3H), 2.10-2.05 (m, 1H), 1.59 (s, 3H), 1.10 (t, J = 7.6 Hz, 3H); LC-MS: 531.9 [M + H]+.
    53
    Figure US20180200247A1-20180719-C00192
         		1H NMR (300 MHz, CDCl3): δ 7.97-7.90 (m, 4H), 7.75 (d, J = 9 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.53 (d, , J = 9 Hz, 2H), 3.88 (s, 2H), 3.16-3.08 (m, 3H), 3.03-2.99 (m, 2H), 2.69 (s, 3H), 1.58 (s, 6H), 1.31- 1.21 (m, 5H); LC-MS: 547 [M + H]+.
    54
    Figure US20180200247A1-20180719-C00193
         		1H NMR (300 MHz, CDCl3): δ 8.34 (d, J = 8.99 Hz, 1H), 8.18 (t, J = 8.99 Hz, 2H), 8.05 (d, J = 4.49 Hz, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 4.5 Hz, 1H), 7.75- 7.70 (m, 2H), 7.59 (d, J = 8.4 Hz, 2H), 4.51 (d, J = 11.7 Hz, 1H), 3.88 (s, 2H), 3.38- 3.22 (m, 1H), 3.18-3.10 (m, 3H), 3.01-2.98 (m, 1H), 1.33 (t, J = 15 Hz, 3H), 1.04 (d, J = 6.6 Hz, 3H); LC-MS: 504.0 [M + H]+.
    55
    Figure US20180200247A1-20180719-C00194
         		1H NMR (300 MHz, CDCl3): δ 8.6 (br, 1H), 8.40 (d, J = 9 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 9 Hz, 2H), 7.76 (d, J = 9 Hz, 1H), 7.68 (d, 3.88, J = 9.3 Hz, 1H), 7.54 (d, J = 8.1 Hz, 2H), 3.86 (s, 2H), 3.49 (s, 1H), 3.16-3.05 (m, 6H), 2.41- 2.42 (m, 1H), 1.31-1.21 (m, 5H); LC-MS: 532 [M + H]+.
    56
    Figure US20180200247A1-20180719-C00195
         		1H NMR (300 MHz, CDCl3): δ 8.45 (d, J = 8.7 Hz, 1H), 8.28 (s, 2H), 8.16 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 6.6 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 3.85 (s, 3H), 3.83 (s, 2H), 3.08-3.15 (m, 2H), 2.70-2.88 (m, 3H), 2.15-2.25 (m, 1H), 1.61 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H); LC-MS: 495.0 [M + H]+.
    57
    Figure US20180200247A1-20180719-C00196
         		1H NMR (400 MHz, DMSO-d6): δ 11.0 (br s, 1H), 8.39 (d, J = 4.4 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 9.2 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 9.2 Hz, 2H), 5.29- 5.26 (m, 1H), 3.85 (s, 2H), 3.26-3.20 (m, 3H), 2.90-2.86 (m, 1H), 2.66-2.59 (m, 2H), 1.45 (s, 3H), 1.26 (d, J = 6.0 Hz, 6H), 1.10 (t, J = 7.6 Hz, 3H); LC-MS: 522.8 [M + H]+.
    58
    Figure US20180200247A1-20180719-C00197
         		1H NMR (300 MHz, CDCl3): δ 8.44 (d, J = 8.70 Hz, 1H), 8.25 (s, 1H), 8.13 (d, J = 8.70 Hz, 1H), 7.85 (d, J = 4.50 Hz, 1H), 7.72-7.57 (m, 4H), 7.37 (s, 1H), 3.83 (s, 2H), 3.74-3.66 (m, 1H), 3.49-3.48 (m, 1H), 3.16-3.09 (m, 2H), 2.97-2.91 (m, 1H), 2.73-2.62 (m, 1H), 2.45 (s, 3H), 2.20-2.11 (m, 1H), 1.84 (s, 3H), 1.32 (t, J = 15 Hz, 3H); LC-MS: 535.9 [M + H]+.
    59
    Figure US20180200247A1-20180719-C00198
         		1H NMR (400 MHz, DMSO-d6): δ 11.21 (br s, 1H), 8.42 (d, J = 8.4.8 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.89-7.83 (m, 3H), 7.62-7.59 (m, 3H), 3.88 (s, 2H), 3.56-3.53 (m, 1H), 3.19 (s, 3H), 2.98-2.96 (m, 1H), 2.50-2.49 (m, 2H), 2.35 (s, 3H), 2.10-2.05 (m, 1H), 1.70 (s, 3H); LC-MS: 503.6 [M + H]+.
    60
    Figure US20180200247A1-20180719-C00199
         		1H NMR (400 MHz, CDCl3): δ 8.43-8.38 (m, 2H) 8.29 (d, J = 2.4 Hz, 1H), ) 8.19 (d, J = 8.8 Hz, 1H), 8.01 (s, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 3.85 (s, 2H), 3.14-3.09 (m, 4H), 2.99-2.92 (m, 1H), 2.78-2.73 (m, 1H), 2.62-2.58 (m, 1H), 2.10-2.04 (m, 1H), 1.68 (s, 3H), 1.30 (t, J = 7.6 Hz, 3H), 1.14-1.12 (m, 6H). LC-MS: 506.9 [M + H]+.
    61
    Figure US20180200247A1-20180719-C00200
         		1H NMR (300 MHz, CDCl3): δ 8.26 (s, 2H), 7.99 (br s, 1H), 7.88-7.91 (m, 3H), 7.53 (d, J = 8.1 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 2H), 3.07-3.15 (m, 2H), 2.80-2.88 (m, 3H), 2.70 (s, 3H), 2.13-2.17 (m, 1H), 1.54 (s, 3H), 1.30 (t, J = 7.5 Hz, 3H); LC- MS: 509.2 [M + H]+.
    62
    Figure US20180200247A1-20180719-C00201
         		1H NMR (400 MHz, CDCl3): δ 7.90-7.83 (m, 4H), 7.54 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 9.2 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.8 Hz, 1H), 3.78 (s, 2H), 3.21- 3.18 (m, 1H) 3.12-2.96 (m, 4H), 2.55 (t, J = 8.4 Hz, 2H), 1.80 (s, 3H), 1.33-1.24 (m, 9H), LC-MS: 507.6 [M + H]+.
    63
    Figure US20180200247A1-20180719-C00202
         		1H NMR (400 MHz, CDCl3): δ 7.92-7.89 (m, 4H), 7.53 (d, J = 8.0 Hz, 2H), 7.30- 7.23 (m, 2H), 3.80 (s, 2H), 3.50 (d, J = 5.6 Hz, 1H), 3.12-3.09 (m, 2H) 3.02- 2.92 (m, 4H), 2.69 (s, 3H), 2.41 (s, 3H), 2.30-2.20 (m, 2H), 1.57 (s, 3H), 1.35-1.26 (m, 6H); LC-MS: 507.0 [M + H]+.
    64
    Figure US20180200247A1-20180719-C00203
         		1H NMR (300 MHz, CD3OD): δ 8.33 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 2H), 7.63 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 3.89 (s, 2H), 3.79 (s, 3H), 3.23-3.16 (m, 2H), 3.06-2.98 (m, 1H), 2.93-2.79 (m, 2H), 2.38 (s, 3H), 1.54 (s, 3H), 1.28-1.18 (m, 3H). LC-MS: 509.3 [M + H]+.
    65
    Figure US20180200247A1-20180719-C00204
         		1H NMR (300 MHz, CDCl3): δ 8.38 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.04 (br s, 1H), 7.91 (d, J = 6.3 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 6.22 (s, 1H), 3.87 (s, 3H), 3.82 (s, 2H), 3.08-3.15 (m, 2H), 2.83- 2.92 (m, 3H), 2.12-2.16 (m, 1H), 2.51 (s, 3H), 1.50 (s, 3H), 1.30 (t, J = 7.5 Hz, 3H); LC-MS: 509.3 [M + H]+.
    66
    Figure US20180200247A1-20180719-C00205
         		1H NMR (300 MHz, CDCl3): δ 8.44 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 8.08 (br s, 1H), 7.91 (d, J = 8.1 Hz, 2H), 7.52- 7.67 (m, 2H), 7.55 (d, J = 8.1 Hz, 2H), 3.82 (s, 2H), 3.57-3.65 (m, 1H), 3.07-3.15 (m, 2H), 2.90-2.98 (m, 1H), 2.67-2.73 (m, 1H), 2.39 (s, 3H), 2.11-2.18 (m, 1H), 1.82 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H); LC- MS: 535.9 [M + H]+.
    67
    Figure US20180200247A1-20180719-C00206
         		1H NMR (400 MHz, CDCl3): δ 7.91 (d, J = 8.4 Hz, 3H), 7.55 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 1H), 7.00 (s, 1H), 3.81 (s, 2H), 3.14-3.09 (m, 2H), 3.02 (t, J = 8.0 Hz, 2H) 2.60 (s, 2H), 2.59 (t, J = 8.4 Hz, 2H), 1.75 (s, 3H), 1.31 (t, J = 7.6 Hz, 3H); LC-MS: 547.3 [M + H]+.
    68
    Figure US20180200247A1-20180719-C00207
         		1H NMR (400 MHz, CD3OD): δ 8.38 (d, J = 8.8 Hz, 2H), 8.306 (d, J = 4.4 Hz, 2H), 8.09 (d, J = 8.8 Hz 1H), 7.92 (d, J = 8 Hz, 2H) 7.76 (s, 1H), 7.68 (d, J = 7.6 Hz 2H), 7.62 (d, J = 4.4 Hz, 1H) 4.86 (s, 2H), 3.70- 3.33 (m, 2H), 3.30-3.24 (m, 2H), 3.15-3.05 (m, 1H), 2.75-2.68 (m, 1H), 2.45 (s, 3H), 2.20-2.16 (m, 2H), 1.80 (s, 3H), 1.29-1.22 (m, 3H); LC-MS: 518.4 [M + H]+.
    69
    Figure US20180200247A1-20180719-C00208
         		1H NMR (400 MHz, CDCl3): δ 8.31 (d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 6.85 (s, 1H), 3.87 (s, 2H), 3.67 (s, 1H), 3.33-3.29 (m, 1H), 3.16-3.11 (m, 2H), 2.83-2.79 (m, 1H), 2.53 (s, 3H), 2.47 (s, 3H), 1.32-1.25 (m, 3H), 1.08 (s, 3H), 0.99 (s, 3H). LC-MS: 506.9 [M + H]+.
    70
    Figure US20180200247A1-20180719-C00209
         		1H NMR (400 MHz, CDCl3): δ 7.90-7.96 (m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 9.6 Hz, 1H), 6.90 (d, J = 9.6 Hz, 1H), 3.82 (s, 2H), 3.64 (s, 3H), 3.09-3.13 (m, 2H), 2.98-3.00 (m, 2H), 2.65 (s, 3H), 2.59- 2.64 (m, 1H), 2.12-2.15 (m, 1H), 1.48 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H). LC-MS: 509.3 [M + H]+.
    71
    Figure US20180200247A1-20180719-C00210
         		1H NMR (400 MHz, CDCl3): δ 8.44 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 8.07 (s, 1H), 8.01 (d, J = 4.4 Hz, 1H), 7.91 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 4.4 Hz, 1H) 7.54 (d, J = 8.0 Hz, 2H), 7.39 (s, 1H), 3.82 (s, 2H), 3.63-3.60 (m, 1H), 3.14-3.08 (m, 2H) 3.08-2.98 (m, 1H), 2.73-2.65 (m, 1H), 2.23- 2.13 (m, 1H), 1.82 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H), 1.22-1.18 (m, 1H), 1.07-1.05 (m,
    2H), 0.73-0.80 (m 2H); LC-MS: 544.6
    [M + H]+.
    72
    Figure US20180200247A1-20180719-C00211
         		1H NMR (400 MHz, CDCl3): δ 8.46 (d, J = 8.8 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.99-7.92 (m, 3H), 7.97 (d, J = 8.0 Hz, 1H) 7.57 (d, J = 8.0 Hz, 2H), 3.86 (s, 2H), 3.69-3.62 (m, 1H), 3.17-3.11 (m, 2H) 3.02-2.98 (m, 1H), 2.73-2.65 (m, 1H), 2.23-2.2.16 (m, 1H), 1.87 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H); LC-MS: 572.1 [M + H]+.
    73
    Figure US20180200247A1-20180719-C00212
         		1H NMR (400 MHz, CDCl3): δ 8.79 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 7.92 (s, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H) 6.76 (d, J = 2.8 Hz, 1H), 3.85 (s, 2H), 3.82 (s, 2H), 3.14-3.01 (m, 4H), 2.92- 2.90 (m, 1H), 2.68 (s, 3H), 2.23-2.01 (m, 1H), 1.61-1.59 (m, 3H), 1.30-1.26 (m, 3H). LC-MS: 509.5 [M + H]+.
    74
    Figure US20180200247A1-20180719-C00213
         		1H NMR (400 MHz, CDCl3): δ 8.43 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.06 (d, J = 4.4 Hz, 1H), 7.99 (s, 1H), 7.94-7.91 (m, 4H), 7.55 (d, J = 8.0 Hz, 2H) 3.84 (s, 1H), 3.55-3.48 (m, 1H), 3.15- 3.09 (m, 2H) 3.09-3.14 (m, 1H), 2.82- 2.77 (m, 1H), 2.16-2.09 (m, 1H), 1.83 (s, 3H), 1.31 (t, J = 7.6 Hz, 3H); LC-MS: 572.4 [M + H]+.
    75
    Figure US20180200247A1-20180719-C00214
         		1H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 7.96 (s, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 9.6 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.8 Hz, 1H), 3.80 (s, 2H), 3.13-3.09 (m, 2H), 2.99-2.96 (m, 2H), 2.80-2.76 (m, 2H), 2.69 (s, 3H), 2.44 (s, 3H), 2.24-2.13 (m, 2H), 1.60-1.57 (m, 3H) 1.33-1.28 (m, 4H), 0.88-0.81 (m, 2H). LC- MS: 532.4 [M + H]+.
    76
    Figure US20180200247A1-20180719-C00215
         		1H NMR (400 MHz, CDCl3): δ 7.94-7.89 (m, 4H), 7.53 (d, J = 8.0 Hz, 2H), 6.67 (s, 1H), 4.11 (s, 3H) 3.80 (s, 2H), 3.14-3.05 (m, 3H), 2.95-2.86 (m, 2H), 2.65 (s, 3H), 2.20-2.03 (m, 2H), 1.50 (s, 3H), 1.30-1.26 (m, 6H). 1.08-1.02 (m, 2H), 0.90-0.86 (m, 2H), 0.76-0.72 (m, 1H), 0.66-0.63 (m, 1H), LC-MS: 549.3 [M + H]+
    77
    Figure US20180200247A1-20180719-C00216
         		1H NMR (400 MHz, CDCl3): δ 7.96-7.87 (m, 5H), 7.81 (s, 1H), 7.70 (s, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 9.60 Hz, 1H) 3.81 (s, 2H), 3.14-3.10 (m, 2H), 3.01-3.00 (m, 2H), 2.70 (s, 3H), 2.25-2.40 (m, 1H), 1.59 (s, 3H), 1.30-1.26 (m, 4H). LC-MS: 518.4 [M + H]+.
    78
    Figure US20180200247A1-20180719-C00217
         		1H NMR (400 MHz, CDCl3): δ 8.38 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.07 (s, 1H), 7.92 (d, J = 7.2 Hz, 2H), 7.54 (d, J = 7.2 Hz, 2H), 7.18 (s, 1H), 3.84 (s, 1H), 3.13-3.11 (m, 2H), 3.03-2.95 (m, 2H), 2.55 (s, 3H), 2.27-2.20 (m, 2H), 1.58 (s, 3H), 1.3 (t, J = 6.4 Hz, 3H); LC-MS: 547.2 [M + H]+.
    79
    Figure US20180200247A1-20180719-C00218
         		1H NMR (400 MHz, CDCl3): δ 9.64 (br s, 1H), 9.13 (d, J = 2.4 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.20-8.11 (m, 2H), 7.54 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 4.02 (s, 2H), 3.19-3.14 (m, 2H), 2.97-2.93 (m, 3H), 2.61 (s, 3H), 2.38 (s, 3H), 2.16-2.11 (m, 1H), 1.52 (s, 3H), 1.34 (t, J = 4.8 Hz, 3H); LC-MS: 494.6 [M + H]+.
    80
    Figure US20180200247A1-20180719-C00219
         		1H NMR (300 MHz, CDCl3): δ 9.40 (br s, 1H), 9.12 (d, J = 2.4 Hz, 1H), 8.19-8.22 (m, 1H), 7.91 (br s, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 9.3 Hz, 1H), 6.91 (d, J = 9.3 Hz, 1H), 4.07 (s, 3H), 4.00 (s, 2H), 3.13-3.12 (m, 2H), 2.89-3.14 (m, 3H), 2.68 (s, 3H), 2.18-2.20 (m, 1H), 1.59 (s, 3H), 1.35 (t, J = 7.5 Hz, 3H); LC-MS: 510.3 [M + H]+.
    81
    Figure US20180200247A1-20180719-C00220
         		1H NMR (400 MHz, CDCl3): δ 8.34 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 8.06 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 6.88 (s, 1H), 3.86 (s, 2H), 3.15-3.03 (m, 3H), 2.83- 2.77 (m, 1H), 2.44-2.39 (m, 6H), 1.64 (s, 3H), 1.31-1.27 (m, 3H), 1.13-1.10 (m, 3H). LC-MS: 507.7 [M + H]+.
    82
    Figure US20180200247A1-20180719-C00221
         		1H NMR (400 MHz, CDCl3): δ 8.30 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 7.94 (d, J = 6.4 Hz, 2H), 7.57- 7.55 (m, 2H), 6.84 (s, 1H), 3.87 (s, 2H), 3.49 (d, J = 10.8 Hz, 1H), 3.16-3.10 (m, 3H), 2.87-2.83 (m, 2H), 2.65 (s, 3H), 2.49 (s, 3H), 1.31-1.28 (m, 3H), 0.99-0.98 (m, 2H). LC-MS: 493.1 [M + H]+.
    83
    Figure US20180200247A1-20180719-C00222
         		1H NMR (300 MHz, DMSO-d6): δ 11.1 (s, 1H), 8.26 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.13 (s, 1H), 3.89 (s, 2H), 3.25 (s, 3H), 2.76-2.72 (m, 2H), 2.43 (s, 3H), 2.36 (s, 3H), 1.45 (s, 3H), 1.1-1.05 (m, 3H). LC-MS: 493.3 [M + H]+.
    • Example-2 Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-84)
  • Figure US20180200247A1-20180719-C00223
    • Step-i: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-((4-methoxybenzyl)oxy)pyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-((4-methoxybenzyl)oxy)pyridin-3 -yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide was prepared by procedure similar to the one described in Example-1 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions. LC-MS: 614.4 [M+H]+.
    • Step-ii: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • To a stirred solution of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-((4-methoxybenzyl)oxy)pyridin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.08 g, 0.13 mmol) in methanol/ethyl acetate (3 mL/3 mL) was added 10% palladium on carbon (0.015 g) under nitrogen atmosphere and the reaction mixture was stirred under the positive pressure of hydrogen using a bladder for 12 h. The Pd-C was filtered off and filtrate concentrated to get crude, which on purification by preparative HPLC afforded the titled compound (0.01 g, 15.6%). 1H NMR (400 MHz, CDCl3): δ 11.58-11.71 (m, 1H), 9.34 (br s, 1H), 7.74-7.89 (m, 3H), 7.44 (d, J=8.02 Hz, 3H), 7.15 (d, J=6.06 Hz, 1H), 6.29 (t, J=6.75 Hz, 1H), 3.60-3.82 (m, 2H), 3.00-3.15 (m, 3H), 2.82-2.97 (m, 2H), 2.58 (s, 3H), 1.70-1.81 (m, 1H), 1.51 (s, 3H), 1.24-1.27 (m, 3H). LC-MS: 494.6 [M+H]+.
  • The below compounds (85-91) were prepared by a procedure similar to the one described in Example-2 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Com-
    pound
    No. Compound Structure Characterization Data
    85
    Figure US20180200247A1-20180719-C00224
         		1H NMR (400 MHz, CDCl3): δ 8.37 (br s, 1H), 8.02-8.14 (m, 2H), 7.85-7.96 (m, 3H), 7.51 (d, J = 8.06 Hz, 2H), 7.03-7.13 (m, 2H), 3.81 (s, 2H), 3.32-3.47 (m, 1H), 3.04-3.17 (m, 3H), 2.88-2.99 (m, 1H), 2.62 (s, 3H), 2.03-2.15 (m, 1H), 1.60 (s, 3H), 1.28 (t, J = 7.39 Hz, 3H); LC-MS: 494.3 [M + H]+.
    86
    Figure US20180200247A1-20180719-C00225
         		1H NMR (400 MHz, DMSO-d6): δ 11.55 (br s, 1H), 11.00 (s, 1H), 7.75-7.92 (m, 3H), 7.61 (d, J = 8.33 Hz, 2H), 7.37 (d, J = 6.98 Hz, 1H), 6.00 (d, J = 6.98 Hz, 1H), 3.97 (br s, 1H), 3.88 (s, 2H), 3.28 (q, J = 7.25 Hz, 2H), 2.97-3.07 (m, 1H), 2.78-2.88 (m, 1H), 2.61-2.70 (m, 1H), 2.11 (s, 3H), 1.63-1.76 (m, 1H), 1.33 (s, 3H), 1.09 (t, J = 7.25 Hz, 3H); LC-MS: 508.3 [M + H]+.
    87
    Figure US20180200247A1-20180719-C00226
         		1H NMR (400 MHz, DMSO-d6): δ 11.24 (s, 1H), 10.07 (br s, 1H), 8.12-8.18 (m, 1H), 8.06 (d, J = 8.60 Hz, 1H), 7.83-7.88 (m, 2H), 7.63 (d, J = 8.06 Hz, 2H), 7.22 (d, J = 6.98 Hz, 1H), 7.09 (br s, 1H), 4.16 (br s, 1H), 3.93 (s, 2H), 3.24-3.30 (m, 2H), 3.17 (s, 1H), 2.69 (d, J = 15.85 Hz, 1H), 2.09 (s, 1H), 1.08 (d, J = 11.82 Hz, 5H), 0.92 (br s, 3H); LC-MS: 494.2 [M + H]+.
    88
    Figure US20180200247A1-20180719-C00227
         		1H NMR (300 MHz, DMSO-d6): δ 11.03 (s, 1H), 9.81 (s, 1H), 7.95 (s, 1H), 7.79-7.87 (m, 3H), 7.58 (d, J = 8.24 Hz, 2H), 7.08 (d, J = 1.32 Hz, 2H), 4.03 (q, J = 7.25 Hz, 1H), 3.85 (s, 2H), 3.26 (d, J = 7.58 Hz, 1H), 2.72 (br s, 2H), 2.56 (s, 3H), 2.03-2.20 (m, 1H), 1.99 (s, 1H), 1.34 (s, 3H), 1.08 (t, J = 7.25 Hz, 3H); LC-MS: 494.4 [M + H]+.
    89
    Figure US20180200247A1-20180719-C00228
         		1H NMR (300 MHz, CDCl3): δ 8.36 (br s, 1H), 8.11 (d, J = 2.20 Hz, 2H), 7.90-7.99 (m, 3H), 7.53 (d, J = 8.23 Hz, 2H), 7.05-7.15 (m, 2H), 3.83 (s, 2H), 3.51 (br s, 1H), 3.33-3.47 (m, 1H), 3.12 (d, J = 5.12 Hz, 1H), 3.07 (s, 3H), 2.90-3.01 (m, 1H), 2.64 (s, 3H), 2.06-2.16 (m, 1H), 1.67 (br s, 2H); LC-MS: 480.3 [M + H]+.
    90
    Figure US20180200247A1-20180719-C00229
         		1H NMR (300 MHz, CDCl3): δ 8.26-8.33 (m, 2H), 8.14 (d, J = 8.57 Hz, 1H), 7.90 (d, J = 8.57 Hz, 3H), 7.52 (d, J = 8.24 Hz, 2H), 6.99 (s, 2H), 3.84 (s, 2H), 3.64 (s, 1H), 3.25 (d, J = 17.48 Hz, 1H), 3.13 (q, J = 7.25 Hz, 2H), 2.70 (d, J = 17.15 Hz, 1H), 1.29 (t, J = 7.42 Hz, 3H), 1.06 (s, 3H), 0.91 (s, 3H); LC-MS: 494.3 [M + H]+.
    91
    Figure US20180200247A1-20180719-C00230
         		1H NMR (300 MHz, CDCl3): δ 8.26-8.33 (m, 2H), 8.14 (d, J = 8.57 Hz, 1H), 7.90 (d, J = 8.57 Hz, 3H), 7.52 (d, J = 8.24 Hz, 2H), 6.99 (s, 2H), 3.84 (s, 2H), 3.64 (s, 1H), 3.25 (d, J = 17.48 Hz, 1H), 3.13 (q, J = 7.25 Hz, 2H), 2.70 (d, J = 17.15 Hz, 1H), 1.29 (t, J = 7.42 Hz, 3H), 1.06 (s, 3H), 0.91 (s, 3H); LC-MS: 479.8 [M + H]+.
    • Example-3 Synthesis of N-(6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (Compound-92)
  • Figure US20180200247A1-20180719-C00231
  • Step-i: Synthesis 3-bromo-6-chloropyrazin-2-amine
  • To a solution of 6-chloropyrazin-2-amine (15.0 g, 115 mmol) in DCM (150 mL), N-bromo succinimide (20.6 g, 115 mmol) was slowly added in portions at −10° C. and stirred for 4 h. The reaction mixture was washed with water and the organic layer was separated. The organic layer was dried over Na2SO4, and concentrated under reduced pressure to afford the crude product. The crude product was purified by column chromatography over silica gel (100-200 mesh) eluting with DCM to afford 3-bromo-6-chloropyrazin-2-amine (7.5 g, 31%).
    • Step-ii: Synthesis of 8-bromo-5-chloroimidazo[1,2-a]pyrazine
  • A mixture of 3-bromo-6-chloropyrazin-2-amine (5 g, 24.0 mmol) and bromoacetaldehyde diethyl acetal (5.2 g, 26.0 mmol) in DMF (20 mL) was stirred at 50° C. for 12 h. The volatiles were evaporated under high vacuum to get a residue. The residue was dissolved in ethanol (20 mL) and refluxed for 12 h. The volatiles were evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography over silica gel (100-200 mesh) eluting with DCM to afford 8-bromo-5-chloroimidazo[1,2-a]pyrazine (0.35 g, 6%).
    • Step-iii: Synthesis of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-methoxy-6-methyl-7,8-dihydroquinolin-5(6H)-one
  • This step was done using the same protocol explained in the preparation of Intermediate-38
    • Step-iv: Synthesis of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-hydroxy-6-methyl-7,8-dihydro quinolin-5(6H)-one
  • A mixture of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-methoxy-6-methyl-7,8-dihydroquinolin-5(6H)-one (0.12 g, 0.35 mmol), trimethylsilyl chloride (0.041 g, 0.38 mmol) and sodium iodide (0.06 g, 0.38 mmol) in acetonitrile (10 mL) was stirred at 60° C. for 1 h. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-hydroxy-6-methyl-7,8-dihydroquinolin-5(6H)-one (0.08 g, 70%).
    • Step-v: Synthesis of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydro quinolin-2-yl trifluoromethanesulfonate
  • To a solution of 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-2-hydroxy-6-methyl-7,8-dihydroquinolin-5(6H)-one (0.08 g, 0.24 mmol) in pyridine (10 mL) at 0° C., was added triflic anhydride (0.14 g, 0.48 mmol) and stirred at room temperature for 0.5 h. The volatiles were evaporated from the reaction mixture to get a residue. The residue was dissolved in ethyl acetate and washed with water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7, 8-tetrahydroquinolin-2-yl trifluoromethanesulfonate (0.07 g, 63%).
    • Step-vi: Synthesis of N-(6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • 6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methytl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl trifluoromethanesulfonate was coupled using the same protocol as explained in Example-1.
  • 1H NMR (400 MHz,CDCl3): δ 8.44 (d, J=8.4 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.11 (s, 1H), 7.92 (d, J=8.4 Hz, 2H), 7.80-7.77(m,3H), 7.55 (d, J=8.4 Hz, 2H), 3.84 (s, 1H), 3.62-3.56 (m, 1H), 3.14-3.09 (m, 2H) 3.05-2.99 (m, 1H), 2.80-2.73 (m, 1H), 2.17-2.12 (m, 1H),1.88(s, 3H), 1.31 (t, J=7.6 Hz, 3H); LC-MS: 538.1 [M+H]+.
    • Compound-93: Synthesis of N-(6-(6-chloropyridazin-3-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • Figure US20180200247A1-20180719-C00232
  • This compound was prepared by procedure similar to the one described in Example-3 with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • 1H NMR (400 MHz,CDCl3): δ 8.34 (d, J=8.8 Hz, 1H), 8.13 (d, J=8.8Hz, 1H), 8.05 (s, 1H) 7.90 (d, J=8.0Hz, 2H), 7.53 (d, J=8.0Hz, 2H), 7.42 (s, 2H), 3.82 (s, 2H), 3.13-2.92 (m, 5H) 2.32-2.25 (m, 1H), 1.61 (s, 3H), 1.29 (t, J=7.6 Hz, 3H)LC-MS:499.1 [M+H]+.
    • Example-4 Synthesis of 3-(2-(2-(4-(ethylsulfonyl)phenyl)acetamido)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-6-yl)-6-methoxypyridazine 1-oxide (Compound-94)
  • Figure US20180200247A1-20180719-C00233
  • A mixture of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.1 g, 0.196 mmol) in Dichloromethane (5 mL) was added mCPBA (0.34 g, 0.196 mmol) at 0° C. and was warmed to RT and stirred at room temperature for 4 h. The reaction mixture was then quenched with ice water and diluted with dichloromethane and washed with water. The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to get residue. The residue was purified by flash chromatography using 80% ethyl acetate in hexanes to get pure title compound (0.03 g, 29%).
  • 1H NMR (400 MHz, CDCl3): δ 10.39 (s,1H), 8.22 (s,1H) 7.94 (d, J=8.0 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.30 (s,1H), 6.95 (d, J=9.2 Hz 1H), 4.07 (s,3H), 3.93(S,2H), 3.39-3.34 (m, 1H), 3.15-3.10 (m, 2H), 2.97-2.93 (m,2H), 2.72 (s, 3H), 2.28-2.19 (m, 1H), 1.55 (s, H), 1.31-1.27 (m,3H); LC-MS:525.3 [M+H]+.
    • Example-5 Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-4-methylpyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-95) and 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-5-methylpyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-96)
  • Figure US20180200247A1-20180719-C00234
  • A mixture of 2-chloro-6-(6-methoxy-4-methylpyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one and 2-chloro-6-(6-methoxy-5-methylpyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one was coupled using the same protocol explained in example-1.
    • Purification and separation of regio-isomers: The crude product was subjected to column chromatography (60-120 mesh silica gel, 30-70% hexane in ethyl acetate) followed by preparative HPLC [Column: Kinetex EVO C18 100A axia (21.2 mm×150 mm, 5μ); Mobile phase: water and 1:1 mixture of acetonitrile and methanol] to obtain the fast moving isomer 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-4-methylpyridazin-3 -yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.042 g, 13%) and the slow moving isomer 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-5-methylpyridazin-3 -yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.03 g, 10%). The spectral data are depicted below respectively.
    • Compound-95:
  • 1H NMR (300 MHz, CDCl3): δ 7.89-7.95 (m, 4H), 7.54 (d, J=8.1 Hz, 1H), 6.66 (s, 1H), 4.07 (s, 3H), 3.81 (s, 2H), 2.89-3.15 (m, 5H), 2.67 (s, 3H), 2.05-2.12 (m, 1H), 2.14 (s, 3H), 1.65 (s, 3H), 1.3 (t, J=7.5 Hz, 3H); LC-MS: 523.3 [M+H]+.
    • Compound-96: 1H NMR (300 MHz, CDCl3): δ 7.89-7.92 (m, 4H), 7.54 (d, J=8.1 Hz, 1H), 7.08 (d, J=0.9 Hz, 1H), 4.08 (s, 3H), 3.80 (s, 2H), 3.08-3.15 (m, 2H), 2.91-2.96 (m, 3H), 2.69 (s, 3H), 2.05-2.14 (m, 1H), 2.16 (s, 3H), 1.53 (s, 3H), 1.3 (t, J=7.5 Hz, 3H); LC-MS: 523.2 [M+H]+.
    Example-6 Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-97)
  • Figure US20180200247A1-20180719-C00235
  • To a solution of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-6) (0.4 g, 0.8 mmol) in acetonitrile (15 mL) at 0° C., was added a solution of Selectfluor® (0.28 g, 0.145 mmol) in THF:Water (1:1, 15 mL) for 20 min. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 48 h. The reaction mixture was evaporated under reduced pressure to get the residue. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by preparative HPLC (Column: Gemini NX C18: 1.2 mm*150 mm; mobile phase: acetonitrile and water) to get 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.03 g, 7%).
  • 1H NMR (300 MHz, CDCl3): δ 8.46 (d, J=8.7 Hz, 1H), 8.19 (d, J=8.7 Hz, 1H), 7.93 (d, J=6.6 Hz, 2H), 7.72-7.78 (m, 2H), 7.56 (d, J=8.1Hz, 2H), 7.27-7.29 (m, 1H), 3.84 (s, 2H, 3.54-3.59 (m, 1H), 3.08-3.15 (m, 2H), 2.96-3.08 (m, 1H), 2.79 -2.81 (m, 1H), 2.11-2.17 (m, 1H), 1.82 (s, 3H), 1.31 (t, J=7.5 Hz, 3H); LC-MS: 522.4 [M+H]+.
    • Example-7 Synthesis of N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (Compound-98)
  • Figure US20180200247A1-20180719-C00236
    • Step-i: Synthesis of 2-amino-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • A mixture of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-31) (0.5 g, 0.098 mmol) and 48% HBr in water (10 ml) was stirred at 60° C. for 3 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted with ethyl acetate. The organic was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to give 2-amino-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.25 g, 89%),1H NMR (300 MHz, DMSO-d6): δ 12.79 (br s, 1H), 7.45 (d, J=9.9 Hz, 1H), 6.83 -6.77 (m, 3H), 6.10 (s, 1H), 2.41 (s, 3H), 1.96-1.93 (m, 2H), 1.33 (s, 3H) 1.21-1.06 (m, 2H); LC-MS: 285.1 [M+H]+.
    • Step-ii: Synthesis of 2-amino-6-(6-chloropyridazin-3-yl)-4,6-dimethyl-7,8-dihydro quinolin-5(6H)-one
  • The mixture of 2-amino-6-(6-hydroxypyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.24 g, 0.000.84 mmol) and phosphorous oxychloride (15 mL) was stirred at 130° C. for 3 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was neutralized with 10% sodium bicarbonate solution and extracted ethyl acetate. The organic was washed with water, brine, dried over anhydrous sodium sulphate and evaporated under reduced pressure to give 2-amino-6-(6-chloropyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one(0.18 g, 72%), LC-MS: 303.3.0 [M+H]+.
    • Step-iii: Synthesis of 2-amino-6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one
  • A mixture 2-amino-6-(6-chloropyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.17 g, 0.56 mmol) and 40% dimethylamine in water (5.0 ml) was stirred at100° C. in seal tube for 12 h and then cooled to get the solids. The solids collected by filtration to obtain 2-amino-6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.1 g, 58%). LC-MS: 312.2 [M+H]+.
    • Step-iv: N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydro quinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • To a solution of 2-amino-6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-7,8-dihydroquinolin-5(6H)-one (0.08 g, 0.26 mmol), 2-(4-(ethylsulfonyl)phenyl)acetic acid (0.07 g, 0.31 mmol) and triethyl amine (0.052 g, 0.5 mmol) in dichloromethane (20 mL) was added 50 wt. % propylphosphonic anhydride solution in ethyl acetate (0.245 mL, 0.52 mmol) and stirred at room temperature for 2 h. The reaction mixture was washed with water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography (50-100% ethyl acetate in hexane) to get N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (0.04 g, 30%).
  • 1H NMR (400 MHz,CDCl3): δ 8.20 (br s, 1H) 7.90-7.88 (m, 3H), 7.533 (s, 1H), 7.51 (s, 1H), 7.08 (d, J=9.6 Hz, 1H), 6.7 (d, J=9.6 Hz, 1H), 3.80 (s,2H), 3.12-3.08 (m, 5H), 2.99-2.92 (m, 2H), 2.67(s, 3H), 2.18-2.16 (m, 2H), 1.51(s, 3H), 1.298-1.261 (t, J=7.2 Hz, 3H); LC-MS: 522.3 [M+H]+.
    • Example-8 Synthesis of 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide (Compound-99)
  • Figure US20180200247A1-20180719-C00237
    • Step-i: 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carbonitrile
  • A mixture of 2-chloro-6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-7,8-dihydroquinolin-5(6H)-one (2.5 g, 8.3 mmol) in dimethyl acetamide (25 mL) was added zinc cyanide (1.9 g, 17.7 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.38 g, 0.33 mmol). The resulting reaction mixture was stirred at 120° C. for 2 h. The reaction mixture was cooled to room temperature and filtered through a pad of celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography (30-50% ethyl acetate in hexane) to get 6-(2,6-dimethyl pyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carbonitrile (1.5 g, 63%). LC-MS: 293.3 [M+H]+.
    • Step-ii: 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxylic acid
  • A mixture of 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carbonitrile (0.5 g, 1.7 mmol) in concentrated hydrochloric acid (4.0 mL) and water (6.0 mL) was stirred at 100° C. for 6 h. The volatiles were evaporated under reduced pressure to get the residue. The residue was basified with triethyl amine and extracted with dichloromethane. The organic layer was evaporated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography (0-10% methanol in chloroform) to get 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxylic acid (0.4 g, 75%). LC-MS: 312.3 [M+H]+.
    • Step-iii: 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide
  • To a solution of 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydro quinoline-2-carboxylic acid (0.22 g, 0.7 mmol), (4-(ethylsulfonyl)phenyl)methanamine (0.141 g, 0.7 mmol) and DIPEA (0.182 g, 1.4 mmol) in DMF (10 mL) was added HATU (0.4 g, 1.0 mmol) and stirred at room temperature for 12 h. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by flash column chromatography (0-2% methanol in chloroform) to get 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide (0.11 g, 32%).
  • 1H NMR (400 MHz,CDCl3): δ 8.54 (d, J=7.6 Hz, 1H), 8.49 (br s, 1H), 8.20 (d, J=8.0 Hz, 1H), 7.87 (d, J=8.0 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 6.80 (s, 1H), 4.76 (d, J=6.0 Hz, 2H), 3.12-3.07 (m, 2H), 3.07-3.04 (m, 2H) 2.97-2.94 (m, 1H), 2.58 (s, 3H), 2.41 (s, 3H), 2.27-2.17 (m, 1H), 1.57 (s, 3H), 1.28 (t, J=5.1 Hz, 3H); LC-MS: 493.4 [M+H]+.
    • Example-9 Synthesis of N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (Compound-100)
  • Figure US20180200247A1-20180719-C00238
    • Step-i: Synthesis of 2-(2,6-dimethylpyrimidin-4-yl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
  • The compound was prepared according to the protocol as described in the synthesis of Intermediate-38a. LC-MS: 283.0 [M]+.
    • Step-ii: Synthesis of 2-(2,6-dimethylpyrimidin-4-yl)-6-methoxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one
  • The compound was prepared according to the protocol as described in the synthesis of Intermediate-38. LC-MS: 297.02 [M]+.
    • Step-iii: Synthesis of 2-(2,6-dimethylpyrimidin-4-yl)-6-hydroxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one
  • A suspension of 2-(2,6-dimethylpyrimidin-4-yl)-6-methoxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one (1.0 g, 0.35 mmol) in 30% aq HBr in acetic acid (10 mL) was heated to 100° C. for 12 h. The reaction was quenched with NH4OH solution, extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get the pure compound (0.45 g). LC-MS: 283.4 [M]+.
    • Step-iv: Synthesis of 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
  • To a solution of 2-(2,6-dimethylpyrimidin-4-yl)-6-hydroxy-2-methyl-3,4-dihydronaphthalen-1(2H)-one (0.35 g, 0.12 mmol) in DCM (10 mL) was added Et3N (0.52 mL, 0.377 mmol), triflic anhydride (0.42 g, 0.14 mmol) at 0° C. The reaction mixture was stirred at RT for 2 h. The reaction was quenched with ice water, extracted with DCM. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get the pure compound (0.40 g). LC-MS: 415.3 [M]+.
    • Step-v: Synthesis of N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  • To a solution of 6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate (0.4 g, 0.96 mmol) in 1,4-dioxane (10 mL) was added 2-(4-(ethylsulfonyl)phenyl)acetamide (0.2 g, 0.96 mmol), Cs2CO3 (0.62 g, 1.92 mmol), Pd2(dba)3 (0.0.088 g, 0.096 mmol), XantPhos (0.055 g, 0.096 mmol) under nitrogen atmosphere. The reaction mixture was purged with nitrogen for 15 min and then heated to 100° C. for 12 h. The reaction was quenched with ice water, extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get the title compound (0.06 g, 12.6%).
  • 1H NMR (400 MHz, CDCl3): δ 8.07 (d, J=8.4 Hz, 1H), 7.89 (d, J=8.40 Hz, 2H), 7.54-7.51 (M, 3H), 7.43 (s, 1H), 7.26-7.21 (m, 1H), 6.76 (s, 1H), 3.81 (s, 2H), 3.14-3.09 (m, 2H), 2.91-2.82 (m, 3H), 2.62 (s, 3H), 2.37 (s, 3H), 2.12-2.10 (m, 1H), 1.51 (s, 3H), 1.30-1.26 (m, 2H). LC-MS: 492.4 [M+H]+.
    • Example-10 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-101 and 102)
  • Figure US20180200247A1-20180719-C00239
  • Enantiomeric mixture of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide was separated by chiral preparative HPLC to obtain two separated enantiomers (Isomer-1, Compound-101 & Isomer-2, Compound-102). Method: Column: Chiralpak IA (250 mm×10.00 mm), 5.0μ; Hexane: 0.1% DEA in EtOH: Ethanol: (40:60); Flow Rate: 7 mL/min.
  • Characterization data of Isomer-1: 1H NMR (400 MHz, CDCl3): δ 8.11 (d, J=2.96 Hz, 1H), 7.89-7.97 (m, 3H), 7.53 (d, J=8.33 Hz, 2H), 7.07-7.16 (m, 2H), 3.82 (s, 2H), 3.44-3.55 (m, 1H), 3.08-3.17 (m, 3H), 2.95 (td, J=4.57, 18.00 Hz, 1H), 2.66 (s, 3H), 2.05-2.18 (m, 1H), 1.26-1.32 (m, 6H). LC-MS: 493.9 [M+H]+.
  • Characterization data of Isomer-2: 1H NMR (400 MHz, CDCl3): δ 8.28 (br s, 1H), 8.07-8.11 (m, 1H), 7.87-7.94 (m, 3H), 7.52 (d, J=8.33 Hz, 2H), 7.04-7.15 (m, 2H), 3.81 (s, 2H), 3.34-3.47 (m, 1H), 3.12 (q, J=7.43 Hz, 3H), 2.94 (td, J=4.84, 18.00 Hz, 1H), 2.63 (s, 3H), 2.01-2.17 (m, 1H), 1.61 (s, 3H), 1.29 (t, J=7.39 Hz, 3H). LC-MS: 494.3 [M+H]+.
  • The below compounds (103-128) were separated by a procedure similar to the one described in Example-10 with appropriate variation in separation methods as shown in the table.
  • Compound
    No Structure/Method of separation Characterization Data
    103
    Figure US20180200247A1-20180719-C00240
         		1H NMR (400 MHz, DMSO-d6): δ 11.22 (br s, 1H), 8.25 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 9.2 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 1H), 7.11 (s, 1H), 3.88 (s, 2H), 3.28-3.23 (m, 2H), 2.90-2.75 (m, 1H), 2.73-2.72 (m, 2H), 2.43 (s, 3H), 2.35 (s, 3H), 2.18-2.16 (m, 1H), 1.44 (s, 3H), 1.09-1.05 (m, 3H); LC-MS: 493.05 [M + H]+.
    104
    Figure US20180200247A1-20180719-C00241
         		1H NMR (400 MHz, DMSO-d6): δ 11.22 (s, 1H), 8.25 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 9.2 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 1H), 7.11 (s, 1H), 3.88 (s, 2H), 3.28-3.23 (m, 2H), 2.90-2.75 (m, 1H), 2.73-2.72 (m, 2H), 2.43 (s, 3H), 2.35 (s, 3H), 2.18-2.16 (m, 1H), 1.44 (s, 3H), 1.09-1.05 (m, 3H); LC-MS: 493.05 [M + H]+.
    105
    Figure US20180200247A1-20180719-C00242
         		1H NMR (400 MHz, DMSO-d6): δ 8.42 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 4.0 Hz, 1H), 7.56-7.50 (m, 3H), 7.34 (s, 1H), 3.84 (s, 2H), 3.70-3.64 (m, 2H), 3.12-3.06 (m, 2H), 2.93-2.89 (m, 2H), 2.69-2.63 (m, 2H), 2.61 (s, 3H), 2.42-2.12 (m, J = 7.25 Hz, 2H), 1.82 (s, 3H), 1.28-1.25 (m, 3H); LC-MS: 518.2 [M + H]+.
    106
    Figure US20180200247A1-20180719-C00243
         		1H NMR (400 MHz, DMSO-d6): δ 8.42 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 4.0 Hz, 1H), 7.56-7.50 (m, 3H), 7.34 (s, 1H), 3.84 (s, 2H), 3.70-3.64 (m, 2H), 3.12-3.06 (m, 2H), 2.93-2.89 (m, 2H), 2.69-2.63 (m, 2H), 2.61 (s, 3H), 2.42-2.12 (m, 2H), 1.82 (s, 3H), 1.28-1.25 (m, 3H); LC-MS: 518.2 [M + H]+.
    107
    Figure US20180200247A1-20180719-C00244
         		1H NMR (400 MHz, DMSO-d6): δ 11.03 (s, 1H), 7.83 (d, J = 3.6 Hz, 2H), 7.80 (s, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.15 (s, 1H), 3.84 (s, 2H), 3.28-3.22. (m, 2H), 2.95-2.90 (m, 1H), 2.79-2.65 (m, 2H), 2.55 (s, 3H), 2.40 (s, 3H), 2.35 (s, 3H), 2.16-2.09 (m, 1H), 1.37 (s, 3H), 1.08-1.05 (m, 3H); LC-MS: 507.3 [M + H]+.
    108
    Figure US20180200247A1-20180719-C00245
         		1H NMR (400 MHz, DMSO-d6): δ 11.03 (br s, 1H), 7.83 (d, J = 3.6 Hz, 2H), 7.80 (s, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.15 (s, 1H), 3.84 (s, 2H), 3.28-3.22 (m, 2H), 2.95-2.90 (m, 1H), 2.79-2.65 (m, 2H), 2.55 (s, 3H), 2.48 (s, 3H), 2.40 (s, 3H), 2.16-2.09 (m, 1H), 1.37 (s, 3H), 1.08-1.05 (m, 3H); LC-MS: 507.3 [M + H]+.
    109
    Figure US20180200247A1-20180719-C00246
         		1H NMR (400 MHz, CDCl3): δ 7.92-7.89 (m, 4H), 7.53 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.8 Hz, 1H) , 6.92 (d, J = 8.8 Hz, 1H), 4.08 (s, 3H), 3.81 (s, 2H), 3.12-3.10 (m, 2H) 2.94-2.92 (m, 2H), 2.30-2.20 (m, 2H), 1.57 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H). LC-MS: 508.6 [M + H]+.
    110
    Figure US20180200247A1-20180719-C00247
         		1H NMR (400 MHz, CDCl3): δ 7.97 (s, 1H) 7 92-7 89 (m, 4H) 7.53 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 4.08 (s, 3H), 3.81 (s, 2H), 3.12-3.10 (m, 2H) 2.94-2.92 (m, 2H), 2.30-2.20 (m, 2H), 1.57 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H), LC-MS: 508.6 [M + H]+.
    111
    Figure US20180200247A1-20180719-C00248
         		1H NMR (300 MHz, CDCl3): δ 8.43 (d, J = 8.7 Hz, 1H), 8.27 (s, 2H), 8.14 (d, J = 8.7 Hz, 1H), 7.96 (br s, 1H), 7.92 (d, J = 6.6 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 3.84 (s, 3H), 3.82 (s, 2H), 3.07-3.15 (m, 2H), 2.70-2.89 (m, 3H), 2.16-2.24 (m, 1H), 1.60 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H); LC-MS: 495.0 [M + H]+.
    112
    Figure US20180200247A1-20180719-C00249
         		1H NMR (300 MHz, CDCl3): δ 8.45 (d, J = 8.7 Hz, 1H), 8.28 (s, 2H), 8.14 (d, J = 8.7 Hz, 1H), 7.96 (br s, 1H), 7.91 (d, J = 6.6 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 3.84 (s, 3H), 3.82 s, 2H), 3.07-3.15 (m, 2H), 2.70-2.89 (m, 3H), 2.15-2.25 (m, 1H), 1.60 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H); LC-MS: 495.0 [M + H]+.
    113
    Figure US20180200247A1-20180719-C00250
         		1H NMR (400 MHz, CDCl3): δ 8.45 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.72 (s, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.49 (s, 1H), 3.83 (s, 1H), 3.69-3.62 (m, 1H), 3.15-3.09 (m, 2H) 3.19-2.96 (m, 1H), 2.77-2.70 (m, 1H), 2.47 (s, 3H), 2.19-2.12 (m, 1H), 1.84 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); LC-MS: 518.1 [M + H]+.
    114
    Figure US20180200247A1-20180719-C00251
         		1H NMR (400 MHz, CDCl3): δ 8.45 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.72 (s, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.49 (s, 1H), 3.83 (s, 1H), 3.69-3.62 (m, 1H), 3.15-3.09 (m, 2H) 3.19-2.96 (m, 1H), 2.77-2.70 (m, 1H), 2.47 (s, 3H), 2.19-2.12 (m, 1H), 1.84 (s, 3H), 1.31 (t, J = 7.2 Hz, 3H); LC-MS: 518.1 [M + H]+.
    115
    Figure US20180200247A1-20180719-C00252
         		1H NMR (300 MHz, CDCl3): δ 8.38 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.99 (br s, 1H), 7.91 (d, J = 6.3 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 6.27 (s, 1H), 3.87 (s, 3H), 3.82 (s, 2H), 3.08-3.15 (m, 2H), 2.83-2.92 (m, 3H), 2.51 (s, 3H), 2.12-2.16 (m, 1H), 1.50 (s, 3H), 1.30 (t, J = 7.5 Hz, 3H); LC-MS: 509.6 [M + H]+.
    116
    Figure US20180200247A1-20180719-C00253
         		1H NMR (300 MHz, CDCl3): δ 8.38 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.99 (br s, 1H), 7.92 (d, J = 6.3 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 6.27 (s, 1H), 3.87 (s, 3H), 3.82 (s, 2H), 3.08-3.15 (m, 2H), 2.83-2.91 (m, 3H), 2.51 (s, 3H), 2.12-2.16 (m, 1H), 1.49 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H); LC-MS: 509.6 [M + H]+.
    117
    Figure US20180200247A1-20180719-C00254
         		1H NMR (400 MHz, CD3OD): δ 8.38 (d, J = 8.8 Hz, 2H), 8.30 (d, J = 4.4 Hz, 2H), 8.09 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 8 Hz, 2H) 7.76 (s, 1H), 7.68 (d, J = 7.6 Hz, 2H), 7.62 (d, J = 4.4 Hz, 1H), 4.86 (s, 2H), 3.70-3.33 (m, 2H), 3.30-3.24 (m, 2H), 3.15-3.05 (m, 1H), 2.75-2.68 (m, 1H), 2.45 (s, 3H), 2.20-2.16 (m, 2H), 1.80 (s, 3H), 1.29-1.22 (m, 3H); LCMS: 518.3 [M + H]+.
    118
    Figure US20180200247A1-20180719-C00255
         		1H NMR (400 MHz, CD3OD): δ 8.38 (d, J = 8.8 Hz, 2H), 8.30 (d, J = 4.4 Hz, 2H), 8.09 (d, J = 8.8 Hz 1H), 7.92 (d, J = 8 Hz, 2H) 7.76 (s, 1H), 7.68 (d, J = 7.6 Hz, 2H), 7.62 (d, J = 4.4 Hz, 1H), 4.86 (s, 2H), 3.70-3.33 (m, 2H), 3.30-3.24 (m, 2H), 3.15-3.05 (m, 1H), 2.75-2.68 (m, 1H), 2.45 (s, 3H), 2.20-2.16 (m, 2H), 1.80 (s, 3H), 1.29-1.22 (m, 3H); LCMS: 518.3 [M + H]+.
    119
    Figure US20180200247A1-20180719-C00256
         		1H NMR (400 MHz, CDCl3): δ 8.39-8.37 (d, J = 8.8 Hz, 1H), 8.19-8.18 (m, 1H), 8.06 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 3.89 (s, 3H), 3.84 (s, 2H), 3.13-3.11 (m, 2H), 2.98-2.90 (m, 2H), 2.36 (s, 3H), 2.21-2.1 (m, 1H), 1.53 (s, 3H), 1.31-1.27 (m, 3H). LC-MS: 509.4 [M + H]+.
    120
    Figure US20180200247A1-20180719-C00257
         		1H NMR (400 MHz, CDCl3): δ 8.37-8.35 (d, J = 8.0 Hz, 1H), 8.13-8.09 (m, 2H), 7.9-7.88 (d, J = 8.0 Hz, 2H), 7.53-7.51 (d, J = 8.0 Hz, 2H), 6.57 (s, 1H), 3.86 (s, 3H), 3.81 (s, 2H), 3.12-3.07 (m, 2H), 2.90-2.83 (m, 3H), 2.34 (s, 3H), 2.15-2.12 (m, 1H), 1.51 (s, 3H), 1.28-1.23 (m, 3H). LC-MS: 509.4 [M + H].
    121
    Figure US20180200247A1-20180719-C00258
         		1H NMR (400 MHz, CDCl3): δ 8.43 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.06 (d, J = 4.4 Hz, 1H), 7.99 (s, 1H), 7.94-7.91 (m, 4H), 7.55 (d, J = 8.0 Hz, 2H) 3.84 (s, 1H), 3.55-3.48 (m, 1H), 3.15-3.09 (m, 2H) 3.09-3.04 (m, 1H), 2.82-2.77 (m, 1H), 2.16-2.09 (m, 1H), 1.83 (s, 3H), 1.31 (t, J = 7.6 Hz, 3H); LC-MS: 572.1 [M + H]+.
    122
    Figure US20180200247A1-20180719-C00259
         		1H NMR (400 MHz, CDCl3): δ 8.43 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.06 (d, J = 4.4 Hz, 1H), 7.99 (s, 1H), 7.94-7.91 (m, 4H), 7.55 (d, J = 8.0 Hz, 2H) 3.84 (s, 1H), 3.55-3.48 (m, 1H), 3.15-3.09 (m, 2H) 3.09-3.04 (m, 1H), 2.82-2.77 (m, 1H), 2.16-2.09 (m, 1H), 1.83 (s, 3H), 1.31 (t, J = 7.6 Hz, 3H); LC-MS: 572.0 [M + H]+.
    123
    Figure US20180200247A1-20180719-C00260
         		1H NMR (400 MHz, CDCl3): δ 9.64 (br s, 1H) 9.13 (d, J = 2.4 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.20-8.11 (m, 2H), 7.54 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 4.02 (s, 2H), 3.19-3.14 (m, 2H), 2.97-2.93 (m, 3H), 2.61 (s, 3H), 2.38 (s, 3H), 2.16-2.11 (m, 1H), 1.52 (s, 3H), 1.34 (t, J = 4.8 Hz, 3H); LC-MS: 494.6 [M + H]+.
    124
    Figure US20180200247A1-20180719-C00261
         		1H NMR (400 MHz, CDCl3): δ 9.64 (br s, 1H) 9.13 (d, J = 2.4 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.20-8.11 (m, 2H), 7.54 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 4.02 (s, 2H), 3.19-3.14 (m, 2H), 2.97-2.93 (m, 3H), 2.61 (s, 3H), 2.38 (s, 3H), 2.16-2.11 (m, 1H), 1.52 (s, 3H), 1.34 (t, J = 4.8 Hz, 3H); LC-MS: 494.6 [M + H]+.
    125
    Figure US20180200247A1-20180719-C00262
         		1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 7.6 Hz, 1H), 8.49 (br s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 6.80 (s, 1H), 4.76 (d, J = 6.0 Hz, 2H), 3.12-3.07 (m, 2H), 3.07-3.04 (m, 2H) 2.97-2.94 (m, 1H), 2.58 (s, 3H), 2.41 (s, 3H), 2.27-2.17 (m, 1H), 1.57 (s, 3H), 1.28 (t, J = 5.1 Hz, 3H); LC-MS: 493.4 [M + H]+.
    126
    Figure US20180200247A1-20180719-C00263
         		1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 7.6 Hz, 1H), 8.49 (br s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 6.80 (s, 1H), 4.76 (d, J = 6.0 Hz, 2H), 3.12-3.07 (m, 2H), 3.07-3.04 (m, 2H) 2.97-2.94 (m, 1H), 2.58 (s, 3H), 2.41 (s, 3H), 2.27-2.17 (m, 1H), 1.57 (s, 3H), 1.28 (t, J = 5.1 Hz, 3H); LC-MS: 493.4 [M + H]+.
    127
    Figure US20180200247A1-20180719-C00264
         		1H NMR (400 MHz, DMSO-d6): δ 11.2 (s, 1H), 8.25-8.13 (d, J = 8.4 Hz, 1H), 8.06-8.04 (d, J = 8.4 Hz, 1H), 7.84-7.82 (d, J = 8.4 Hz, 2H), 7.60-7.58 (d, J = 8.4 Hz, 2H), 7.12 (s, 1H), 3.89 (s, 2H), 3.2 (m, 2H), 3.0-2.6 (m, 4H), 2.4 (s, 3H), 2.36 (s, 3H), 1.44 (s, 3H), 1.10-1.05 (t, J = 7.2 Hz, 3H; LC-MS: 493.3 [M + H]+.
    128
    Figure US20180200247A1-20180719-C00265
         		1H NMR (400 MHz, DMSO-d6): δ 8.39-8.37 (d, J = 8.8 Hz, 1H), 7.97 (s, 1H), 8.148-8.126 (d, J = 8.8 Hz, 1H), 7.922-7.902 (d, J = 8.0 Hz, 2H), 7.54-7.52 (d, J = 8.4 Hz, 2H), 6.77 (s, 1H), 3.83 (s, 2H), 3.14-3.09 (m, 2H), 2.94-2.86 (m, 3H), 2.6 (s, 3H), 2.38 (s, 3H), 2.4-2.1 (m, 1H), 1.52 (s, 3H), 1.30-1.26 (t, J = 7.2 Hz, 3H); LC-MS: 493.3 [M + H]+.
    • Example-11: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-129)
  • Figure US20180200247A1-20180719-C00266
  • To a solution of 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (Compound-105) (0.075 g, 0.145 mol) in acetonitrile (5 mL) at 0° C., was added a solution of Selectfluor (0.05 g, 0.145 mol.) in THF:Water (1:1, 5 mL) for 20 min. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 48 h. The reaction mixture was evaporated under reduced pressure to get the residue. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated under reduced pressure to get the crude product. The crude product was purified by preparative thin layer chromatography (70:30 ethyl acetate: hexane) to get 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide (0.025 g, 32%).
  • 1H NMR (300 MHz, CDCl3): δ 8.44 (d, J=8.7 Hz, 1H), 8.17 (d, J=8.7 Hz, 1H), 8.07 (br s, 1H), 7.92 (d, J=8.1 Hz, 2H), 7.63-7.68 (m, 2H), 7.55 (d, J=8.1 Hz, 2H), 3.82 (s, 2H), 3.59-3.64 (m, 1H), 3.08-3.15 (m, 2H), 2.90-2.97 (m, 1H), 2.69-2.77 (m, 1H), 2.39 (s, 3H), 2.11-2.17 (m, 1H), 1.82 (s, 3H), 1.31 (t, J=7.5 Hz, 3H); LC-MS: 536.5 [M+H]+.
    • Compound-130: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • Figure US20180200247A1-20180719-C00267
  • 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide was prepared using the same protocol used for the synthesis of compound-126 of Example-9. Yield (0.025 g, 32%).
  • 1H NMR (300 MHz, CDCl3): δ 8.44 (d, J=8.7 Hz, 1H), 8.17 (d, J=8.7 Hz, 1H), 8.06 (br s, 1H), 7.92 (d, J=8.1 Hz, 2H), 7.63-7.68 (m, 2H), 7.55 (d, J=8.1 Hz, 2H), 3.82 (s, 2H), 3.59-3.64 (m, 1H), 3.08-3.15 (m, 2H), 2.90-2.97 (m, 1H), 2.69-2.77 (m, 1H), 2.39 (s, 3H), 2.11-2.17 (m, 1H), 1.82 (s, 3H), 1.31 (t, J=7.5 Hz, 3H); LC-MS: 536.4 [M+H]+.
    • Compound-131: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • Figure US20180200247A1-20180719-C00268
  • This compound was prepared using the same protocol explained in step-v of Example-9.
  • 1H NMR (300 MHz, CDCl3): δ 8.39 (d, J=8.7 Hz, 1H), 8.14 (d, J=9.0 Hz, 1H), 8.02 (br s, 1H), 7.92 (d, J=6.6 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 6.77 (s, 1H), 3.83 (s, 2H), 3.15 (m, 2H), 2.85-3.15 (m, 3H), 2.60-2.67 (m, 5H), 2.12-2.16 (m, 1H), 1.52 (m, 3H), 1.30 (t, J=7.5 Hz, 3H), 1.22 (d, J=7.5 Hz, 3H); LC-MS: 507.3 [M+H]+.
  • The below compounds (132-133) were prepared by a procedure similar to the one described above (for compound-131) with appropriate variations in reactants, quantities of reagents, solvents and reaction conditions.
  • Compound
    No. Structure Characterization Data
    132
    Figure US20180200247A1-20180719-C00269
         		1H NMR (300 MHz, CDCl3): δ 8.39 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 9.0 Hz, 1H), 8.05 (br s, 1H), 7.92 (d, J = 6.6 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 6.78 (s, 1H), 3.82 (s, 2H), 3.07-3.15 (m, 2H), 2.81-2.95 (m, 5H), 2.39 (s, 3H), 2.11-2.18 (m, 1H), 1.52 (s, 3H), 1.20-1.30 (m, 6H); LC-MS: 507.0 [M + H]+.
    133
    Figure US20180200247A1-20180719-C00270
         		1H NMR (300 MHz, CDCl3): δ 8.39 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.03 (br s, 1H), 7.91 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 7.8 Hz, 2H), 6.78 (s, 1H), 3.82 (s, 2H), 3.10-3.15 (m, 2H), 2.81-2.96 (m, 5H), 2.61-2.68 (m, 2H), 2.10-2.18 (m, 1H), 1.53 (s, 3H), 1.17-1.30 (m, 9H); LC-MS: 521.4 [M + H]+.
    • Compound-134: Synthesis of 7-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxamide
  • Figure US20180200247A1-20180719-C00271
    • Step-i: Synthesis of methyl 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylate
  • A solution of 3-chloro-7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-6,7-dihydroisoquinolin-8(5H)-one (0.1 g, 0.54 mmol) in dry MeOH (4 mL) was added Et3N (0.016 g, 0.10 mmol), Pd(dppf)Cl2 (0.045 g, 0.054 mmol). The reaction mixture was purged with nitrogen for 15 min and reaction mixture was strirred at 60 oC under positive pressure of carbon monoxide using a bladder stirred at same temperature for 12 h. The reaction was quenched with ice water extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get the crude compound was purified by combiflash chromatography to obtained the title compound LC-MS: 326.3 [M+H]+
    • Step-ii: Synthesis of 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylic acid
  • A solution of methyl 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylate (0.1 g, 0.54 mmol) in THF:Ethanol:water(3:1:1) was added lithium hydroxide(0.063 g, 1.53 mmol) at RT and the reaction mixture was stirred for 3 h. Reaction mixture concentrated to residue, pH was adjusted to pH-4 using citric acid. This portion was extracted using 5% methanol in chloroform. The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated to get the titled compound LC-MS: 312.3 [M+H]+
    • Step-iii: Synthesis of 7-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxamide
  • A solution of 7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylic acid (0.1 g, 0.32 mmol) in DMF (5 mL) was added DIPEA (0.2 g,1.60 mmol), HATU (0.24 g, 0.64 mmol), (4-(ethylsulfonyl)phenyl)methanaminen (0.077 g, 0.38 mmol) at 0 oC. The reaction mixture was stirred at RT for 12 h. This was then quenched with ice water and extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulphate, filtered and concentrated to get the crude compound. Crude compound was purified by combiflash chromatography to obtain the titled compound. 1H NMR (400 MHz, CDCl3): δ 8.54 (d, J=8.0 Hz, 1H), 8.48 (m, 1H), 8.18 (d, J=8.0 Hz, 1H), 7.87 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 6.80 (s, 1H), 4.75 (d, J=6.4 Hz, 2H), 3.10-2.84 (m, 5H), 2.58 (s, 3H), 2.41 (s, 3H), 2.24-2.19 (m, 1H), 1.56 (s, 3H), 1.28-1.24 (m, 3H).LC-MS: 493.3 [M+H]+.
    • Compound-135: Synthesis of 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide
  • Figure US20180200247A1-20180719-C00272
  • This compound was prepared using the same protocol explained in Example-1.
  • 1H NMR (400 MHz, CDCl3): δ 7.94-7.89 (m, 3H), 7.53 (d, J=8.4 Hz, 1H), 6.58 (s, 1H), 3.85 (s, 3H), 3.81 (s, 2H), 3.14-3.08 (m, 2H), 2.90-2.80 (m, 2H), 2.79 (s, 3H), 2.36 (s, 3H), 2.15-2.14 (m, 1H), 1.49 (s, 3H), 1.30-1.24 (m, 3H). LC-MS: 523.3 [M+H]+.
  • Although the present invention has been illustrated by certain preceding examples, it is not to be construed as being limited thereby; but rather, the present invention encompasses the generic area as hereinbefore disclosed. Various modifications and embodiments can be made without departing from the spirit and scope thereof. For example, the following compounds which can be prepared by following similar procedures as described above with suitable modifications known to the one ordinary skilled in the art are also included in the scope of the present invention.
  • Com-
    pound
    No. Structure
    136
    Figure US20180200247A1-20180719-C00273
    137
    Figure US20180200247A1-20180719-C00274
    138
    Figure US20180200247A1-20180719-C00275
    139
    Figure US20180200247A1-20180719-C00276
    140
    Figure US20180200247A1-20180719-C00277
    141
    Figure US20180200247A1-20180719-C00278
    142
    Figure US20180200247A1-20180719-C00279
    • Expression and Purification of RORγ
  • Gene corresponding to the ligand binding domain of RORγ (247-497 amino acids) was sub-cloned into pGEX4T1 vector. Transformants of E.coli BL21 (DE3) containing pGEX4T1-RORγ (247-497) were grown to an OD of 0.8 at 37° C. and induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 18 hours at 18° C. Cells were harvested and resuspended in 20 mM Tris-HCl (pH 8.5), 0.3 M NaCl, 10% Glycerol, 2 mM β-Me (β-Mercaptoethanol), 2 mM CHAPS, protease inhibitors, 0.6 mM PMSF and Lysozyme. Supernatant of lysate was passed through glutathione sepharose 4B affinity beads (GE health care) pre-equilibrated with 20 mM Tris-HCl (pH 8.5), 0.3 M NaCl, 10% Glycerol, 2 mM β-Me. RORγ was eluted using a gradient of reduced glutathione (3-20 mM). Fractions containing RORγ protein were pooled, concentrated and passed through Superdex 75 gel filtration (GE health care) column equilibrated with 20 mM Na-phosphate pH 8.0, 0.2 M NaCl, 10% glycerol. The peak fractions from gel filtration column were pooled and stored at −80° C. for Binding assay.
    • In-Vitro Biochemical Data ROR Gamma Radio-Ligand Binding Assay:
  • ROR gamma radioligand binding was performed using 3H 25-Hydroxycholesterol in a competitive displacement assay using dextran charcoal method. Using 5 nM 3H 25-Hydroxycholesterol with 300 ng RORγ LBD (in house expressed in E.coli) along with the compound were incubated in the binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.01% BSA and 5 mM MgCl2) for 30 min at room temperature. Then dextran-charcoal mixture (0.5% charcoal: 0.05% dextran) was used for separation and the supernatant was read on the Perkin Elmer Trilux Microbeta counter. Dose response curves were generated for 10 compound concentrations using GraphPad Prism software Version 5 (San Diego, Calif., USA) using non-linear regression curve fit for sigmoidal dose response (variable slope).
    • ROR Gamma Luciferase Reporter Assay:
  • The Ligand Binding Domain (LBD) of ROR gamma was cloned into pFN26A (BIND) hRluc-neo Flexi vector (Promega) which expresses a fusion protein comprised of a DNA binding domain of the yeast GAL4 gene, a linker segment and ROR gamma ligand binding domain. For the reporter assay 0.02×106 HEK293 cells were seeded per well in a 96 well plate in complete media and incubated overnight in an incubator with 5% CO2 at 37° C. before transfection. Cells were then co-transfected with pFN26A hRluc-neo Flexi vector containing the LBD of ROR gamma and pGL4.35 [luc2P/9XGAL4 UAS/Hygro] Vector (Promega) in low serum media. Post transfection and recovery, cells were treated with the test compounds for 48 hours. The assay was terminated using the Bright-Glo Luciferase assay system from Promega and the Luminescence was measured using a luminescence reader. The luminescence values were used to calculate the potency of the compounds.
  • The selected compounds were screened at 1 μM/10 μM concentration followed by IC50 measurement and the results are summarized in the Table-1 below along with IC50 (nM) details for selected compounds. The IC50 values of the selected compounds (in range) are set forth in below table wherein “A” refers to an IC50 value of less than 150 nM, “B” refers to an IC50 value in a range of 150-300 nM and C refers to an IC50 value of greater than 300 nM.
  • TABLE 1
    RORγ ligand binding assay data
    RORγ ligand RORγ ligand
    binding assay: binding assay: RORγ ligand
    Compound % inhibition % inhibition @ binding assay:
    No. @1 μM 10 μM IC50 (nM)
    2 84 89 A
    6 72 96 B
    7 91 100 A
    9 90 100 A
    11 25 71 —
    12 — — A
    14 0 26 —
    15 95 92 A
    16 86 93 B
    17 92 96 —
    19 98 98 B
    20 76 95 —
    21 94 92 B
    22 76 95 A
    26 65 99 C
    28 77 100 B
    29 84 91 B
    31 90 88 A
    34 74 97 C
    35 80 98 B
    40 44 88 —
    41 47 82 —
    42 94 92 A
    43 82 — A
    45 66 73 —
    46 56 92 C
    47 82 98 A
    49 93 82 B
    50 91 90 A
    56 96 94 A
    61 90 74 A
    62 96 91 A
    84 82 100 B
    85 62 95 C
    86 72 100 A
    87 82 99 B
    88 86 90 B
    89 53 79 C
    90 57 84 B
    91 36 100 C
    92 96 80 A
    103 26 0 —
    104 94 88 A
    105 100 97 A
    106 70 1 —
    107 91 90 A
    108 78 28 C
    109 91 36 C
    110 100 81 A
    111 62 19 C
    112 100 73 A
    127 14 46 —
    128 79 110 A
    131 51 42 —
    132 99 103 A
    133 96 109 A
    135 90 104 A
  • The IC50 values of RORγ luciferase reporter assay for selected compounds are set forth in the Table-2 below wherein “A” refers to an IC50 value of less than 100 nM, “B” refers to an IC50 value in a range of 100-500 nM and C refers to an IC50 value of greater than 500 nM.
  • TABLE 2
    RORy luciferase reporter assay data
    RORγ luciferase
    Reporter assay:
    IC50 (nM) (in range) Compound No.
    A 15, 16, 17, 21, 29, 31, 45, 51, 52, 56, 64, 65, 66, 72, 74, 81, 105,
    110, 113, 115, 118, 120, 125 and 129.
    B 2, 6, 7, 9, 12, 20, 22, 26, 28, 35, 49, 50, 58, 60, 68, 71, 75, 76, 77,
    78, 83, 92, 96, 98, 104, 107, 112, 124 and 134.
    C 11, 14, 34, 40, 41, 48, 53, 57, 59, 62, 67, 70, 73, 82, 88, 89, 90, 91,
    93, 94, 95, 97, 103, 106, 108, 109, 111, 114, 116, 117, 123 and
    126.

Claims (28)

1. A compound of formula (I):
Figure US20180200247A1-20180719-C00280
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
ring Het is heterocyclyl;
each Y1, Y2 and Y3 are independently CRa or N, wherein 0-2 of Y1, Y2 and Y3 are N;
each Z1, Z2, Z3, Z4 and Z5 are independently CRa or N, wherein 0-3 of Z1, Z2, Z3, Z4 and Z5 are N;
L is .—NRb—C(O)—(CRbRc)n—, .—C(O)—NRb—(CRbRc)n—, .—NRb—S(O)2—(CRbRc)n— or .—S(O)2—NRb—(CRbRc)n—; wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3;
each R1, R2, R6 and R7 are independently hydrogen, halo, alkyl, hydroxy, hydroxyalkyl, cyano, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, —CORd or —COORd;
R3 at each occurrence is independently hydroxy, halo, alkyl, alkylamino, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; alternatively, two R3 on the same carbon together form an oxo (═O) group;
R4 is hydrogen, alkyl or alkoxy;
R5 is alkyl, —(CH2)nNRbRc, hydroxyalkyl, cycloalkyl, aryl or heterocyclyl;
Ra is hydrogen, alkyl, alkoxy, halo, cycloalkyl or aryl;
Rb and Rc are each independently hydrogen, alkyl or alkoxyalkyl;
alternatively, Rb and Rc on the same atom together form a ring;
Rd is hydrogen, alkyl, alkoxy or cycloalkyl;
m is 0 to 3; and
n is0 to 3.
2. The compound according to claim 1, is a compound of formula (IA):
Figure US20180200247A1-20180719-C00281
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
ring Het, R1, R2, R3, R4, R5, R6, R7, Ra, L, Z1, Z2, Z3, Z4, Z5 and m are same as defined in claim 1.
3. The compound according to claim 1, is a compound of formula (IB):
Figure US20180200247A1-20180719-C00282
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
ring Het, R1, R2, R3, R4, R5, Y1, Y2, Y3 and m are same as defined in claim 1.
4. The compound according to claim 1, is a compound of formula (IC):
Figure US20180200247A1-20180719-C00283
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
ring Het, R1, R2, R3, R4, R5, Ra and m are same as defined in claim 1.
5. The compound according to claim 1, is a compound of formula (ID):
Figure US20180200247A1-20180719-C00284
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
L, R1, R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5 and m are same as defined in claim 1.
6. The compound according to claim 1, is a compound of formula (IE):
Figure US20180200247A1-20180719-C00285
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
L, R1, R2, R3, R4, R5, Z1, Z2, Z3, Z4, Z5 and m are same as defined in claim 1.
7. The compound according to claim 1, is a compound of formula (IF):
Figure US20180200247A1-20180719-C00286
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
L, R1, R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5 and m are same as defined in claim 1.
8. The compound according to claim 1, is a compound of formula (IG):
Figure US20180200247A1-20180719-C00287
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
L, R1, R2, R3, R4, R5, Y1, Y2, Y3, Z1, Z2, Z3, Z4 and Z5 are same as defined in claim 1.
9. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein ring Het is pyridyl, pyridazinyl, pyridazinone, pyrimidinyl, pyrazinyl, pyrazolyl, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl, imidazopyridazinyl or tetrahydroisoquinolinonyl.
10. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein,
Figure US20180200247A1-20180719-C00288
11. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein
Figure US20180200247A1-20180719-C00289
12. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein L is .—NHCOCH2— or .—CONHCH2— wherein the group marked with . is connected to the ring containing Y1, Y2 and Y3.
13. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein each R1, R2, R6 and R7 are hydrogen; R4 is alkyl.
14. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein R5 is alkyl.
15. The compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein Ra is hydrogen or alkyl.
16. A compound that is selected from the group consisting of:
Compound No. IUPAC Name 1 N-(4,6-dimethyl-5-oxo-6-(pyridin-2-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4- (ethylsulfonyl)phenyl)acetamide; 2 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-3-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 3 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(6-(trifluoromethyl)pyridin- 3-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 4 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridin-2-yl)-7,7-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 5 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridin-2-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 6 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-6-methyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 7 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 8 N-(6-methyl-5-oxo-6-(5-(trifluoromethyl)pyridin-2-yl)-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 9 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 10 N-(6-(5-chloropyridin-2-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)- 2-(4-(methylsulfonyl)phenyl)acetamide; 11 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-3,6-dimethyl- 5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 12 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 13 N-(6-(imidazo[1,2-a]pyridin-8-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 14 N-(6-ethyl-6-(imidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin- 2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 15 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(pyrrolo[1,2-a]pyrazin-1- yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 16 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 17 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 18 N-(4,6-dimethyl-5-oxo-6-(pyridin-3-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4- (ethylsulfonyl)phenyl)acetamide; 19 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 20 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 21 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyrimidin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 22 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 23 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoropyridin-2-yl)-4,6-dimethyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 24 N-(6-(5-chloro-3-methoxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 25 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidin-5-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 26 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-4,6-dimethyl- 5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 27 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrazin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 28 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 29 N-(6-(4,6-dimethylpyrimidin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 30 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidin-4-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 31 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 32 N-(4,6-dimethyl-5-oxo-6-(5-(trifluoromethyl)pyridin-2-yl)-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 33 N-(6-(imidazo[1,2-a]pyrazin-8-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 34 N-(4,6-dimethyl-6-(6-methylpyridazin-3-yl)-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 35 N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 36 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-hydroxypyrimidin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 37 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-4-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 38 N-(6-(5-chloro-3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 39 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 40 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridin-3-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 41 N-(6-(6-ethylpyridazin-3-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2- yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 42 N-(6-(benzo[d][1,3]dioxol-5-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 43 N-(4,6-dimethyl-6-(1-methyl-1H-benzo[d]imidazol-5-yl)-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 44 N-(4,6-dimethyl-6-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 45 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(5-methylthiophen-2-yl)-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 46 N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 47 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(1H-pyrazol-1-yl)-5,6,7,8- tetrahydroquinolin-2-yl)acetamide; 48 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-6,8-dimethyl- 5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 49 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 50 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-isopropylpyrimidin-4-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 51 N-(6-(2,6-dimethylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 52 N-(4,6-dimethyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 53 N-(4,6-dimethyl-5-oxo-6-(6-(trifluoromethyl)pyridazin-3-yl)-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 54 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazin-8-yl)-7-methyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 55 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(6- (trifluoromethyl)pyridazin-3-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 56 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 57 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropoxypyridazin-3-yl)-6-methyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 58 2-(4-(ethylsulfonyl)-2-fluorophenyl)-N-(6-methyl-6-(2-methylimidazo[1,2- a]pyrazin-8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 59 N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin-8-yl)-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 60 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-isopropylpyrazin-2-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 61 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 62 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropylpyridazin-3-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 63 N-(6-(6-ethylpyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin- 2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 64 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 65 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 66 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8- yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 67 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methyl-6-(trifluoromethyl)- pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 68 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(5-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 69 N-(6-(2,6-dimethylpyrimidin-4-yl)-7,7-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 70 N-(4,6-dimethyl-6-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 71 N-(6-(3-cyclopropylimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 72 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(2-(trifluoromethyl)- imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 73 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridazin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 74 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3-(trifluoromethyl)- imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 75 N-(4,6-dimethyl-6-(2-methylimidazo[1,2-b]pyridazin-6-yl)-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 76 N-(6-(5-cyclopropyl-6-methoxypyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 77 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-b]pyridazin-6-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 78 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methyl-2-(trifluoromethyl)- pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 79 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide; 80 2-(5-(ethylsulfonyl)pyridin-2-yl)-N-(6-(6-methoxypyridazin-3-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 81 N-(6-(2,6-dimethylpyrimidin-4-yl)-6,7-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 82 N-(6-(2,6-dimethylpyrimidin-4-yl)-7-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 83 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8- tetrahydroisoquinolin-3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 84 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 85 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 86 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxy-4-methylpyridin-3-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 87 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-7,7-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 88 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 89 N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin- 2-yl)-2-(4-(methylsulfonyl)phenyl)acetamide; 90 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridin-2-yl)-7,7-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 91 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-7-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 92 N-(6-(5-chloroimidazo[1,2-a]pyrazin-8-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 93 N-(6-(6-chloropyridazin-3-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2- yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 94 3-(2-(2-(4-(ethylsulfonyl)phenyl)acetamido)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-6-yl)-6-methoxypyridazine 1-oxide; 95 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-4-methylpyridazin-3-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 96 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-5-methylpyridazin-3-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 97 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoroimidazo[1,2-a]pyrazin-8-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 98 N-(6-(6-(dimethylamino)pyridazin-3-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 99 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinoline-2-carboxamide; 100 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydronaphthalen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 101 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound- 84); 102 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridin-2-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound- 84); 103 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-7); 104 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-7); 105 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-9); 106 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-9); 107 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-28); 108 N-(6-(2,6-dimethylpyrimidin-4-yl)-4,6-dimethyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-28); 109 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound- 31); 110 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazin-3-yl)-4,6-dimethyl-5- oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound- 31); 111 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-56); 112 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidin-2-yl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-56); 113 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-49); 114 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(3-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-49); 115 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-65); 116 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxy-2-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-65); 117 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-16); 118 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(6-methylimidazo[1,2-a]pyrazin- 8-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-16); 119 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-1 of Compound-64); 120 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-6- methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; (Isomer-2 of Compound-64); 121 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3- (trifluoromethyl)imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2- yl)acetamide; (Isomer-1 of Compound-74); 122 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-5-oxo-6-(3- (trifluoromethyl)imidazo[1,2-a]pyrazin-8-yl)-5,6,7,8-tetrahydroquinolin-2- yl)acetamide; (Isomer-2 of Compound-74); 123 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide; (Isomer- 1 of Compound-79); 124 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(5-(ethylsulfonyl)pyridin-2-yl)acetamide; (Isomer- 2 of Compound-79); 125 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinoline-2-carboxamide; (Isomer-1 of Compound-99); 126 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-6-methyl-5-oxo- 5,6,7,8-tetrahydroquinoline-2-carboxamide; (Isomer-2 of Compound-99); 127 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8- tetrahydroisoquinolin-3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-83); 128 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8- tetrahydroisoquinolin-3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-83); 129 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8- yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 130 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoro-2-methylimidazo[1,2-a]pyrazin-8- yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 131 N-(6-(6-ethyl-2-methylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 132 N-(6-(2-ethyl-6-methylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 133 N-(6-(2,6-diethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8-tetrahydroquinolin- 2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 134 7-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-methyl-8-oxo- 5,6,7,8-tetrahydroisoquinoline-3-carboxamide; 135 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxy-6-methylpyrimidin-4-yl)-4,6- dimethyl-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 136 N-(7-(2,6-dimethylpyrimidin-4-yl)-7-methyl-8-oxo-5,6,7,8- tetrahydroquinolin-3-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 137 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinazolin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 138 N-(6-(2,6-dimethylpyrimidin-4-yl)-6-methyl-5-oxo-5,6,7,8- tetrahydroquinoxalin-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide; 139 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl-6-(2-methyl-6-(trifluoromethoxy)- pyrimidin-4-yl)-5-oxo-5,6,7,8-tetrahydroquinolin-2-yl)acetamide; 140 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-isopropyl-5- oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide; 141 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-8-isopropyl-5- oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide; and 142 6-(2,6-dimethylpyrimidin-4-yl)-N-(4-(ethylsulfonyl)benzyl)-7-isopropyl-6- methyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carboxamide;
or a pharmaceutically acceptable salt or a stereoisomer thereof.
17. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof and at least one pharmaceutically acceptable carrier or excipient.
18. (canceled)
19. A method of modulating the function of RORγ in a subject in need thereof by administering to a subject a therapeutically effective amount of the compound of claim 1.
20. A method of treating a disorder or disease mediated by RORγ in a subject in need thereof comprising administering to the subject a compound of claim 1.
21. The method of claim 20, wherein the disorder or disease mediated by RORγ is an immune disorder or an inflammatory disease.
22. The method according to claim 21, wherein the disease or disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, asthma, epidermal hyperplasia, scleroderma or ulcerative colitis.
23. The method according to claim 21, wherein the disease or disorder is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis or an immune disorder associated with or arising from activity of pathogenic lymphocytes.
24. The method of claim 19, further comprising conjointly administering to the subject a second therapeutic agent.
25. A method of reducing an amount of IL-17 and other effector cytokines of Th17 cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.
26. The method of claim 19, wherein the subject is a human or other mammal.
27. (canceled)
28. (canceled)
US15/574,243 2015-05-15 2016-05-13 Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators Abandoned US20180200247A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2448/CHE/2015 2015-05-15
IN2448CH2015 2015-05-15
PCT/IB2016/052773 WO2016185342A1 (en) 2015-05-15 2016-05-13 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/052773 A-371-Of-International WO2016185342A1 (en) 2015-05-15 2016-05-13 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/709,692 Continuation US11229636B2 (en) 2015-05-15 2019-12-10 Substituted tetrahydroquinolinone compounds as ROR gamma modulators

Publications (1)

Publication Number Publication Date
US20180200247A1 true US20180200247A1 (en) 2018-07-19

Family

ID=57319522

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/574,243 Abandoned US20180200247A1 (en) 2015-05-15 2016-05-13 Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators
US16/709,692 Active 2036-06-17 US11229636B2 (en) 2015-05-15 2019-12-10 Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US17/570,693 Active 2038-06-12 US12377088B2 (en) 2015-05-15 2022-01-07 Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US19/263,745 Pending US20250332155A1 (en) 2015-05-15 2025-07-09 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/709,692 Active 2036-06-17 US11229636B2 (en) 2015-05-15 2019-12-10 Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US17/570,693 Active 2038-06-12 US12377088B2 (en) 2015-05-15 2022-01-07 Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US19/263,745 Pending US20250332155A1 (en) 2015-05-15 2025-07-09 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Country Status (26)

Country Link
US (4) US20180200247A1 (en)
EP (2) EP3294713B1 (en)
JP (2) JP6684516B2 (en)
KR (1) KR102702236B1 (en)
CN (2) CN108026045B (en)
AU (2) AU2016262969C1 (en)
BR (1) BR112017024517A2 (en)
CA (1) CA2985547C (en)
CU (1) CU24487B1 (en)
CY (1) CY1124129T1 (en)
DK (1) DK3294713T5 (en)
EA (1) EA036679B1 (en)
ES (1) ES2868175T3 (en)
HR (1) HRP20210745T1 (en)
HU (1) HUE054009T2 (en)
IL (2) IL255522B (en)
LT (1) LT3294713T (en)
MX (2) MX394388B (en)
MY (1) MY189194A (en)
PH (1) PH12017502052A1 (en)
PL (1) PL3294713T4 (en)
PT (1) PT3294713T (en)
RS (1) RS62016B1 (en)
SI (1) SI3294713T1 (en)
SM (1) SMT202100286T1 (en)
WO (1) WO2016185342A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724089A (en) * 2021-01-05 2021-04-30 烟台共进医药科技有限公司 Synthesis process of 2-amino-3-bromo-6-chloropyrazine
US11229636B2 (en) 2015-05-15 2022-01-25 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6448867B2 (en) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Isoindole compounds
TWI705958B (en) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 ROR GAMMA (RORγ) MODULATORS
CN108218845B (en) * 2016-12-21 2022-11-29 江苏柯菲平医药股份有限公司 A class of chroman-6-sulfonamide ROR gamma regulator and its use
CA3051239C (en) 2017-01-23 2023-12-19 Magic Leap, Inc. Eyepiece for virtual, augmented, or mixed reality systems
CN107129488A (en) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 A kind of Ai Le replaces the preparation method of Buddhist nun
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109111418B (en) * 2017-06-23 2022-10-11 江苏柯菲平医药股份有限公司 2,3-dihydro-1H-indene-4-sulfonamide ROR gamma regulator and application thereof
EP3581565A1 (en) * 2018-06-14 2019-12-18 Beijing Zhibo Bio-Medical Technology Co., Ltd. Phenyl benzyl ether derivative and preparation method and application thereof
CN109232416B (en) * 2018-10-24 2021-09-24 福州大学 A kind of method of synthesizing 4-trifluoromethyl-2-pyrone/pyridone compound
AR117169A1 (en) 2018-11-28 2021-07-14 Bayer Ag (TIO) PYRIDAZINE AMIDES AS FUNGICIDE COMPOUNDS
BR112021010152A2 (en) 2018-12-20 2021-11-09 Bayer Ag Heterocyclyl pyridazine as fungicidal compounds
EP3927329A4 (en) * 2019-02-20 2022-11-23 The Regents of the University of California TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR y (RORy)-DEPENDENT CANCERS
CN109970631A (en) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 A kind of synthetic method of the iodo- 2- pyridylacetic acid of 5-
CN113121463A (en) * 2019-12-31 2021-07-16 广东东阳光药业有限公司 Amide compound with bicyclic structure and application thereof in medicines
US20230165252A1 (en) 2020-05-27 2023-06-01 Bayer Aktiengesellschaft Active compound combinations
MX2022015970A (en) 2020-06-18 2023-01-24 Bayer Ag Active compound combinations.
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024229569A1 (en) * 2023-05-09 2024-11-14 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1341774T3 (en) 2000-12-06 2006-06-12 Hoffmann La Roche Condensed heteroaromatic glucokinase activators
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
US9708268B2 (en) * 2012-04-30 2017-07-18 Innov17 Llc ROR modulators and their uses
MX363350B (en) * 2012-05-08 2019-03-20 Merck Sharp & Dohme BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE.
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) * 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
WO2015017335A1 (en) * 2013-07-30 2015-02-05 Boehringer Ingelheim International Gmbh Azaindole compounds as modulators of rorc
EP3041821B1 (en) * 2013-09-05 2018-05-30 Boehringer Ingelheim International GmbH Bicylic compounds as modulators of rorgamma
RS58650B1 (en) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gamma (rory) modulators
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
KR102408261B1 (en) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Dihydropyrrolopyridine inhibitors of ror-gamma
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
UA120094C2 (en) 2014-04-14 2019-10-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Compounds as modulators of ror gamma
SG11201607518RA (en) 2014-04-16 2016-10-28 Glenmark Pharmaceuticals Sa Aryl and heteroaryl ether compounds as ror gamma modulators
JP2016034607A (en) 2014-08-01 2016-03-17 住友電気工業株式会社 Water treatment system
DK3207043T6 (en) 2014-10-14 2020-01-20 Vitae Pharmaceuticals Llc DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR GAMMA
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
CN108026045B (en) 2015-05-15 2021-04-27 奥瑞基尼探索技术有限公司 Substituted tetrahydroquinolinone compounds useful as RORγ modulators
WO2016193894A1 (en) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
WO2017010399A1 (en) 2015-07-10 2017-01-19 塩野義製薬株式会社 COMPOUNDS HAVING RORγt INHIBITORY EFFECTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (en) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 Modulators of ror-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229636B2 (en) 2015-05-15 2022-01-25 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US12377088B2 (en) 2015-05-15 2025-08-05 Aurigene Oncology Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators
CN112724089A (en) * 2021-01-05 2021-04-30 烟台共进医药科技有限公司 Synthesis process of 2-amino-3-bromo-6-chloropyrazine

Also Published As

Publication number Publication date
RS62016B1 (en) 2021-07-30
AU2016262969C1 (en) 2022-02-24
US12377088B2 (en) 2025-08-05
JP6982376B2 (en) 2021-12-17
EA036679B1 (en) 2020-12-08
IL290153A (en) 2022-03-01
CN108026045A (en) 2018-05-11
US20200113892A1 (en) 2020-04-16
MX2017014621A (en) 2018-06-28
EP3845526A1 (en) 2021-07-07
PT3294713T (en) 2021-05-24
HK1255229A1 (en) 2019-08-09
LT3294713T (en) 2021-06-10
CN108026045B (en) 2021-04-27
JP2020117514A (en) 2020-08-06
SMT202100286T1 (en) 2021-07-12
NZ738256A (en) 2024-09-27
CY1124129T1 (en) 2022-05-27
HRP20210745T1 (en) 2021-06-25
MX394388B (en) 2025-03-21
PL3294713T3 (en) 2021-07-26
IL255522A (en) 2018-01-31
US11229636B2 (en) 2022-01-25
CA2985547A1 (en) 2016-11-24
ES2868175T3 (en) 2021-10-21
DK3294713T3 (en) 2021-05-10
EP3294713B1 (en) 2021-02-17
EA201792515A1 (en) 2018-03-30
PL3294713T4 (en) 2021-07-26
JP6684516B2 (en) 2020-04-22
MX385357B (en) 2025-03-18
KR102702236B1 (en) 2024-09-04
BR112017024517A2 (en) 2018-07-24
KR20180029971A (en) 2018-03-21
CU20170144A7 (en) 2018-04-03
PH12017502052A1 (en) 2018-04-30
CA2985547C (en) 2024-02-20
US20220125780A1 (en) 2022-04-28
AU2016262969A1 (en) 2018-01-04
CU24487B1 (en) 2020-11-30
AU2016262969B2 (en) 2020-10-22
AU2021200330B2 (en) 2022-07-28
US20210113551A9 (en) 2021-04-22
IL255522B (en) 2022-03-01
HUE054009T4 (en) 2021-06-28
DK3294713T5 (en) 2021-05-31
MY189194A (en) 2022-01-31
JP2018515531A (en) 2018-06-14
EP3294713A1 (en) 2018-03-21
WO2016185342A1 (en) 2016-11-24
EP3294713A4 (en) 2018-10-24
SI3294713T1 (en) 2021-08-31
US20250332155A1 (en) 2025-10-30
CN113121497A (en) 2021-07-16
AU2021200330A1 (en) 2021-03-18
HUE054009T2 (en) 2021-08-30
MX2021009561A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US12377088B2 (en) Substituted tetrahydroquinolinone compounds as ROR gamma modulators
US9932343B2 (en) Fused tricyclic benzimidazoles derivatives as modulators of TNF activity
CN104470924B (en) Imidazopyrazines derivant as TNF active regulator
JP6730200B2 (en) Indolizine derivatives as phosphoinositide 3-kinase inhibitors
WO2015083130A1 (en) Fused pyridine and pyrimidine derivatives as ror gamma modulators
CN109195969B (en) Fused pentacyclic imidazole derivatives as modulators of TNF activity
AU2007248603A1 (en) Pyrido [2, 3-b] pyrazine and [1, 8] -naphthyridine derivatives as ALK and c-Met inhibitors
JPH06287188A (en) New heterocyclic derivative
JP6779899B2 (en) Heterocyclic compounds useful as TNF inhibitors
JP2018508554A (en) Tricyclic heterocyclic compounds useful as TNF inhibitors
CN107690434B (en) Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity
US20240051954A1 (en) Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
HK40045074A (en) Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
WO2019154329A1 (en) Compound having bet inhibitory activity and preparation method and use therefor
CN110938071A (en) Heteroaromatic compound with kinase inhibition activity
HK1255229B (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE